Mutant myocilin disease models and uses thereof
Non-human animals with a humanized MYOC locus and CRISPR/Cas systems replicate glaucoma symptoms, addressing the inadequacy of existing models by accurately mimicking MYOC-induced trabecular meshwork stress and intraocular pressure.
Patent Information
- Application Number
- JP2024534253
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-08
- Filing Date
- 2022-12-08
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-12-08
AI Technical Summary
Current animal models fail to accurately reproduce the glaucoma phenotype caused by MYOC toxic gain-of-function mutant proteins, leading to increased trabecular meshwork stress and intraocular pressure.
Development of non-human animals with a humanized MYOC locus, incorporating human MYOC sequences and mutations associated with glaucoma, using CRISPR/Cas-based systems to enhance MYOC expression and model glaucoma pathophysiology.
The humanized MYOC locus models effectively replicate glaucoma symptoms, including elevated intraocular pressure and MYOC protein expression, providing a reliable model for evaluating glaucoma therapeutic agents.
Smart Images

Figure 2024545127000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application No. 63 / 287,281, filed December 8, 2021, which is incorporated by reference herein in its entirety for all purposes.
[0002] Reference to sequence listings submitted as text files via EFS Web The sequence listing set forth in file 588714SEQLIST.xml is 302 kilobytes, was created on December 1, 2022, and is incorporated herein by reference. [Background technology]
[0003] Mutations in myocilin (MYOC) are responsible for the most common genetic cause of glaucoma, accounting for 8–10% of cases of autosomal dominant familial juvenile open-angle glaucoma and 2–3% of cases of primary open-angle glaucoma (POAG). MYOC toxic gain-of-function mutant proteins aggregate intracellularly, leading to trabecular meshwork (TM) stress, elevated intraocular pressure (IOP), and glaucoma. Better animal models are needed to recapitulate the MYOC-induced glaucoma phenotype. Summary of the Invention
[0004] Non-human animals, non-human animal cells, and non-human animal genomes containing a humanized MYOC locus, as well as methods of making and using such non-human animals, non-human animal cells, and non-human animal genomes, are provided. Also provided are humanized non-human animal MYOC genes, nucleic acids containing the humanized non-human animal MYOC genes, targeting vectors for use in humanizing non-human animal MYOC genes, and methods of making and using such humanized MYOC genes.
[0005] In one aspect, non-human animals, non-human animal cells, and non-human animal genomes are provided that comprise a humanized endogenous MYOC locus in their genome, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence. In some such non-human animals, non-human animal cells, and non-human animal genomes, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences.
[0006] In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises a mutation associated with glaucoma. In some such non-human animals, non-human animal cells, and non-human animal genomes, the human MYOC sequence comprises a mutation. In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises a Y437H mutation. In some such non-human animals, non-human animal cells, and non-human animal genomes, the human MYOC sequence comprises a Y437H mutation.
[0007] In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises an endogenous MYOC promoter, and the human MYOC sequence is operably linked to the endogenous MYOC promoter. In some such non-human animals, non-human animal cells, and non-human animal genomes, at least one intron and at least one exon of the endogenous MYOC locus have been deleted and replaced with the corresponding human MYOC sequence. In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises a human MYOC 3' untranslated region. In some such non-human animals, non-human animal cells, and non-human animal genomes, the endogenous MYOC 5' untranslated region has not been deleted and replaced with the corresponding human MYOC sequence.
[0008] In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus encodes a human myocilin protein. In some such non-human animals, non-human animal cells, and non-human animal genomes, the human myocilin protein sequence comprises the sequence set forth in SEQ ID NO:4, and optionally, the human myocilin protein sequence is encoded by a coding sequence comprising the sequence set forth in SEQ ID NO:5.
[0009] In some such non-human animals, non-human animal cells, and non-human animal genomes, the entire MYOC coding sequence of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence, and in some such non-human animals, non-human animal cells, and non-human animal genomes, the region of the endogenous MYOC locus from the MYOC start codon to the MYOC stop codon has been deleted and replaced with the corresponding human MYOC sequence.
[0010] In some such non-human animals, non-human animal cells, and non-human animal genomes, a region of the endogenous MYOC locus from the MYOC start codon to the MYOC stop codon has been deleted and replaced with a human MYOC sequence comprising the corresponding human MYOC sequence and the human MYOC 3' untranslated region, wherein the human MYOC sequence comprises a Y437H mutation, the endogenous MYOC 5' untranslated region has not been deleted or replaced with the human MYOC sequence, the humanized endogenous MYOC locus comprises an endogenous MYOC promoter, and the human MYOC sequence is operably linked to the endogenous MYOC promoter.
[0011] In some such non-human animals, non-human animal cells, and non-human animal genomes, the human MYOC sequence in the humanized endogenous MYOC locus comprises a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 87. In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus encodes a myocilin protein comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 4. In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises a myocilin-coding sequence comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 5. In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus comprises a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 88 or 89.
[0012] In some such non-human animals, non-human animal cells, and non-human animal genomes, the humanized endogenous MYOC locus does not comprise a selection cassette or reporter gene. Some such non-human animals, non-human animal cells, and non-human animal genomes are homozygous for the humanized endogenous MYOC locus. Some such non-human animals, non-human animal cells, and non-human animal genomes are heterozygous for the humanized endogenous MYOC locus. In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal comprises a humanized endogenous MYOC locus in its germline.
[0013] In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a mammal. In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a rat or a mouse. In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a mouse.
[0014] Some such non-human animals, non-human animal cells, and non-human animal genomes further comprise an expression cassette integrated into their genomes, the expression cassette comprising (a) a nucleic acid encoding a chimeric Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains. Some such non-human animals, non-human animal cells, and non-human animal genomes further comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which the chimeric adaptor protein can specifically bind, each of the one or more guide RNAs capable of forming a complex with and directing the Cas protein to a target sequence within the target gene, and at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus. Optionally, the one or more guide RNAs, or one or more expression cassettes encoding one or more guide RNAs, are within the trabecular meshwork.
[0015] Some such non-human animals, non-human animal cells, and non-human animal genomes further comprise an expression cassette integrated into the second genome encoding one or more guide RNAs, each comprising one or more adapter binding elements to which a chimeric adapter protein can specifically bind, wherein each of the one or more guide RNAs is capable of forming a complex with and directing a Cas protein to a target sequence within the target gene, and at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus.
[0016] In some such non-human animals, non-human animal cells, and non-human animal genomes, the first expression cassette is integrated into the Rosa26 locus, and the Cas protein is expressed by Streptococcus pyogenes. the one or more transcription activation domains in the chimeric adapter protein comprise p65 and HSF1; the non-human animal further comprises one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, wherein the one or more guide RNAs or the one or more expression cassettes encoding one or more guide RNAs are located within the trabecular meshwork; each of the one or more guide RNAs comprises two adapter binding elements to which the chimeric adapter protein can specifically bind, the two adapter binding elements comprising a first adapter binding element within a first loop of each of the one or more guide RNAs and a second adapter binding element within a second loop of each of the one or more guide RNAs; and the target sequence is within a region 200 base pairs upstream of the transcription start site and 1 base pair downstream of the transcription start site.
[0017] In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a mouse, and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90 to 95. In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a mouse, and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93 to 94. In some such non-human animals, non-human animal cells, and non-human animal genomes, the non-human animal is a mouse, and the one or more guide RNAs target the guide RNA target sequence set forth in SEQ ID NO: 93.
[0018] Some such non-human animals or non-human animal cells have at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression relative to a control non-human animal or non-human animal cell that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. Some such non-human animals have at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. Some such non-human animals have at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. Some such non-human animals have at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs.Some such non-human animals have at least a 2-fold, at least a 3-fold, at least a 4-fold, at least a 5-fold, at least a 6-fold, at least a 7-fold, at least a 8-fold, at least a 9-fold, at least a 10-fold, at least a 11-fold, at least a 12-fold, at least a 13-fold, at least a 14-fold, or at least a 15-fold increase in MYOC mRNA or protein expression in the trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs.
[0019] In some such non-human animals, the non-human animal has elevated intraocular pressure relative to a wild-type or control non-human animal. Optionally, the non-human animal has an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg. Optionally, the non-human animal has an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of the control non-human animal.
[0020] In another aspect, a nucleic acid is provided that includes a humanized non-human animal MYOC gene (i.e., a humanized non-human animal MYOC locus described above) in which a region of the endogenous MYOC gene has been deleted and replaced with the corresponding human MYOC sequence. Optionally, the region of the endogenous MYOC gene includes both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence includes both MYOC exon and MYOC intron sequences.
[0021] In another aspect, a targeting vector is provided for generating a humanized endogenous MYOC locus (i.e., a humanized endogenous MYOC locus described above) in which a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence, wherein the targeting vector comprises an insert nucleic acid comprising a corresponding human MYOC sequence flanked by a 5' homology arm that targets a 5' target sequence in the endogenous MYOC locus and a 3' homology arm that targets a 3' target sequence in the endogenous MYOC locus. Optionally, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences.
[0022] In another aspect, methods are provided for evaluating the activity of a human MYOC-targeting reagent or candidate glaucoma therapeutic agent in the non-human animals and non-human animal cells described above. Some such methods include (a) administering a human MYOC-targeting reagent or candidate glaucoma therapeutic agent to any of the non-human animals described above, and (b) evaluating the activity of the human MYOC-targeting reagent or candidate glaucoma therapeutic agent in the non-human animal. Some such methods include (a) administering a human MYOC-targeting reagent or candidate glaucoma therapeutic agent to any of the non-human animal cells described above, and (b) evaluating the activity of the human MYOC-targeting reagent or candidate glaucoma therapeutic agent in the non-human animal cells.
[0023] In some such methods, the non-human animal further comprises an expression cassette integrated into its genome, the expression cassette comprising (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains. Some such methods further comprise, prior to step (a), administering one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which the chimeric adaptor protein can specifically bind, each of the one or more guide RNAs capable of forming a complex with and directing the Cas protein to a target sequence within the target gene, and at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus.
[0024] In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target the guide RNA target sequence set forth in SEQ ID NO: 93.
[0025] In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via adenovirus-mediated delivery, lentivirus-mediated delivery, or adeno-associated virus (AAV)-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via recombinant AAV2.Y3F-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via lentivirus-mediated delivery.
[0026] In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered to the non-human animal via intravitreal or intracameral injection. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered to the non-human animal at least one week prior to step (a), or from about one week to about ten weeks prior to step (a).
[0027] In some such methods, step (b) comprises evaluating the activity of the human MYOC targeting reagent or candidate glaucoma therapeutic agent in the eye of the non-human animal. In some such methods, step (a) comprises administering a human MYOC targeting reagent, and step (b) comprises measuring expression of MYOC messenger RNA encoded by the humanized endogenous MYOC locus. In some such methods, step (a) comprises administering a human MYOC targeting reagent, and step (b) comprises measuring expression of myocilin protein encoded by the humanized endogenous MYOC locus. In some such methods, step (a) comprises administering a human MYOC targeting reagent, the human MYOC targeting reagent is a genome editing agent, and step (b) comprises evaluating modification of the humanized endogenous MYOC locus. In some such methods, step (b) comprises measuring the frequency of insertions or deletions within the humanized endogenous MYOC locus.
[0028] In some such methods, the human MYOC targeting reagent comprises a nuclease agent designed to target a region of the human MYOC gene. In some such methods, the nuclease agent comprises a Cas protein and a guide RNA designed to target a guide RNA target sequence in the human MYOC gene. Optionally, the Cas protein is a Cas9 protein.
[0029] In some such methods, step (a) comprises administering a human MYOC targeting reagent, wherein the human MYOC targeting reagent comprises an exogenous donor nucleic acid, wherein the exogenous donor nucleic acid is designed to target the human MYOC gene, and optionally, the exogenous donor nucleic acid is delivered via AAV.
[0030] In some such methods, the human MYOC targeting reagent is an RNAi agent or an antisense oligonucleotide. In some such methods, the human MYOC targeting reagent is an antigen binding protein. In some such methods, the human MYOC targeting reagent is a small molecule.
[0031] In some such methods, assessing the activity of a human MYOC targeting reagent or candidate glaucoma therapeutic agent in a non-human animal includes assessing intraocular pressure.
[0032] In some such methods, the evaluation is performed in comparison to an untreated control non-human animal.
[0033] In some such methods, step (a) comprises administering a candidate glaucoma therapeutic agent and step (b) comprises assessing intraocular pressure. In some such methods, the candidate glaucoma therapeutic agent is an inhibitor of aqueous humor formation. In some such methods, the candidate glaucoma therapeutic agent increases aqueous humor outflow.
[0034] In some such methods, the candidate glaucoma therapeutic agent is an ANGPTL7-targeting reagent. In some such methods, the ANGPTL7-targeting reagent is an RNAi agent or an antisense oligonucleotide.
[0035] In another aspect, methods for optimizing the activity of a human MYOC-targeting reagent or candidate glaucoma therapeutic agent are provided. Some such methods include: (i) performing any of the above-described methods for evaluating the activity of a human MYOC-targeting reagent or candidate glaucoma therapeutic agent in non-human animals and non-human animal cells a first time with a first non-human animal or a first non-human animal cell; (ii) altering a variable element and performing the method of step (I) a second time with a second non-human animal or a second non-human animal cell using the altered variable element; and (iii) comparing the activity of the human MYOC-targeting reagent or candidate glaucoma therapeutic agent in step (I) with the activity of the human MYOC-targeting reagent or candidate glaucoma therapeutic agent in step (II) and selecting a method that results in higher activity.
[0036] In another aspect, a method of producing any of the above non-human animals comprising a humanized endogenous MYOC locus is provided.
[0037] Some such methods include (a) introducing into a non-human animal host embryo a genetically modified non-human animal embryonic stem (ES) cell comprising a humanized endogenous MYOC locus in its genome, wherein a region of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence, and (b) gestating the non-human animal host embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus. Some such methods further include, prior to step (a), modifying the genome of the non-human animal ES cell to comprise the humanized endogenous MYOC locus.
[0038] Some such methods include (a) modifying the genome of a non-human animal one-cell stage embryo to include in its genome a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence, thereby producing a genetically-modified non-human animal embryo; and (b) gestating the genetically-modified non-human animal embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically-modified non-human animal that includes the humanized endogenous MYOC locus.
[0039] Some such methods include mating an F0 progeny genetically modified non-human animal containing a humanized endogenous MYOC locus with a non-human animal that contains, integrated into its genome, a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and further comprising a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains.
[0040] In another aspect, provided is a method of producing any of the above non-human animals comprising a humanized endogenous MYOC locus and a genomically integrated expression cassette, the method comprising: (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains; and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains.
[0041] Some such methods include (a) introducing into a non-human animal host embryo a genetically modified non-human animal embryonic stem (ES) cell, the genome of which contains (i) a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence, and (ii) a genomically integrated expression cassette, the genomically integrated expression cassette comprising a nucleic acid encoding a Cas protein, the Cas protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and a nucleic acid encoding a chimeric adaptor protein, the adaptor protein comprising a fused to one or more transcription activation domains; and (b) gestating the non-human animal host embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus and the genomically integrated expression cassette. Some such methods further include, prior to step (a), modifying the genome of the non-human animal ES cell to contain the humanized endogenous MYOC locus and the genomically integrated expression cassette.
[0042] Some such methods include (a) providing a non-human animal one-cell stage embryo comprising, in its genome, (i) a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence, and (ii) a genomically integrated expression cassette, wherein the genomically integrated expression cassette comprises a nucleic acid encoding a Cas protein, wherein the Cas protein is a nuclease-inactive Cas protein fused to one or more transcription activation domains, and a nucleic acid encoding a chimeric adaptor protein, wherein the adaptor protein is fused to one or more transcription activation domains; and (b) gestating the non-human animal one-cell stage embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus and the genomically integrated expression cassette.
[0043] In some such methods, the non-human animal is a mouse or a rat. In some such methods, the non-human animal is a mouse.
[0044] In another aspect, methods for increasing MYOC expression in a non-human animal are provided. Some such methods include administering to any of the above-described non-human animals (comprising a humanized endogenous MYOC locus and a genomically integrated expression cassette comprising (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains) one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which the chimeric adaptor protein can specifically bind, each of the one or more guide RNAs capable of forming a complex with and directing the Cas protein to a target sequence within the target gene, and at least one of the one or more RNAs targets the humanized endogenous MYOC locus.
[0045] In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target the guide RNA target sequence set forth in SEQ ID NO: 93.
[0046] In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via adenovirus-mediated delivery, lentivirus-mediated delivery, or adeno-associated virus (AAV)-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via recombinant AAV2.Y3F-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via lentivirus-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered to the non-human animal via intravitreal injection or intracameral injection.
[0047] In some such methods, the methods result in increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork. Optionally, the methods result in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not contain one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the methods result in increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the limbal ring. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the trabecular meshwork.Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the trabecular meshwork relative to a control non-human animal that does not include one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs.
[0048] In some such methods, the method results in elevated intraocular pressure. Optionally, the method results in a non-human animal having an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of a control non-human animal. Optionally, the method results in an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg.
[0049] In another aspect, methods of increasing intraocular pressure in a non-human animal are provided. Some such methods include administering to any of the non-human animals described above (comprising a humanized endogenous MYOC locus and a genomically integrated expression cassette comprising (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains) one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which the chimeric adaptor protein can specifically bind, each of the one or more guide RNAs capable of forming a complex with and directing the Cas protein to a target sequence within the target gene, and at least one of the one or more RNAs targets the humanized endogenous MYOC locus.
[0050] In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target the guide RNA target sequence set forth in SEQ ID NO: 93.
[0051] In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via adenovirus-mediated delivery, lentivirus-mediated delivery, or adeno-associated virus (AAV)-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via recombinant AAV2.Y3F-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via lentivirus-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered to the non-human animal via intravitreal injection or intracameral injection.
[0052] In some such methods, the methods result in increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork. Optionally, the methods result in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not contain one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the methods result in increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the limbal ring. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the trabecular meshwork.Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the trabecular meshwork relative to a control non-human animal that does not include one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs.
[0053] In some such methods, the method results in elevated intraocular pressure. Optionally, the method results in a non-human animal having an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of a control non-human animal. Optionally, the method results in an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg.
[0054] In another aspect, methods for increasing model glaucoma in a non-human animal are provided. Some such methods include administering to any of the non-human animals described above (comprising a humanized endogenous MYOC locus and a genomically integrated expression cassette comprising (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains) one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which the chimeric adaptor protein can specifically bind, each of the one or more guide RNAs capable of forming a complex with and directing the Cas protein to a target sequence within the target gene, and at least one of the one or more RNAs targets the humanized endogenous MYOC locus.
[0055] In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94. In some such methods, the non-human animal is a mouse and the one or more guide RNAs target the guide RNA target sequence set forth in SEQ ID NO: 93.
[0056] In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via adenovirus-mediated delivery, lentivirus-mediated delivery, or adeno-associated virus (AAV)-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via recombinant AAV2.Y3F-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered via lentivirus-mediated delivery. In some such methods, the guide RNA or one or more expression cassettes encoding one or more guide RNAs are administered to the non-human animal via intravitreal injection or intracameral injection.
[0057] In some such methods, the methods result in increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork. Optionally, the methods result in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not contain one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the methods result in increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring or trabecular meshwork relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the limbal ring. Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the limbal ring relative to a control non-human animal that does not comprise one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs. In some such methods, the method results in increased MYOC mRNA or protein expression in the trabecular meshwork.Optionally, the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the trabecular meshwork relative to a control non-human animal that does not include one or more guide RNAs or one or more expression cassettes encoding one or more guide RNAs.
[0058] In some such methods, the method results in elevated intraocular pressure. Optionally, the method results in a non-human animal having an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of a control non-human animal. Optionally, the method results in an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg. [Brief explanation of the drawings]
[0059] [Figure 1] Schematics (not to scale) of the wild-type mouse Myoc locus, the wild-type human MYOC locus, the targeted allele of the humanized mouse MYOC locus containing the Y437H mutation and with a self-deleting neomycin (SDC-Neo) selection cassette (MAID 8533), and the targeted allele of the humanized mouse MYOC locus containing the Y437H mutation and with a loxP scar from removal of the SDC-Neo selection cassette (MAID 8534) are shown. [Figure 2] A schematic diagram (not to scale) of the strategy for screening the humanized mouse MYOC locus is shown, including allelic loss assays (7578mTU and 7578mTD), allelic gain assays (7578hTU, 7578hTD, Cre903, and Hyg), and allelic discrimination assays (8533hAS2.WT and 8533hAS2.Mut). [Figure 3]An alignment of human and mouse myocilin proteins is shown. [Figure 4A] Shown (not to scale) is the lox-stop-lox (LSL) dCas9 synergistic activation mediator (SAM) allele (LSL-SAM allele), which includes, from 5' to 3', the 3' splicing sequence, the first loxP site, the neomycin resistance gene, the polyadenylation signal, the second loxP site, the dCas9-NLS-VP64 coding sequence (NLS-dCas9-NLS-VP64), the T2A peptide coding sequence, the MCP-NLS-p65-HSF1 coding sequence, and the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). [Figure 4B] An allele from FIG. 4A in which the loxP-integrated neomycin resistance gene and polyadenylation signal have been removed (SAM allele) is shown (not to scale). [Figure 5] A general schematic for targeting the LSL-SAM allele from Figure 4A into the first intron of the Rosa26 (R26) locus is shown (not to scale). [Figure 6] Schematic of a generic single guide RNA (SEQ ID NO: 68) in which the tetraloop and stem-loop 2 are replaced with an MS2-binding aptamer to promote recruitment of a chimeric MS2 coat protein (MCP) fused to a transcription activation domain. [Figure 7] Ad5, AAV2.Y3F, and lentivirus expression in the trabecular meshwork (TM), ciliary body (CB), and corneal endothelium (CE) are shown. The rectangular box indicates the TM. [Figure 8] The location of the mouse Myoc SAM guide RNA target sequence is shown. [Figure 9] A schematic diagram of the anatomy of the eye is shown. [Figure 10A] Mouse Myoc expression relative to Gapdh expression as measured by qPCR in the limbal ring (trabecular meshwork (TM), iris, and ciliary body (CB); Figure 10A), retina (Figure 10B), and cornea (Figure 10C) following administration of mouse Myoc SAM guide RNA versus control guide RNA. [Figure 10B] Mouse Myoc expression relative to Gapdh expression as measured by qPCR in the limbal ring (trabecular meshwork (TM), iris, and ciliary body (CB); Figure 10A), retina (Figure 10B), and cornea (Figure 10C) following administration of mouse Myoc SAM guide RNA versus control guide RNA. [Figure 10C] Mouse Myoc expression relative to Gapdh expression as measured by qPCR in the limbal ring (trabecular meshwork (TM), iris, and ciliary body (CB); Figure 10A), retina (Figure 10B), and cornea (Figure 10C) following administration of mouse Myoc SAM guide RNA versus control guide RNA. [Figure 11] Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with AAV2.Y3F-SAM-g4, AAV2.Y3F-SAM-g5, AAV2.Y3F-SAM-LacZ control, or no treatment (naive). [Figure 12] Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with AAV2.Y3F-SAM-g4 or no treatment (naive), and the AAV2.Y3F-SAM-g4-treated mice were subsequently treated with either timolol or RHOPRESSA®. [Figure 13]Figure 1 shows human MYOC expression relative to Gapdh expression as measured by qPCR following administration of mouse Myoc SAM guide RNAs g4 and g5 or SAM LacZ control gRNA in SAM mice containing a humanized MYOC locus containing the Y437H mutation that is either heterozygous or homozygous for the humanized MYOC locus. [Figure 14] 1 shows human MYOC expression as measured by RNASCOPE® following administration of mouse Myoc SAM guide RNAs g4 and g5 or SAM LacZ control gRNA in SAM mice containing a humanized MYOC locus containing the Y437H mutation that is either heterozygous or homozygous for the humanized MYOC locus. [Figure 15A] 1 shows the experimental setup for testing the effect of human MYOC siRNA#1 on intraocular pressure (IOP) in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with a mixture of AAV2.Y3F-SAM-g4 and LV-SAM-g4. [Figure 15B] Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with AAV2.Y3F-SAM-g4 or no treatment (naive). AAV2.Y3F-SAM-g4-treated mice were then treated with either human MYOC siRNA or control luciferase siRNA. [Figure 16A] 1 shows the experimental setup for testing the effects of human MYOC siRNAs #1, #2, #3, #4, and #5 on intraocular pressure (IOP) in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4. [Figure 16B]Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with human MYOC siRNA #1, #2, #3, #4, or #5. [Figure 16C] Figure 1 shows qPCR results showing the percentage of human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with human MYOC siRNA #1, #2, #3, #4, or #5. [Figure 16D-1] RNASCOPE® analysis of human MYOC mRNA expression in eyes from SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with human MYOC siRNA #2 or #3. [Figure 16D-2] RNASCOPE® analysis of human MYOC mRNA expression in eyes from SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with human MYOC siRNA #2 or #3. [Figure 17A] 1 shows the experimental setup for testing the effects of human MYOC siRNA #2 and #3 on intraocular pressure (IOP) in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4. [Figure 17B]Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. The LV-SAM-g4-treated mice were then treated with human MYOC siRNA #2 or #3. [Figure 17C] Figure 1 shows qPCR results showing the percentage of human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with human MYOC siRNA #2 or #3. [Figure 18A] qPCR results showing the percentage of human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. [Figure 18B] qPCR results showing the percentage of Angptl7 mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. [Figure 18C] qPCR results showing the percentage of human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with AAV-SAM-g4 or no treatment (naive). [Figure 18D] qPCR results showing the percentage of human Angptl7 mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with AAV-SAM-g4 or no treatment (naive). [Figure 19A] Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with 15 μg of Angptl7 siRNA #1 or #2. [Figure 19B] qPCR results showing the percentage of human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with 15 μg of Angptl7 siRNA #1 or #2. [Figure 19C] qPCR results showing the percentage of human Angptl7 mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4 or PBS. LV-SAM-g4-treated mice were then treated with 15 μg of Angpt7 siRNA #1 or #2. [Figure 20A] 1 shows the experimental setup for testing the effects of Angptl7 siRNA #1 and #2 on intraocular pressure (IOP) in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4. [Figure 20B] Intraocular pressure (IOP) is shown in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4. The LV-SAM-g4-treated mice were then treated with 7.5 μg of Angptl7 siRNA #1 or #2 or PBS. [Figure 20C]qPCR results showing the percentage of Angptl7 and human MYOC mRNA expression relative to Gapdh in SAM mice containing a humanized MYOC locus containing the Y437H mutation (SAM-MYOC mice, homozygous for each allele) treated with LV-SAM-g4. The LV-SAM-g4-treated mice were then treated with 7.5 μg of Angptl7 siRNA #1 or #2 or PBS. DETAILED DESCRIPTION OF THE INVENTION
[0060] definition The terms "protein," "polypeptide," and "peptide," used interchangeably herein, include polymeric forms of amino acids of any length, including coded and non-coded amino acids and amino acids that are chemically or biochemically modified or derivatized. These terms also include modified polymers, such as polypeptides having modified peptide backbones. The term "domain" refers to any portion of a protein or polypeptide having a specific function or structure.
[0061] Proteins are said to have an "N-terminus" (amino terminus) and a "C-terminus" (carboxy or carboxyl terminus). The term "N-terminus" refers to the beginning of a protein or polypeptide, which ends with an amino acid having a free amine group (-NH2). The term "C-terminus" refers to the end of an amino acid chain (protein or polypeptide) terminated by a free carboxyl group (-COOH).
[0062] The terms "nucleic acid" and "polynucleotide," used interchangeably herein, include polymeric forms of nucleotides of any length, containing ribonucleotides, deoxyribonucleotides, or analogs or modified versions thereof. These include single-, double-, and multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, and polymers that contain purine bases, pyrimidine bases, or other natural, chemically modified, biochemically modified, non-natural, or derivatized nucleotide bases.
[0063] Nucleic acids are said to have a "5' end" and a "3' end" because mononucleotides react to form oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is unidirectionally linked to the 3' oxygen of its neighbor via a phosphodiester bond. An end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring. An end of an oligonucleotide is referred to as the "3' end" if its 3' oxygen is not linked to the 5' phosphate of another mononucleotide pentose ring. A nucleic acid sequence, even if it is internal to a larger oligonucleotide, can also be said to have 5' and 3' ends. In either a linear or circular DNA molecule, distinct elements are referred to as being "upstream" or "downstream" 5' or 3' elements.
[0064] The term "genomically integrated" refers to a nucleic acid that has been introduced into a cell such that the nucleotide sequence is integrated into the genome of the cell. Any protocol can be used for stable integration of a nucleic acid into the genome of a cell.
[0065] The term "expression vector" or "expression construct" or "expression cassette" refers to a recombinant nucleic acid containing a desired coding sequence operably linked to appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host cell or organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, as well as other sequences. Eukaryotic cells are well known to generally utilize promoters, enhancers, and termination and polyadenylation signals, and some elements can be deleted and others added without sacrificing the required expression.
[0066] The term "targeting vector" refers to a recombinant nucleic acid that can be introduced into a target location in the genome of a cell by homologous recombination, non-homologous end joining-mediated ligation, or any other recombinant means.
[0067] The term "viral vector" refers to a recombinant nucleic acid that contains at least one element of viral origin and contains elements sufficient for or that allow packaging into a viral vector particle. The vectors and / or particles can be used to introduce DNA, RNA, or other nucleic acids into cells in vitro, ex vivo, or in vivo. Many forms of viral vectors are known.
[0068] The term "isolated" with respect to cells, tissues (e.g., liver samples), lipid droplets, proteins, and nucleic acids includes cells, tissues (e.g., liver samples), lipid droplets, proteins, and nucleic acids that are relatively purified with respect to other bacteria, viruses, cells, or other components that may normally be present in situ, and includes up to and including substantially pure preparations of cells, tissues (e.g., liver samples), lipid droplets, proteins, and nucleic acids. The term "isolated" also includes cells, tissues (e.g., liver samples), lipid droplets, proteins, and nucleic acids that have no naturally occurring counterpart, are chemically synthesized, and therefore are substantially free from other contaminating cells, tissues (e.g., liver samples), lipid droplets, proteins, and nucleic acids, or are separated or purified from most other components (e.g., cellular or biological components) that naturally accompany them (e.g., other cellular proteins, nucleic acids, or cellular or extracellular components).
[0069] The term "wild-type" includes entities having a structure and / or activity found in a normal state or context (as opposed to mutant, diseased, altered, etc.). Wild-type genes and polypeptides often exist in multiple alternative forms (e.g., alleles).
[0070] The term "endogenous sequence" refers to a nucleic acid sequence that is naturally occurring in a rat cell or in a rat. For example, an endogenous Myoc sequence in a mouse refers to the native Myoc sequence that is naturally occurring at the Myoc locus in a mouse.
[0071] An "exogenous" molecule or sequence includes a molecule or sequence that is not normally present in a cell in that form. Normal presence includes presence with respect to a particular developmental stage and environmental conditions of the cell. An exogenous molecule or sequence can include, for example, a mutated version of a corresponding endogenous sequence in a cell, such as a humanized version of an endogenous sequence, or can include a sequence that corresponds to an endogenous sequence within the cell but in a different form (i.e., not within a chromosome). In contrast, an endogenous molecule or sequence includes a molecule or sequence that is normally present in that form in a particular cell, at a particular developmental stage, and under particular environmental conditions.
[0072] The term "heterologous" when used in the context of a nucleic acid or a protein indicates that the nucleic acid or protein comprises at least two segments that do not naturally occur together in the same molecule. For example, the term "heterologous" when used with reference to a segment of a nucleic acid or a segment of a protein indicates that the nucleic acid or protein comprises two or more subsequences that are not found in the same relationship to each other (e.g., linked together) in nature. As an example, a "heterologous" region of a nucleic acid vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with that other molecule in nature. For example, a heterologous region of a nucleic acid vector can include a coding sequence adjacent to sequences not found in association with the coding sequence in nature. Similarly, a "heterologous" region of a protein is a segment of amino acids within or attached to another peptide molecule that is not found in association with that other peptide molecule in nature (e.g., a fusion protein or a tagged protein). Similarly, a nucleic acid or protein can include a heterologous tag or a heterologous secretion or localization sequence.
[0073] "Codon optimization" refers to the process of modifying a nucleic acid sequence for enhanced expression in a particular host cell by taking advantage of codon degeneracy, as indicated by the diversity of three-base pair codon combinations that specify amino acids, generally by replacing at least one codon of the native sequence with a codon more frequently or most frequently used in the host cell's genes while maintaining the native amino acid sequence. For example, a nucleic acid encoding a myocilin protein can be modified to use alternative codons that have a higher frequency of use in a given prokaryotic or eukaryotic cell, including bacterial cells, yeast cells, human cells, non-human cells, mammalian cells, rodent cells, mouse cells, rat cells, hamster cells, or any other host cell, compared to the naturally occurring nucleic acid sequence. Codon usage tables are readily available, for example, in "codon usage databases." These tables can be applied in a variety of ways. See Nakamura et al. (2000) Nucleic Acids Res. 28(1):292, incorporated herein by reference in its entirety for all purposes. Computer algorithms are also available for codon optimization of a particular sequence for expression in a particular host (see, eg, Gene Forge).
[0074] The term "locus" refers to the specific location of a gene (or key sequence), DNA sequence, polypeptide-coding sequence, or position on a chromosome in the genome of an organism. For example, a "MYOC locus" can refer to a specific location of the MYOC gene, a MYOC DNA sequence, a myocilin-coding sequence, or a MYOC location on a chromosome in the genome of an organism that has been identified with respect to where such a sequence is located. A "MYOC locus" can include regulatory elements of the MYOC gene, including, for example, an enhancer, promoter, 5' and / or 3' untranslated region (UTR), or a combination thereof.
[0075] The term "gene" refers to a DNA sequence in a chromosome that, when naturally occurring, may contain at least one coding region and at least one non-coding region. A DNA sequence in a chromosome that encodes a product (e.g., but not limited to, an RNA product and / or a polypeptide product) may include coding regions interrupted by non-coding introns and sequences located adjacent to the coding region at both the 5' and 3' ends, such that the gene corresponds to a full-length mRNA (including 5' and 3' untranslated sequences). Additionally, other non-coding sequences, including regulatory sequences (e.g., but not limited to, promoters, enhancers, and transcription factor binding sites), polyadenylation signals, internal ribosome entry sites, silencers, insulating sequences, and matrix attachment regions, may also be present in a gene. These sequences may be adjacent (e.g., within 10 kb) or distant from the coding region of a gene, and they affect the level or rate of transcription and translation of the gene.
[0076] The term "allele" refers to variant forms of a gene. Some genes have different forms located at the same position, or locus, on a chromosome. Diploid organisms have two alleles at each locus. Each pair of alleles represents a genotype at a particular locus. A genotype is described as homozygous if there are two identical alleles at a particular locus, and heterozygous if the two alleles are different.
[0077] The "coding region" or "coding sequence" of a gene consists of the DNA or RNA portion of the gene, composed of exons, that encodes the protein. This region begins with an initiation codon at the 5' end and ends with a termination codon at the 3' end.
[0078] A "promoter" is a regulatory region of DNA that typically contains a TATA box that can direct RNA polymerase II to begin RNA synthesis at the appropriate transcription start site for a particular polynucleotide sequence. In some cases, a promoter may additionally contain other regions that affect the rate of transcription initiation. The promoter sequences disclosed herein regulate the transcription of an operably linked polynucleotide. The promoter may be active in one or more of the cell types disclosed herein (e.g., mouse cells, rat cells, pluripotent cells, one-cell stage embryos, differentiated cells, or a combination thereof). The promoter may be, for example, a constitutively active promoter, a conditional promoter, an inducible promoter, a temporally restricted promoter (e.g., a developmentally regulated promoter), or a spatially restricted promoter (e.g., a cell-specific or tissue-specific promoter). Examples of promoters can be found, for example, in International Publication No. WO 2013 / 176772, which is incorporated by reference in its entirety for all purposes.
[0079] "Operable linkage" or "operably linked" includes the juxtaposition of two or more components (e.g., a promoter and another sequence element) that allows for the normal function of both components and the potential for at least one of the components to mediate the function of at least one of the other components. For example, a promoter can be operably linked to a coding sequence if it controls the level of transcription of the coding sequence depending on the presence or absence of one or more transcriptional regulatory factors. Operable linkage can include proximity of such sequences to each other or acting in trans (e.g., regulatory sequences can act at a distance to control transcription of the coding sequence).
[0080] The methods and compositions provided herein use a variety of different components. Some components throughout the description may have active variants and fragments. The term "functional" refers to the inherent ability of a protein or nucleic acid (or a fragment or variant thereof) to exhibit biological activity or function. The biological function of a functional fragment or variant may be the same as compared to the original molecule, or may actually be altered (e.g., with respect to their specificity, selectivity, or efficacy), while retaining the basic biological function of the molecule.
[0081] The term "variant" refers to a nucleotide sequence (eg, a single nucleotide) that differs from the most common sequence in a population, or a protein sequence (eg, a single amino acid) that differs from the most common sequence in a population.
[0082] The term "fragment," when referring to a protein, refers to a protein that is shorter or has fewer amino acids than the full-length protein. The term "fragment," when referring to a nucleic acid, refers to a nucleic acid that is shorter or has fewer nucleotides than the full-length nucleic acid. A protein fragment can be, for example, an N-terminal fragment (i.e., removal of a portion of the C-terminus of the protein), a C-terminal fragment (i.e., removal of a portion of the N-terminus of the protein), or an internal fragment (i.e., removal of a portion of each of the N-terminus and C-terminus of the protein). A nucleic acid fragment can be, for example, a 5' fragment (i.e., removal of a portion of the 3' terminus of the nucleic acid), a 3' fragment (i.e., removal of a portion of the 5' terminus of the nucleic acid), or an internal fragment (i.e., removal of a portion of each of the 5' terminus and 3' terminus of the nucleic acid).
[0083] "Sequence identity" or "identity" in the context of two polynucleotide or polypeptide sequences refers to the residues of the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When using percentage sequence identity with respect to proteins, non-identical residue positions often differ by conservative amino acid substitutions, in which an amino acid residue is replaced with another amino acid residue having similar chemical properties (e.g., charge or hydrophobicity) and therefore does not alter the functional properties of the molecule. When sequences differ by conservative substitutions, the percent sequence identity may be adjusted upward to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity." Means for making this adjustment are well known. Typically, this involves scoring conservative substitutions as partial rather than complete mismatches, thereby increasing the percentage sequence identity. Thus, for example, where identical amino acids are given a score of 1 and non-conservative substitutions are given a score of 0, conservative substitutions are given a score of 0 to 1. Scoring of conservative substitutions is calculated, for example, as implemented in the program PC / GENE (Intelligenetics, Mountain View, California).
[0084] "Percentage of sequence identity" includes a value determined by comparing two optimally aligned sequences (maximum number of perfectly matched residues) over a comparison window, where the portion of the polynucleotide sequence in the comparison window may contain additions or deletions (i.e., gaps) when compared to a reference sequence (not including additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity. Unless otherwise specified (e.g., the shorter sequence includes a concatenated non-homologous sequence), the comparison window is the full length of the shorter of the two sequences being compared.
[0085] Unless otherwise specified, sequence identity / similarity values include values obtained using GAP version 10 with the following parameters: % identity and % similarity for nucleotide sequences using a GAP weight of 50 and a length weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for amino acid sequences using a GAP weight of 8 and a length weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. "Equivalent program" includes any sequence comparison program that produces alignments with identical nucleotide or amino acid residue matches and identical percent sequence identity for any two sequences in question when compared to corresponding alignments produced by GAP version 10.
[0086] The term "conservative amino acid substitution" refers to the substitution of an amino acid normally present in a sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine, or leucine for another non-polar residue. Similarly, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another, such as between arginine and lysine, between glutamine and asparagine, or between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine, or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another, are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue, e.g., isoleucine, valine, leucine, alanine, or methionine, for a polar (hydrophilic) residue, e.g., cysteine, glutamine, glutamic acid, or lysine, and / or a polar residue for a non-polar residue. Typical amino acid classifications are summarized below.
[0087] [Table 1]
[0088] A "homologous" sequence (e.g., a nucleic acid sequence) includes a sequence that is identical to or substantially similar to a known reference sequence, e.g., at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the known reference sequence. Homologous sequences can include, for example, orthologous and paralogous sequences. For example, homologous genes typically originate from a common ancestral DNA sequence through either speciation events (orthologous genes) or gene duplication events (paralogous genes). "Orthologous" genes include genes from different species that evolved from a common ancestral gene through speciation. Orthologs typically retain the same function during evolution. "Paralogous" genes include genes that are related by duplication within a genome. Paralogs can evolve new functions during evolution.
[0089] The term "in vitro" includes an artificial environment and processes or reactions that occur within an artificial environment (e.g., a test tube or an isolated cell or cell line). The term "in vivo" refers to a natural environment (e.g., an organism or body, or a cell or tissue within an organism or body) and processes or reactions that occur within a natural environment. The term "ex vivo" includes cells removed from an individual's body and processes or reactions that occur within such cells.
[0090] The term "reporter gene" refers to a nucleic acid having a sequence encoding a gene product (typically an enzyme) that is easily and quantitatively assayed when a construct containing a reporter gene sequence operably linked to a heterologous promoter and / or enhancer element is introduced into a cell that contains (or can be made to contain) the factors necessary for activation of the promoter and / or enhancer element. Examples of reporter genes include, but are not limited to, the gene encoding beta-galactosidase (lacZ), the bacterial chloramphenicol acetyltransferase (cat) gene, the firefly luciferase gene, the gene encoding beta-glucuronidase (GUS), and genes encoding fluorescent proteins. "Reporter protein" refers to the protein encoded by the reporter gene.
[0091] As used herein, the term "fluorescent reporter protein" means a reporter protein that is detectable based on fluorescence, where the fluorescence can be from either the reporter protein directly, the activity of the reporter protein on a fluorogenic substrate, or a protein that has affinity for binding to a fluorescently tagged compound. Examples of fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, Emerald, Azami Green, monomeric Azami). Green, CopGFP, AceGFP, and ZsGreenl), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, and ZsYellowl), blue fluorescent proteins (e.g., BFP, eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, and T-sapphire), cyan fluorescent proteins (e.g., CFP, eCFP, Cerulean, CyPet, AmCyanl, and Midoriishi-Cyan), red fluorescent proteins (e.g., RFP, mKate, mKate2, Examples of suitable fluorescent proteins include mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed monomer, HcRed-Tandem, HcRedl, AsRed2, eqFP611, mRaspberry, mStrawberry, and JRed), orange fluorescent proteins (e.g., mOrange, mKO, Kusabira-Orange, monomeric Kusabira-Orange, mTangerine, and tdTomato), and other suitable fluorescent proteins whose presence within a cell can be detected by flow cytometry.
[0092] Repair in response to double-strand breaks (DSBs) occurs primarily through two conserved DNA repair pathways, homologous recombination (HR) and non-homologous end joining (NHEJ). See Kasparek & Humphrey (2011) Semin. Cell Dev. Biol. 22(8):886-897, incorporated herein by reference in its entirety for all purposes. Similarly, repair of a target nucleic acid mediated by an exogenous donor nucleic acid can include any process of exchange of genetic information between two polynucleotides.
[0093] The term "recombination" includes any process of exchanging genetic information between two polynucleotides and can occur by any mechanism. Recombination can occur via homology-directed repair (HDR) or homologous recombination (HR). HDR or HR includes forms of nucleic acid repair that may require nucleotide sequence homology and use a "donor" molecule as a template for repair of a "target" molecule (i.e., a molecule that has experienced a double-strand break), resulting in the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, such transfer can involve mismatch correction of heteroduplex DNA formed between the broken target and donor, and / or synthesis-dependent strand annealing, in which the donor resynthesizes the genetic information that will become part of the target, and / or related processes. In some cases, the donor polynucleotide, a portion of the donor polynucleotide, a copy of the donor polynucleotide, or a portion of a copy of the donor polynucleotide is integrated into the target DNA. See Wang et al. (2013) Cell 153:910-918, Mandalos et al. (2012) PLoS ONE 7:e45768:1-9, and Wang et al. (2013) Nat. Biotechnol. 31:530-532, each of which is incorporated by reference in its entirety for all purposes.
[0094] Non-homologous end joining (NHEJ) involves the repair of double-strand breaks in nucleic acids by direct ligation of the cut ends to each other or to an exogenous sequence without the need for a homologous template. Ligation of non-adjacent sequences by NHEJ can often result in deletions, insertions, or translocations near the site of the double-strand break. For example, NHEJ can also result in targeted integration of an exogenous donor nucleic acid by directly ligating the cut ends to the ends of the exogenous donor nucleic acid (i.e., NHEJ-based capture). Such NHEJ-mediated targeted integration can be preferred for the insertion of exogenous donor nucleic acids when the homology-directed repair (HDR) pathway is not readily available (e.g., non-dividing cells, primary cells, and cells that perform poorly in homology-based DNA repair). In addition, in contrast to homology-directed repair, knowledge of large regions of sequence identity adjacent to the break site is not required, which can be beneficial when attempting targeted insertion into an organism with a genome with limited knowledge of the genome sequence. Integration can proceed via blunt-end ligation between the exogenous donor nucleic acid and the cleaved genomic sequence, or via sticky-end ligation (i.e., with a 5' or 3' overhang) using an exogenous donor nucleic acid adjacent to an overhang that matches that generated by the nuclease agent in the cleaved genomic sequence. See, for example, U.S. Patent Application Publication No. 2011 / 020722, International Publication No. 2014 / 033644, International Publication No. 2014 / 089290, and Maresca et al. (2013) Genome Res. 23(3):539-546, each of which is incorporated by reference in its entirety for all purposes. If blunt ends are ligated, excision of the target and / or donor may be necessary to generate regions of microhomology necessary for fragment joining, which may result in undesired modifications to the target sequence.
[0095] A composition or method "comprising" or "including" one or more recited elements may include other elements not specifically recited. For example, a composition "comprises" or "includes" a protein may include the protein alone or in combination with other components. The transitional phrase "consisting essentially of" means that the claim scope shall be construed to include the specific elements recited in the claim as well as elements that do not materially affect the basic and novel characteristics of the claimed invention. Thus, the term "consisting essentially of," when used in the claims of the present invention, is not intended to be construed as equivalent to "comprising."
[0096] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes examples when the event or circumstance occurs and examples when it does not occur.
[0097] The designation of a range of values includes every integer within or defining that range, and every subrange defined by integers within that range.
[0098] Unless otherwise clear from the context, the term "about" encompasses values that are ±5% of the stated value.
[0099] The term "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").
[0100] The term "or" refers to any one member of a particular list.
[0101] The singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "protein" or "at least one protein" can include a plurality of proteins, including mixtures thereof.
[0102] Statistically significant means p≦0.05. (Mode for Carrying Out the Invention)
[0103] I. Overview Disclosed herein are non-human animal genomes, cells, and animals containing a humanized MYOC locus, as well as methods of making and using such non-human animal cells and animals. In some such non-human animal genomes, cells, and animals, the humanized MYOC locus contains a mutation associated with glaucoma, such as the Y437H mutation. Some such non-human animal genomes, cells, and animals further contain CRISPR / Cas synergistic activation mediator system components. For example, disclosed herein are non-human animal genomes, cells, and animals containing a clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas)-based synergistic activation mediator (SAM) expression cassette and a humanized MYOC locus (e.g., containing the Y437H mutation), as well as methods of using such non-human animal cells and animals. A MYOC locus containing a Y437H mutation refers to a MYOC locus encoding a myocilin protein that contains the Y437H mutation or a mutation that corresponds to the Y437H mutation in human myocilin when the encoded myocilin protein is optimally aligned (maximum number of perfectly matched residues) with human myocilin. The nomenclature for the amino acid position of the Y437H mutation refers to the position of the mutation in the complete myocilin protein, including the signal peptide. This nomenclature is consistent with the nomenclature used in publications describing this mutation.
[0104] Also disclosed herein are humanized non-human animal MYOC genes, nucleic acids comprising humanized non-human animal MYOC genes, and targeting vectors for use in humanizing non-human animal MYOC genes.
[0105] Non-human animal cells or animals containing a humanized MYOC locus express human myocilin protein or a chimeric myocilin protein containing one or more fragments of the human myocilin protein. Such non-human animal cells and animals can be used to evaluate the delivery or efficacy of human myocilin-targeting agents (e.g., CRISPR / Cas9 genome editing agents, RNAi agents, or ASO agents) in vitro, ex vivo, or in vivo, and can be used in methods to optimize the delivery and efficacy of such agents in vitro, ex vivo, or in vivo. When SAM expression cassettes are present, they can be used to upregulate the transcription of target genes, such as the humanized MYOC gene disclosed herein, in vitro, ex vivo, or in vivo, for example, to achieve higher myocilin expression levels. Such models can be used, for example, to evaluate the delivery or efficacy of candidate therapeutic agents for glaucoma, or to evaluate the delivery or efficacy of candidate glaucoma therapeutic agents or agents for reducing intraocular pressure (IOP).
[0106] In some of the non-human animal cells and animals disclosed herein, some, most, or all of the human MYOC genomic DNA is inserted into the corresponding non-human animal MYOC locus. In some of the non-human animal cells and animals disclosed herein, some, most, or all of the non-human animal genomic DNA is replaced one-to-one with the corresponding human genomic DNA. Because conserved regulatory elements are more likely to remain intact and spliced transcripts that undergo RNA processing are more stable than cDNA, expression levels should be higher if the intron-exon structure and splicing machinery are maintained compared to non-human animals with inserted cDNA. Replacing the non-human animal genomic sequence with the corresponding human genomic sequence is likely to result in faithful expression of the transgene from the endogenous MYOC locus. Similarly, transgenic non-human animals with transgenic insertion of the human MYOC coding sequence at a random genomic locus rather than the endogenous non-human animal MYOC locus will less accurately reflect the endogenous regulation of MYOC expression. Humanized MYOC alleles, resulting from one-to-one replacement of most or all of the non-human animal genomic DNA with corresponding human genomic DNA or insertion of human MYOC genomic sequences into the corresponding non-human MYOC locus, provide the true human target or an approximation of the true human target for human MYOC-targeting reagents (e.g., CRISPR / Cas9 reagents, RNAi reagents, or ASO reagents designed to target human MYOC), thereby enabling testing of the efficacy and mechanism of action of such agents in living animals, as well as pharmacokinetic and pharmacodynamic studies in settings where the humanized protein and gene are the only versions of MYOC present.
[0107] The methods and compositions disclosed herein can optionally employ non-human animal genomes, non-human animal cells, and non-human animals that include a chimeric Cas protein expression cassette, a chimeric adaptor protein expression cassette, or a synergistic activation mediator (SAM) expression cassette (e.g., a chimeric Cas protein coding sequence and a chimeric adaptor protein sequence), such that the components are constitutively available or can be available, for example, in a tissue- or time-specific manner. The cassettes can be integrated into the genome. Such genomes, non-human animal cells, and non-human animals can also include a guide RNA expression cassette (e.g., a MYOC guide RNA expression cassette or a MYOC guide RNA array expression cassette) and / or a recombinase expression cassette, as disclosed elsewhere herein. Alternatively, one or more components (e.g., guide RNA and / or recombinase) can be introduced into cells and non-human animals by other means to induce transcriptional activation of a target gene (e.g., a humanized MYOC gene).
[0108] Because only the guide RNA needs to be introduced into the non-human animal to activate transcription of the target gene, non-human animals containing a SAM expression cassette simplify the process of upregulating the expression of a target gene (e.g., a humanized MYOC gene) in vivo. If the non-human animal also contains a guide RNA expression cassette, the effect of target gene activation or upregulation can be studied without introducing any additional components. In addition, the SAM expression cassette or guide RNA expression cassette can optionally be a conditional expression cassette that can be selectively expressed in specific tissues or developmental stages, which can, for example, reduce the risk of Cas-mediated toxicity in vivo. Alternatively, such expression cassettes can be constitutively expressed to enable testing of activity in all kinds of cells, tissues, and organs.
[0109] Non-human animal genomes, non-human animal cells, and non-human animals are provided that include a humanized MYOC locus (e.g., including the Y437H mutation described elsewhere herein) and one or more nucleic acids encoding a chimeric Cas protein, a chimeric adaptor protein, a guide RNA, a recombinase, or any combination thereof (any combination of such SAM system nucleic acids). The non-human animal genome, non-human animal cell, or non-human animal can be male or female.
[0110] A non-human animal genome, non-human animal cell, or non-human animal can be heterozygous or homozygous for a humanized MYOC locus (e.g., comprising a Y437H mutation). Diploid organisms have two alleles at each locus. Each pair of alleles represents a genotype at a particular locus. A genotype is described as homozygous if there are two identical alleles at a particular locus and heterozygous if the two alleles are different. A non-human animal comprising a humanized MYOC locus (e.g., comprising a Y437H mutation described herein) can comprise the humanized MYOC locus in its germline.
[0111] The SAM nucleic acid or expression cassette can be stably integrated into the genome (i.e., chromosomally) of the non-human animal cell or non-human animal, or can be located outside of a chromosome (e.g., the DNA is replicated extrachromosomally). The SAM nucleic acid or expression cassette can be randomly integrated into the genome of the non-human animal (i.e., transgenic), or can be integrated into a predetermined region of the genome of the non-human animal (e.g., a safe harbor locus) (i.e., knock-in). The target genomic locus into which the SAM nucleic acid or expression cassette is stably integrated can be heterozygous for the nucleic acid or expression cassette, or homozygous for the nucleic acid or expression cassette. A non-human animal containing a stably integrated SAM nucleic acid or expression cassette described herein can contain the nucleic acid or expression cassette in its germline.
[0112] For example, a non-human animal genome, a non-human animal cell, or a non-human animal can comprise a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, or a synergistic activation mediator (SAM) expression cassette (comprising both a chimeric Cas protein coding sequence and a chimeric adapter protein sequence) disclosed herein. In one example, a non-human animal genome, a non-human animal cell, or a non-human animal comprises a SAM expression cassette comprising both a chimeric Cas protein coding sequence and a chimeric adapter protein coding sequence. In one example, the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adapter protein expression cassette) is stably integrated into the genome. The stably integrated SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adapter protein expression cassette) can be randomly integrated into the genome of the non-human animal (i.e., transgenic) or can be integrated into a predetermined region of the genome of the non-human animal (i.e., knock-in). In one example, the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adapter protein expression cassette) is stably integrated into a predetermined region of the genome, such as a safe harbor locus (e.g., Rosa26). The target genomic locus into which the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adapter protein expression cassette) is stably integrated can be heterozygous or homozygous for the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adapter protein expression cassette).
[0113] Optionally, the non-human animal genome, non-human animal cell, or non-human animal described above can further comprise one or more guide RNA expression cassettes or guide RNA expression cassettes (e.g., guide RNA array expression cassettes). The guide RNA expression cassette can be stably integrated into the genome of the non-human animal cell or non-human animal (i.e., chromosomally), or can be located outside of the chromosome (e.g., by extrachromosomally replicating DNA or by introducing it into the non-human animal cell or non-human animal via AAV, LNP, or any other means disclosed herein). The guide RNA expression cassette can be randomly integrated into the genome of the non-human animal (i.e., transgenic) or can be integrated into a predetermined region of the genome of the non-human animal (e.g., a safe harbor locus) (i.e., knock-in). The target genomic locus into which the guide RNA expression cassette is stably integrated can be heterozygous or homozygous for the guide RNA expression cassette. In one example, the genome, cell, or non-human animal includes both a SAM expression cassette (or a chimeric Cas protein expression cassette or a chimeric adaptor protein expression cassette) and a guide RNA expression cassette. In one example, both cassettes are integrated into the genome. The guide RNA expression cassette can be integrated into a different target genomic locus than the SAM expression cassette (or the chimeric Cas protein expression cassette or the chimeric adaptor protein expression cassette), or can be integrated into the genome at the same target locus (e.g., the Rosa26 locus, such as integrated into the first intron of the Rosa26 locus). For example, the non-human animal genome, non-human animal cell, or non-human animal can be heterozygous for each of the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adaptor protein expression cassette) and the guide RNA expression cassette, and have one allele of the target genomic locus (e.g., Rosa26) that includes the SAM expression cassette (or chimeric Cas protein expression cassette or chimeric adaptor protein expression cassette) and a second allele of the target genomic locus (e.g., Rosa26) that includes the guide RNA expression cassette expression cassette.
[0114] Optionally, any of the non-human animal genomes, non-human animal cells, or non-human animals described above can further comprise a recombinase expression cassette. The recombinase expression cassette can be stably integrated into the genome (i.e., chromosomally) of the non-human animal cell or non-human animal, or can be located outside of the chromosome (e.g., by extrachromosomally replicating DNA or by introducing it into the non-human animal cell or non-human animal via AAV, LNP, HDD, or any other means disclosed herein). The recombinase expression cassette can be randomly integrated into the genome of the non-human animal (i.e., transgenic) or can be integrated into a predetermined region of the genome of the non-human animal (e.g., a safe harbor locus) (i.e., knock-in). The target genomic locus into which the recombinase expression cassette is stably integrated can be heterozygous or homozygous for the recombinase expression cassette. The recombinase expression cassette can be integrated into a different target genomic locus than any of the other expression cassettes disclosed herein, or can be integrated into the genome at the same target locus (e.g., the Rosa26 locus, such as integrated into the first intron of the Rosa26 locus).
[0115] Some non-human animals or non-human animal cells described herein (e.g., non-human animals or non-human animal cells comprising a humanized MYOC locus, a SAM expression cassette, and one or more SAM guide RNAs (or one or more SAM guide RNA expression cassettes) targeting the humanized MYOC locus) have increased human MYOC mRNA or protein expression relative to control non-human animals or non-human animal cells (e.g., non-human animals or non-human animal cells comprising a humanized MYOC locus described herein but that have not been administered one or more SAM guide RNAs). In some non-human animals or non-human animal cells, the increase in expression is at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 11-fold, at least about 12-fold, at least about 13-fold, at least about 14-fold, or at least about 15-fold (e.g., at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold). In some non-human animals or non-human animal cells, increased expression is at least about 2-fold to at least about 25-fold, at least about 3-fold to at least about 25-fold, at least about 4-fold to at least about 25-fold, at least about 5-fold to at least about 25-fold, at least about 6-fold to at least about 25-fold, at least about 7-fold to at least about 25-fold, at least about 8-fold to at least about 25-fold, at least about 9-fold to at least about 25-fold, at least about 10-fold to at least about 25-fold, at least about 2-fold to at least about 20-fold, at least about 2-fold to at least about 15-fold, or at least about 10-fold to at least about 15-fold. Increased human MYOC mRNA or protein expression relative to a control non-human animal can be in the eye, limbal ring, retina, ciliary body, trabecular meshwork, or cornea. In specific examples, increased expression is in the limbal ring (trabecular meshwork (TM), iris, and ciliary body (CB)).
[0116] Some non-human animals or non-human animal cells described herein (e.g., non-human animals or non-human animal cells comprising a humanized MYOC locus, a SAM expression cassette, and one or more SAM guide RNAs (or one or more SAM guide RNA expression cassettes) targeting the humanized MYOC locus) exhibit one or more signs or symptoms of glaucoma. Glaucoma is a chronic optic neuropathy characterized by the progressive loss of retinal ganglion cell (RGC) axons, resulting in irreversible vision loss. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Elevated IOP is caused by increased resistance to aqueous humor outflow through the trabecular meshwork (TM). Aqueous humor is produced by the ciliary body, circulates through the anterior chamber, and drains through the TM meshwork. In most cases of glaucoma, there is increased resistance to aqueous humor in the TM. Pathogenic MYOC mutant proteins aggregate intracellularly, leading to trabecular meshwork (TM) stress, elevated IOP, and glaucoma. Elevated levels of ER stress-inducible proteins have been detected in human glaucomatous TM cells.
[0117] In some non-human animals, the IOP is at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, or at least about 20, at least about 21, or at least about 22 mmHg (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg). In one example, the IOP is about 15 to about 22, about 16 to about 22, about 17 to about 22, about 18 to about 22, about 19 to about 22, about 15 to about 21, about 15 to about 20, or about 16 to about 21 mmHg (e.g., 15 to 22, 16 to 22, 17 to 22, 18 to 22, 19 to 22, 15 to 21, 15 to 20, or 16 to 21 mmHg).
[0118] In some non-human animals, IOP is increased relative to a control non-human animal (e.g., a non-human animal having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or a wild-type non-human animal). In one example, IOP is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, or at least about 6 mmHg (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg) above control baseline in the control non-human animal. In one example, IOP is about 1 to about 7, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 5 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 4 to about 6, or about 5 to about 6 mmHg (e.g., 1 to 6, 2 to 6, 3 to 6, 4 to 6, or 5 to 6 mmHg) above control baseline in the control non-human animal. The control baseline can be, for example, IOP in a non-human animal having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or it can be IOP in a wild-type non-human animal, or it can be IOP in a non-human animal having a humanized MYOC locus described herein but prior to administration of one or more SAM guide RNAs targeting the humanized MYOC locus.
[0119] In some non-human animals, endoplasmic reticulum (ER) stress is increased relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals). Some non-human animals exhibit signs and symptoms of glaucoma as measured by pattern electroretinogram (PERG). Some non-human animals exhibit retinal ganglion cell (RGC) loss relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals). Some non-human animals exhibit increased aqueous humor outflow resistance relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals).
[0120] The MYOC glaucoma model with transgenic overexpression of human myocilin Y437H exhibits an IOP increase of only approximately 2-3 mmHg, even though MYOC is expressed ubiquitously. Additionally, the IOP phenotype is lost during reproduction. The model described herein has the advantage that expression is largely restricted to the trabecular meshwork, the target tissue of disease pathology. Additionally, a further increase in IOP of approximately 5-6 mmHg is observed.
[0121] II. Non-human animals containing a humanized MYOC locus The nucleic acids, non-human animal genomes, non-human animal cells, and non-human animals disclosed herein contain a humanized MYOC locus (e.g., containing the Y437H mutation described herein). Cells or non-human animals containing a humanized MYOC locus express a human myocilin protein or a partially humanized chimeric myocilin protein in which one or more fragments of the native myocilin protein have been replaced with corresponding fragments from human myocilin.
[0122] A. Myocilin (MYOC) The non-human animal genomes, non-human animal cells, and non-human animals disclosed herein contain a humanized MYOC locus. Myocilin (also known as trabecular meshwork-inducible glucocorticoid-responsive protein or MYOC) is encoded by the MYOC gene (also known as GLC1A or TIGR). Myocilin is a secreted glycoprotein (55-57 kDa). MYOC was first reported as a glucocorticoid-inducible gene and protein in cultured human trabecular meshwork (TM) cells. Myocilin mRNA and / or protein are expressed in ocular structures, including the retina, ciliary body, and trabecular meshwork. It may perform a structural function within the cytoplasm or associate with other molecules intracellularly, possibly as a molecular chaperone. Extracellularly, it may be involved in generating resistance to aqueous humor outflow by binding to other extracellular molecules or the plasma membrane of TM cells.
[0123] Many MYOC mutations cause myocilin to accumulate in TM cells, leading to glaucoma. Mutations in myocilin are the most common genetic cause of primary open-angle glaucoma, the most common form of glaucoma. However, the underlying mechanism of MYOC-related glaucoma is not fully understood. The main risk factor for glaucoma is elevated intraocular pressure (IOP), which can be caused by increased resistance to aqueous humor outflow through TM structures. Myocilin is expressed in many ocular tissues, including TM cells and the ciliary body, which are capable of secreting myocilin into aqueous humor. Many different myocilin mutations have been identified. The Y437H mutation is one mutation associated with elevated IOP and the development of glaucoma.
[0124] Human MYOC maps to chromosome 1 at 1q24.3 (NCBI RefSeq Gene ID 4653, Assembly GRCh38.p13 (GCF_000001405.39), location NC_000001.11 (171635417..171652688, complement)). The gene is reported to have three exons. The wild-type human myocilin protein has been assigned UniProt accession number Q99972. The sequence of the canonical wild-type isoform myocilin (NCBI accession number NP_000252.1) is set forth in SEQ ID NO: 1. The mRNA (cDNA) encoding the canonical isoform has been assigned NCBI accession number NM_000261.2 and is set forth in SEQ ID NO: 2. An exemplary coding sequence (CDS) is set forth in SEQ ID NO: 3 (CCDS ID CCDS1297.1). The full-length human myocilin protein set forth in SEQ ID NO:1 has 504 amino acids, including the signal peptide (amino acids 1-32) and mature myocilin (amino acids 33-504), which produces an N-terminal fragment (33-226) and a C-terminal fragment (227-504) after cleavage by CAPN2 in the endoplasmic reticulum following amino acid 226. Delineation between these domains is as specified in UniProt. Reference to human myocilin includes the canonical (wild-type) form as well as all allelic forms and isoforms. Any other form of human myocilin has amino acids numbered for maximum alignment with the wild-type form, and aligned amino acids are designated with the same number. An exemplary human myocilin protein containing the Y437H mutation is set forth in SEQ ID NO:4. An exemplary coding sequence for a human myocilin protein containing the Y437H mutation is set forth in SEQ ID NO:5.
[0125] Mouse Myoc maps to chromosome 1 at 1 H2.1;1 70.29 cM (NCBI RefSeq Gene ID 17926, Assembly GRCm39 (GCF_000001635.27), location NC_000067.7 (162466719..162477263)). The gene is reported to have three exons. The wild-type mouse myocilin protein has been assigned UniProt accession number O70624. The sequence of the canonical isoform, NCBI accession number NP_034995.3, is set forth in 6. An exemplary mRNA (cDNA) isoform encoding the canonical isoform has been assigned NCBI accession number NM_010865.3 and is set forth in SEQ ID NO:7. An exemplary coding sequence (CDS) (CCDS ID CCDS15422.1) is set forth in SEQ ID NO:8. The full-length mouse myocilin protein, set forth in SEQ ID NO:6, has 490 amino acids, including the signal peptide (amino acids 1-18) and mature myocilin (amino acids 19-490), which produces an N-terminal fragment (19-212) and a C-terminal fragment (213-490) after cleavage by CAPN2 in the endoplasmic reticulum following amino acid 212. Delineation between these domains is as specified in UniProt. Reference to mouse myocilin includes the canonical (wild-type) form and all allelic forms and isoforms. Any other form of mouse myocilin has amino acids numbered relative to maximum alignment with the wild-type form, with aligned amino acids indicated by the same number.
[0126] Rat Myoc maps to chromosome 13 at 13q22 (NCBI RefSeq Gene ID 81523, Assembly mRatBN7.2 (GCF_015227675.2), location NC_051348.1 (74976730..74987128)). The gene is reported to have three exons. The wild-type rat myocilin protein has been assigned UniProt accession number Q9R1J4. The sequence of the canonical isoform, NCBI accession number NP_110492.1, is set forth in SEQ ID NO: 9. The mRNA (cDNA) encoding the canonical isoform has been assigned NCBI accession number NM_030865.1 and is set forth in SEQ ID NO: 10. An exemplary coding sequence (CDS) encoding the canonical isoform is set forth in SEQ ID NO: 11. The sequence of another isoform, NCBI Accession Number NP_110492.2, is set forth in SEQ ID NO: 12. The mRNA (cDNA) encoding this isoform has been assigned NCBI Accession Number NM_030865.2 and is set forth in SEQ ID NO: 13. An exemplary coding sequence (CDS) encoding this isoform is set forth in SEQ ID NO: 14. The canonical full-length rat myocilin protein, set forth in SEQ ID NO: 9, has 502 amino acids, including a signal peptide (amino acids 1-31) and mature myocilin (amino acids 32-502), which produces an N-terminal fragment (32-225) and a C-terminal fragment (226-502) after cleavage by CAPN2 in the endoplasmic reticulum following amino acid 225. The delineation between these domains is as specified in UniProt. Reference to rat myocilin includes the canonical (wild-type) form and all allelic forms and isoforms. Any other form of rat myocilin has its amino acids numbered for maximum alignment with the wild-type form, and aligned amino acids are designated with the same number.
[0127] B. Humanized MYOC locus Disclosed herein is a humanized endogenous MYOC locus in which a segment of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence (e.g., a corresponding human MYOC genomic sequence), and a humanized myocilin protein is expressed from the humanized endogenous MYOC locus. The corresponding human MYOC sequence may contain a mutation, such as a mutation associated with glaucoma (e.g., a mutation that causes glaucoma). One example of such a mutation is the Y437H mutation. Nearly 100 different pathogenic MYOC mutations have been identified, the majority of which are clustered in exon 3, which encodes the olfactomedin domain. Examples of such mutations include Y437H, G364V, and Q368X. See, e.g., Lynch et al. (2018) J. Biol. Chem. 293(52):20137-20156, and Jain et al. (2017) Proc. Natl. Acad. Sci. USA 114(42):11199-11204, each of which is incorporated by reference in its entirety for all purposes.
[0128] A humanized MYOC locus can be a MYOC locus in which the entire MYOC gene is replaced with a corresponding human MYOC sequence (e.g., a corresponding orthologous human MYOC sequence) or a codon-optimized version of the corresponding human MYOC sequence, or a MYOC locus in which only a portion of the MYOC gene is replaced with a corresponding human MYOC sequence (i.e., humanized) or a codon-optimized version of the corresponding human MYOC sequence, or a MYOC locus in which a portion of the corresponding human MYOC locus or a codon-optimized version of the corresponding human MYOC locus is inserted, or a MYOC locus in which a portion of the MYOC gene is deleted and a portion of the corresponding human MYOC locus or a codon-optimized version of the corresponding human MYOC locus is inserted. The inserted portion of the corresponding human MYOC locus can, for example, include more of the human MYOC locus than is deleted from the endogenous MYOC locus. A human MYOC sequence corresponding to a particular segment of the endogenous MYOC sequence refers to a region of human MYOC that aligns with a particular segment of the endogenous MYOC sequence when the two sequences are optimally aligned (maximum number of perfectly matched residues). The corresponding human sequence can include, for example, complementary DNA (cDNA) or genomic DNA. Optionally, a codon-optimized version of the corresponding human MYOC sequence can be used, modified to be codon-optimized based on codon usage in the non-human animal. The replaced or inserted (i.e., humanized) region can include coding regions such as exons, non-coding regions such as introns, untranslated regions, or regulatory regions (e.g., promoters, enhancers, or transcriptional repressor-binding elements), or any combination thereof. For example, exons corresponding to one, two, or all three exons of the human MYOC gene can be humanized. For example, exons corresponding to exons 1-3 of the human MYOC gene can be humanized.Alternatively, the region of MYOC encoding the epitope recognized by an anti-human myocilin antigen-binding protein or the region targeted by a human myocilin targeting reagent (e.g., a small molecule) can be humanized. Similarly, introns corresponding to one or all two introns of the human MYOC gene can be humanized or can remain endogenous. For example, the intron corresponding to the intron between exons 1 and 3 of the human MYOC gene (i.e., introns 1-2) can be humanized.
[0129] The adjacent untranslated regions containing regulatory sequences can also be humanized or remain endogenous. For example, the 5' untranslated region (UTR), the 3' UTR, or both the 5' UTR and 3' UTR can be humanized, or the 5' UTR, the 3' UTR, or both the 5' UTR and 3' UTR can remain endogenous. One or both of the human 5' and 3' UTRs can be inserted, and / or one or both of the endogenous 5' and 3' UTRs can be deleted. In a specific example, the human 3' UTR is inserted, and the 5' UTR remains endogenous. Depending on the degree of replacement with the corresponding human sequence, regulatory sequences such as promoters can be endogenous or provided by the corresponding replacing human sequence. For example, a humanized MYOC locus can include an endogenous non-human animal MYOC promoter (i.e., the inserted human MYOC sequence of the humanized MYOC coding sequence can be operably linked to the endogenous non-human animal MYOC promoter).
[0130] One or more or all of the signal peptide, mature myocilin, N-terminal fragment, or C-terminal fragment can be humanized, or one or more of such regions can remain endogenous. Exemplary coding sequences for mouse myocilin signal peptide, mature myocilin, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 31-34, respectively. Exemplary coding sequences for rat myocilin signal peptide, mature myocilin, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 39-42, respectively. Exemplary coding sequences for human myocilin signal peptide, mature myocilin, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 21-24, respectively. An exemplary coding sequence for human mature myocilin containing a Y437H mutation is set forth in SEQ ID NO: 25. An exemplary coding sequence for human myocilin C-terminal fragment containing a Y437H mutation is set forth in SEQ ID NO: 26.
[0131] For example, all or a portion of the region of the MYOC locus encoding the signal peptide can be humanized, and / or all or a portion of the region of the MYOC locus encoding the C-terminal fragment can be humanized, and / or all or a portion of the region of the MYOC locus encoding the N-terminal fragment domain can be humanized, and / or all or a portion of the region of the MYOC locus encoding the mature myocilin protein can be humanized. In one example, all of the region of the MYOC locus encoding the myocilin protein (including the signal peptide and mature myocilin) is humanized. Optionally, the CDS of the human myocilin protein comprises a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 5 (or a degenerate version thereof)). Optionally, the CDS of the human myocilin protein consists essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 5 (or a degenerate version thereof)). Optionally, the CDS of the human myocilin protein consists of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 5 (or a degenerate version thereof)). The myocilin protein can be expressed and retain the activity of native myocilin and / or human myocilin.
[0132] One or more of the regions encoding the signal peptide, the mature myocilin protein, the N-terminal fragment, or the C-terminal fragment may remain endogenous, for example, the region encoding the signal peptide may remain endogenous.
[0133] The myocilin protein encoded by the humanized MYOC locus can include one or more domains derived from the human myocilin protein and / or one or more domains derived from an endogenous (i.e., native) myocilin protein. Exemplary amino acid sequences for the mouse myocilin signal peptide, mature myocilin protein, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 27-30, respectively. Exemplary coding sequences for the rat myocilin signal peptide, mature myocilin protein, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 35-38, respectively. Exemplary amino acid sequences for the human myocilin signal peptide, mature myocilin protein, N-terminal fragment, and C-terminal fragment are set forth in SEQ ID NOs: 15-18, respectively. An exemplary coding sequence for a human mature myocilin protein containing a Y437H mutation is set forth in SEQ ID NO: 19. An exemplary amino acid sequence for a human myocilin C-terminal fragment containing a Y437H mutation is set forth in SEQ ID NO: 20.
[0134] The myocilin protein can include one or more or all of a human myocilin signal peptide, a human myocilin C-terminal fragment, a human myocilin N-terminal fragment, and a human mature myocilin protein. By way of example, the myocilin protein encoded by the humanized MYOC locus can be a complete human myocilin protein (i.e., the signal peptide and the mature myocilin protein).
[0135] The myocilin protein encoded by the humanized MYOC locus can also include one or more domains derived from an endogenous (i.e., naturally occurring) non-human animal myocilin protein.
[0136] A domain in a chimeric or fully human myocilin protein derived from a human myocilin protein can be encoded by a fully humanized sequence (i.e., the entire sequence encoding the domain is replaced with the corresponding human MYOC sequence) or a partially humanized sequence (i.e., a portion of the sequence encoding the domain is replaced with the corresponding human MYOC sequence, and the remaining endogenous (i.e., native) sequence encoding the domain encodes the same amino acids as the corresponding human MYOC sequence, such that the encoded domain is identical to that domain in the human myocilin protein). Similarly, a domain in a chimeric protein derived from an endogenous myocilin protein can be encoded by a fully endogenous sequence (i.e., the entire sequence encoding the domain is the endogenous MYOC sequence) or a partially humanized sequence (i.e., a portion of the sequence encoding the domain is replaced with the corresponding human MYOC sequence, but the corresponding human MYOC sequence encodes the same amino acids as the replaced endogenous MYOC sequence, such that the encoded domain is identical to that domain in the endogenous albumin protein).
[0137] As an example, the myocilin protein encoded by the humanized MYOC locus can include the complete human myocilin protein (i.e., the signal peptide and the mature myocilin protein). The myocilin protein is expressed and retains the activity of native myocilin and / or human myocilin.
[0138] For example, the myocilin protein encoded by the humanized MYOC locus can include a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:4). As another example, the myocilin protein encoded by the humanized MYOC locus can consist essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:4). As another example, the myocilin protein encoded by the humanized MYOC locus can consist of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:4). Optionally, the MYOC coding sequence (CDS) of the humanized MYOC locus can comprise a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:5 (or a degenerate version thereof).Optionally, the MYOC coding sequence (CDS) of the humanized MYOC locus can consist essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:5 (or a degenerate version thereof). Optionally, the MYOC coding sequence (CDS) of the humanized MYOC locus can consist of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:5 (or a degenerate version thereof) (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO:5 (or a degenerate version thereof). In either case, a myocilin protein can be expressed that retains the activity of native myocilin and / or human myocilin.
[0139] Optionally, the humanized MYOC locus can include other elements. Examples of such elements can include a selection cassette, a reporter gene, a recombinase recognition site, or other elements. Alternatively, the humanized MYOC locus can lack other elements (e.g., it can lack a selection marker or selection cassette). Examples of suitable reporter genes and reporter proteins are disclosed elsewhere herein. Examples of suitable selection markers include neomycin phosphotransferase (neomycin phosphotransferase). r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puromycin-N-acetyltransferase, puro r), blasticidin S deaminase (bsr r ), xanthine / guanine phosphoribosyltransferase (gpt), or herpes simplex virus thymidine kinase (HSV-k). Examples of recombinases include Cre, Flp, and Dre recombinase. One example of a Cre recombinase gene is Crei, in which two exons encoding Cre recombinase are separated by an intron, preventing expression in prokaryotic cells. Such recombinases may further contain a nuclear localization signal to promote nuclear localization (e.g., NLS-Crei). Recombinase recognition sites include nucleotide sequences that can be recognized by a site-specific recombinase and serve as substrates for recombination events. Examples of recombinase recognition sites include FRT, FRT11, FRT71, attp, att, rox, and lox sites such as loxP, lox511, lox2272, lox66, lox71, loxM2, and lox5171.
[0140] Other elements, such as a reporter gene or selection cassette, may be a self-deletion cassette flanked by recombinase recognition sites. See, for example, U.S. Patent No. 8,697,851 and U.S. Patent Application Publication No. 2013 / 0312129, each of which is incorporated by reference in its entirety for all purposes. By way of example, the self-deletion cassette may contain a Crei gene (comprising two exons encoding Cre recombinase separated by an intron) operably linked to the mouse Prm1 promoter and a neomycin resistance gene operably linked to the human ubiquitin promoter. By employing the Prm1 promoter, the self-deletion cassette can be specifically deleted in the male germ cells of F0 animals. A polynucleotide encoding a selection marker may be operably linked to a promoter active in the targeted cells. Examples of promoters are described elsewhere herein. As another specific example, a self-deleting selection cassette can include a hygromycin resistance gene coding sequence operably linked to one or more promoters (e.g., both the human ubiquitin and EM7 promoters), followed by a polyadenylation signal, followed by a Crei coding sequence operably linked to one or more promoters (e.g., the mPrm1 promoter), followed by another polyadenylation signal, with the entire cassette flanked by loxP sites.
[0141] The humanized MYOC locus can also be a conditional allele. For example, the conditional allele can be a multifunctional allele, as described in U.S. Patent Application Publication No. 2011 / 0104799, which is incorporated by reference in its entirety for all purposes. For example, the conditional allele can include (a) an actuating sequence in the sense orientation relative to transcription of the target gene, (b) a drug selection cassette (DSC) in the sense or antisense orientation, (c) a nucleotide sequence of interest (NSI) in the antisense orientation, and (d) a conditional by inversion module (COIN, utilizing modules such as exon split introns and invertible gene traps) in the reverse orientation. See, e.g., U.S. Patent Application Publication No. 2011 / 0104799. The conditional allele can further comprise recombinable units that recombine upon exposure to a first recombinase to form a conditional allele that (i) lacks an actuating sequence and a DSC, and (ii) comprises an NSI in a sense orientation and a COIN in an antisense orientation. See, e.g., U.S. Patent Application Publication No. 2011 / 0104799.
[0142] One exemplary humanized MYOC locus (e.g., a humanized mouse MYOC locus) comprises the human MYOC 3'UTR, with the region from the start and stop codons replaced with the corresponding human sequence from the start codon through the stop codon. See Figure 1 and SEQ ID NOs: 88 and 89. Exemplary sequences of the humanized MYOC locus are set forth in SEQ ID NOs: 88 and 89.
[0143] In one specific example, the human MYOC sequence in the humanized endogenous MYOC locus can comprise a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 87 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 87). In another specific example, the humanized MYOC locus can encode a protein comprising a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 4). In another specific example, the humanized MYOC locus can comprise a coding sequence that comprises a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 5 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 5). In another specific example, the humanized MYOC locus can include a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 88 or 89 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 88 or 89).
[0144] In one specific example, the human MYOC sequence in the humanized endogenous MYOC locus can consist essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 87 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 87). In another specific example, the humanized MYOC locus can encode a protein that essentially consists of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO:4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:4). In another specific example, the humanized MYOC locus can include a coding sequence that consists essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO:5 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:5). In another specific example, the humanized MYOC locus can consist essentially of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 88 or 89 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 88 or 89).
[0145] In one specific example, the human MYOC sequence in the humanized endogenous MYOC locus can consist of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 87 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 87). In another specific example, the humanized MYOC locus can encode a protein consisting of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 4 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 4). In another specific example, the humanized MYOC locus can comprise a coding sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 5 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 5). In another specific example, the humanized MYOC locus can consist of a sequence that is at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the sequence set forth in SEQ ID NO: 88 or 89 (e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 88 or 89).
[0146] C. Non-human animal genomes, non-human animal cells, and non-human animals containing a humanized MYOC locus Non-human animal genomes, non-human animal cells, and non-human animals are provided that contain the humanized MYOC locus described elsewhere herein. The genome, cell, or non-human animal can express a humanized myocilin protein encoded by the humanized MYOC locus. The genome, cell, or non-human animal can be male or female. The genome, cell, or non-human animal can be heterozygous or homozygous for the humanized MYOC locus. Diploid organisms have two alleles at each locus. Each pair of alleles represents a genotype at a particular locus. A genotype is described as homozygous if there are two identical alleles at a particular locus and heterozygous if the two alleles are different. A non-human animal containing a humanized MYOC locus can contain the humanized MYOC locus in its germline.
[0147] The non-human animal genomes or cells provided herein can be, for example, any non-human animal genome or cell that contains the MYOC locus or a genomic locus homologous or orthologous to the human MYOC locus. The genome can be derived from or can be a eukaryotic cell, including, for example, an animal cell, a mammalian cell, a non-human mammalian cell, and a human cell. The term "animal" includes any member of the animal kingdom, including, for example, mammals, fish, reptiles, amphibians, birds, and worms. The mammalian cell can be, for example, a non-human mammalian cell, a rodent cell, a rat cell, or a mouse cell. Other non-human mammals include, for example, non-human primates. The term "non-human" excludes humans.
[0148] Cells can also be in any type of undifferentiated or differentiated state. For example, cells can be totipotent cells, pluripotent cells (e.g., human pluripotent cells or non-human pluripotent cells such as mouse embryonic stem (ES) cells or rat ES cells), or non-pluripotent cells (e.g., non-ES cells). Totipotent cells include undifferentiated cells that can give rise to any cell type, while pluripotent cells include undifferentiated cells that have the ability to develop into two or more differentiated cell types. Such pluripotent and / or totipotent cells can be, for example, ES cells or ES-like cells, such as induced pluripotent stem (iPS) cells. ES cells include embryo-derived totipotent or pluripotent cells that, upon introduction into an embryo, can contribute to any tissue of the developing embryo. ES cells can be derived from the inner cell mass of a blastocyst and are capable of differentiating into cells of any of the three vertebrate germ layers (endoderm, ectoderm, and mesoderm).
[0149] The cells provided herein can also be germ cells (e.g., sperm or oocytes). The cells can be mitotically competent or mitotically inactive, meiotically competent or meiotically inactive. Similarly, the cells can also be primary somatic cells or cells that are not primary somatic cells. Somatic cells include any cell that is not a gamete, germ cell, gamete cell, or undifferentiated stem cell. For example, the cells can be ocular cells, such as trabecular meshwork cells.
[0150] Suitable cells provided herein also include primary cells. Primary cells include cells or cell cultures directly isolated from an organism, organ, or tissue. Primary cells include cells that have not been transformed or immortalized. They include any cells obtained from an organism, organ, or tissue that have not previously been passaged in tissue culture, or that have previously been passaged in tissue culture but cannot be passaged indefinitely in tissue culture. For example, primary cells can be ocular cells, such as trabecular meshwork cells.
[0151] Other suitable cells provided herein include immortalized cells. Immortalized cells also include cells from multicellular organisms that do not normally proliferate indefinitely, but that, due to mutations or modifications, can avoid normal cellular senescence and instead continue to divide. Such mutations or modifications can occur naturally or can be intentionally induced. Many types of immortalized cells are known. Immortalized or primary cells typically include cells used for culture or expression of recombinant genes or proteins.
[0152] The cells provided herein also include one-cell stage embryos (i.e., fertilized oocytes or zygotes). Such one-cell stage embryos can be from any genetic background (e.g., in the case of mice, BALB / c, C57BL / 6, 129, or combinations thereof), can be fresh or frozen, and can be derived from natural breeding or in vitro fertilization.
[0153] The cells provided herein can be normal, healthy cells, or can be diseased or harboring mutations.
[0154] Non-human animals comprising the humanized MYOC locus described herein can be produced by methods described elsewhere herein. The term "animal" includes any member of the animal kingdom, including, for example, mammals, fish, reptiles, amphibians, birds, and insects. In a specific example, the non-human animal is a non-human mammal. Non-human mammals include, for example, non-human primates and rodents (e.g., mice and rats). The term "non-human animal" excludes humans. Preferred non-human animals include, for example, rodents such as mice and rats.
[0155] Non-human animals can be from any genetic background. For example, suitable mice can be from the 129 strain, the C57BL / 6 strain, a hybrid of 129 and C57BL / 6, a BALB / c strain, or a Swiss-Webster strain. Examples of 129 strains include 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1 / SV, 129S1 / Svlm), 129S2, 129S4, 129S5, 129S9 / SvEvH, 129S6 (129 / SvEvTac), 129S7, 129S8, 129T1, and 129T2. See, for example, Festing et al. (1999) Mamm. Genome 10(8):836, incorporated herein by reference in its entirety for all purposes. Examples of C57BL strains include C57BL / A, C57BL / An, C57BL / GrFa, C57BL / Kal_wN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr, and C57BL / Ola. Suitable mice can also be hybrids of the aforementioned 129 strain and the aforementioned C57BL / 6 strain (e.g., 50% 129 and 50% C57BL / 6). Similarly, suitable mice can be hybrids of the aforementioned 129 strain or hybrids of the aforementioned BL / 6 strain (e.g., 129S6 (129 / SvEvTac) strain).
[0156] Similarly, rats may be from, for example, the ACI rat strain, the Dark Agouti (DA) rat strain, the Wistar rat strain, the LEA rat strain, the Sprague Dawley (SD) rat strain, or the Fisher rat strain, such as Fisher F344 or Fisher F6. Rats may also be obtained from strains derived from crossbreeds of two or more of the above-mentioned strains. For example, suitable rats may be from the DA strain or the ACI strain. The ACI rat strain has a white belly and paws, and an RT1 av1The Dark Agouti (DA) rat strain is characterized by the presence of the black agouti coat and RT1 haplotype. Such strains are available from a variety of sources, including Harlan Laboratories. av1 The rats are characterized by having a haplotype. Such rats are available from various sources, including Charles River and Harlan Laboratories. Some suitable rats may be derived from inbred rat strains. See, for example, U.S. Patent Application Publication No. 2014 / 0235933, the entire contents of which are incorporated herein by reference for all purposes.
[0157] Some non-human animals or non-human animal cells described herein exhibit one or more signs or symptoms of glaucoma. Glaucoma is a chronic optic neuropathy characterized by the progressive loss of retinal ganglion cell (RGC) axons, resulting in irreversible vision loss. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Elevated IOP is caused by increased resistance to aqueous humor outflow through the trabecular meshwork (TM). Aqueous humor is produced by the ciliary body, circulates in the anterior chamber, and drains through the TM meshwork. In most cases of glaucoma, there is increased resistance to aqueous humor in the TM. Pathogenic MYOC mutant proteins aggregate intracellularly, leading to trabecular meshwork (TM) stress, elevated IOP, and glaucoma. Elevated levels of ER stress-induced proteins have been detected in human glaucomatous TM cells.
[0158] In some non-human animals, the IOP is at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, or at least about 22 mmHg (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg). In one example, the IOP is about 15 to about 22, about 16 to about 22, about 17 to about 22, about 18 to about 22, about 19 to about 22, about 15 to about 21, about 15 to about 20, or about 16 to about 21 mmHg (e.g., 15 to 22, 16 to 22, 17 to 22, 18 to 22, 19 to 22, 15 to 21, 15 to 20, or 16 to 21 mmHg).
[0159] In some non-human animals, IOP is increased relative to a control non-human animal (e.g., a non-human animal having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs targeting the humanized MYOC locus, or a wild-type non-human animal). In one example, IOP is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, or at least about 6 mmHg (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg) above control baseline in the control non-human animal. In one example, IOP is about 1 to about 7, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 5 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 4 to about 6, or about 5 to about 6 mmHg (e.g., 1 to 6, 2 to 6, 3 to 6, 4 to 6, or 5 to 6 mmHg) above control baseline in the control non-human animal. The control baseline can be, for example, IOP in a non-human animal having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or it can be IOP in a wild-type non-human animal, or it can be IOP in a non-human animal having a humanized MYOC locus described herein prior to administration of one or more SAM guide RNAs.
[0160] In some non-human animals, endoplasmic reticulum (ER) stress is increased relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals). Some non-human animals exhibit signs and symptoms of glaucoma as measured by pattern electroretinogram (PERG). Some non-human animals exhibit retinal ganglion cell (RGC) loss relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals). Some non-human animals exhibit increased aqueous humor outflow resistance relative to control non-human animals (e.g., non-human animals having a humanized MYOC locus described herein but not administered one or more SAM guide RNAs, or wild-type non-human animals).
[0161] III. Non-human animals containing a synergistic activation mediator (SAM) expression cassette The non-human animal genomes, non-human animal cells, and non-human animals disclosed herein also include clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas)-based synergistic activation mediator (SAM) expression cassettes for use in methods for activating transcription of a target gene, such as the humanized MYOC gene disclosed herein, in vitro, ex vivo, or in vitro. The SAM system described herein includes a chimeric Cas protein and a chimeric adapter protein and can be used with guide RNAs described elsewhere herein to activate transcription of a target gene, such as the humanized MYOC gene disclosed herein. The guide RNA can be encoded by an expression cassette integrated into the genome or can be provided by AAV or any other suitable means. Chimeric Cas proteins (e.g., chimeric Cas proteins such as a chimeric Streptococcus pyogenes Cas9 protein, a chimeric Campylobacter jejuni Cas9 protein, or a chimeric Cas9 protein derived from a Staphylococcus aureus Cas9 protein) and chimeric adaptor proteins (e.g., adaptor proteins that specifically bind to an adaptor binding element in a guide RNA and include one or more heterologous transcription activation domains) are described in further detail elsewhere herein.
[0162] A CRISPR / Cas system includes transcripts and other elements involved in directing the expression or activity of Cas genes. CRISPR / Cas systems can be, for example, Type I, Type II, Type III, or Type V systems (e.g., subtype VA or subtype VB). CRISPR / Cas systems used in the compositions and methods disclosed herein can be non-naturally occurring. A "non-naturally occurring" system includes any that exhibits the hand of man, such as one or more components of the system being modified or mutated from their naturally occurring state, being at least substantially free of at least one other component with which they are naturally associated, or being associated with at least one other component with which they are not naturally associated. For example, some CRISPR / Cas systems employ non-naturally occurring CRISPR complexes that include non-naturally occurring gRNAs and Cas proteins together, employ non-naturally occurring Cas proteins, or employ non-naturally occurring gRNAs.
[0163] The methods and compositions disclosed herein employ the CRISPR / Cas system by using or testing the ability of a CRISPR complex (comprising a guide RNA (gRNA) complexed with a chimeric Cas protein and a chimeric adaptor protein) to induce transcriptional activation of a target genomic locus in vivo.
[0164] The non-human animal genomes, non-human animal cells, and non-human animals disclosed herein can comprise a chimeric Cas protein expression cassette and / or a chimeric adaptor protein expression cassette. For example, the non-human animal genomes, non-human animal cells, and non-human animals disclosed herein can comprise a synergistic activation mediator (SAM) expression cassette comprising a chimeric Cas protein coding sequence and a chimeric adaptor protein coding sequence.
[0165] Such non-human animal genomes, non-human animal cells, or non-human animals containing a SAM expression cassette have the advantage of only requiring the delivery of a guide RNA to induce transcriptional activation of a target genomic locus. Some such non-human animal genomes, non-human animal cells, or non-human animals also contain one or more guide RNA expression cassettes or guide RNA expression cassettes, so that all components required for transcriptional activation of a target gene are already present. The SAM system can be used in such cells to increase the expression of target genes in any desired manner. For example, the expression of one or more target genes can be increased in a constitutive manner or in a regulated manner (e.g., inducible, tissue-specific, temporally regulated, etc.).
[0166] A. Chimeric Cas Proteins Chimeric Cas proteins are provided that can bind to a guide RNA and activate transcription of a target gene, as disclosed elsewhere herein. Such chimeric Cas proteins can include (a) a DNA-binding domain that is a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein or a functional fragment or variant thereof, capable of forming a complex with the guide RNA and binding to a target sequence, and (b) one or more transcription activation domains or functional fragments or variants thereof. For example, such fusion proteins can include one, two, three, four, five, or more transcription activation domains (e.g., two or more heterologous transcription activation domains or three or more heterologous transcription activation domains). In one example, the chimeric Cas protein can include a catalytically inactive Cas protein (e.g., dCas9) and a VP64 transcription activation domain or a functional fragment or variant thereof. For example, such chimeric Cas proteins can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the dCas9-VP64 chimeric Cas protein sequence set forth in SEQ ID NO: 43. However, chimeric Cas proteins are also provided in which the transcription activation domain comprises other transcription activation domains or functional fragments or variants thereof and / or the Cas protein comprises other Cas proteins (e.g., catalytically inactive Cas proteins). Examples of other suitable transcription activation domains are provided elsewhere herein.
[0167] The transcription activation domain can be located at the N-terminus, C-terminus, or anywhere within the Cas protein. For example, when optimally aligned with the S. pyogenes Cas9 protein, the transcription activation domain can bind to the Rec1 domain, Rec2 domain, HNH domain, or PI domain of the Streptococcus pyogenes Cas9 protein, or any corresponding region of an orthologous Cas9 protein or homologous or orthologous Cas protein. For example, the transcription activation domain can bind to the Rec1 domain at position 553, the Rec1 domain at position 575, or the Rec2 domain at any position within positions 175-306 of the S. pyogenes Cas9 protein, or replace part or all of the region within positions 175-306, the HNH domain at any position within positions 715-901, or replace part or all of the region within positions 715-901, or the PI domain at position 1153. See, e.g., WO 2016 / 049258, which is incorporated by reference in its entirety for all purposes. The transcription activation domain may be flanked on one or both sides by one or more linkers, as described elsewhere herein.
[0168] The chimeric Cas protein can also be operably linked or fused to an additional heterologous polypeptide. The fused or linked heterologous polypeptide can be located at the N-terminus, C-terminus, or anywhere internal to the chimeric Cas protein. For example, the chimeric Cas protein can further comprise a nuclear localization signal. Examples of suitable nuclear localization signals and other modifications to Cas proteins are described in more detail elsewhere herein.
[0169] (1) Cas protein Cas proteins generally contain at least one RNA recognition or binding domain that can interact with a guide RNA. A functional fragment or variant of a Cas protein is one that retains the ability to form a complex with a guide RNA and bind to a target sequence in a target gene (e.g., activate transcription of the target gene).
[0170] In addition to the transcription activation domain described elsewhere herein, Cas proteins can also include a nuclease domain (e.g., a DNase domain or an RNase domain), a DNA-binding domain, a helicase domain, a protein-protein interaction domain, a dimerization domain, and other domains. Some such domains (e.g., a DNase domain) can be derived from a naturally occurring Cas protein. Other such domains can be added to create modified Cas proteins. The nuclease domain has catalytic activity for nucleic acid cleavage, including covalent cleavage of nucleic acid molecules. Cleavage can generate blunt or staggered ends and can be single-stranded or double-stranded. For example, wild-type Cas9 proteins typically generate blunt-end cleavage products. Alternatively, wild-type Cpf1 proteins (e.g., FnCpf1) can result in cleavage products with a 5-nucleotide 5' overhang, with cleavage occurring after the 18th base pair from the PAM sequence on the non-target strand and after the 23rd base on the target strand. The Cas protein can have full cleavage activity and generate a double-stranded break at the target genomic locus (e.g., a double-stranded break with a blunt end), or it can be a nickase that generates a single-stranded break at the target genomic locus. In one example, the Cas protein portion of a chimeric Cas protein disclosed herein is modified to have reduced nuclease activity (e.g., nuclease activity is reduced by at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% compared to the wild-type Cas protein), or to lack substantially all nuclease activity (i.e., nuclease activity is reduced by at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% compared to the wild-type Cas protein, or has about 0% or less, about 1% or less, about 2% or less, about 3% or less, about 5% or less, or about 10% or less of the nuclease activity of the wild-type Cas protein).A nuclease-inactive Cas protein is a Cas protein that either has a mutation in its catalytic (i.e., nuclease) domain that is known to be an inactivating mutation (e.g., inactivating mutation in the RuvC-like endonuclease domain of the Cpfl protein, or inactivating mutation in both the HNH endonuclease domain and the RuvC-like endonuclease domain in Cas9), or has nuclease activity that is reduced by at least about 97%, at least about 98%, at least about 99%, or 100% compared to the wild-type Cas protein. Examples of different Cas protein mutations to reduce or substantially eliminate nuclease activity are disclosed below.
[0171] Examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), ), Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, and homologs or modified versions thereof.
[0172] An exemplary Cas protein is a Cas9 protein or a protein derived from a Cas9 protein. Cas9 proteins are derived from type II CRISPR / Cas systems and typically share four key motifs with a conserved architecture: motifs 1, 2, and 4 are RuvC-like motifs, and motif 3 is an HNH motif. Exemplary Cas9 proteins are Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Staphylococcus aureus, Nocardiopsis dassonvillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Synechococcus sp., Acetohalobium arabaticum, Ammonifex degensii, Caldicelulosiruptor becscii, Candidatus Desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculum thermopropionicum, Acidithiobacillus caldus, Acidithiobacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp., Nitrosococcus halophilus, Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp., Petrotoga mobilis, Thermosipho africanus, Acaryochloris marina, Neisseria meningitidis, or Campylobacter jejuni. Additional examples of Cas9 family members are described in WO 2014 / 131833, which is incorporated by reference in its entirety for all purposes. Cas9 from S. pyogenes (SpCas9), assigned SwissProt accession number Q99ZW2, is an exemplary Cas9 protein. S.Cas9 from S. aureus (SaCas9) (assigned UniProt accession number J7RUA5) is another exemplary Cas9 protein. Cas9 from Campylobacter jejuni (CjCas9) (assigned UniProt accession number Q0P897) is another exemplary Cas9 protein. See, e.g., Kim et al. (2017) Nat. Comm. 8:14500, which is incorporated by reference in its entirety for all purposes. SaCas9 is smaller than SpCas9, and CjCas9 is smaller than both SaCas9 and SpCas9. Cas9 from Neisseria meningitidis (Nme2Cas9) is another exemplary Cas9 protein. See, e.g., Edraki et al. (2019) Mol. Cell 73(4):714-726, which is incorporated by reference in its entirety for all purposes. Cas9 proteins from Streptococcus thermophilus (e.g., Streptococcus thermophilus LMD-9 Cas9 encoded by the CRISPR1 locus (St1Cas9) or Streptococcus thermophilus Cas9 encoded by the CRISPR3 locus (St3Cas9) are other exemplary Cas9 proteins. Cas9 from Francisella novicida (FnCas9) or the RHA Francisella novicida Cas9 variant (E1369R / E1449H / R1556A substitutions) that recognizes an alternative PAM are other exemplary Cas9 proteins. These and other exemplary Cas9 proteins are reviewed, for example, in Cebrian-Serrano and Davies (2017) Mamm. Genome 28(7):247-261, which is incorporated by reference in its entirety for all purposes.
[0173] Another example of a Cas protein is the Cpf1 (CRISPR from Prevotella and Francisella 1) protein. Cpf1 is a large protein (approximately 1300 amino acids) that contains a RuvC-like nuclease domain homologous to the corresponding domain in Cas9, along with a counterpart of Cas9's characteristic arginine-rich cluster. However, Cpf1 lacks the HNH nuclease domain present in Cas9 proteins, and in contrast to Cas9, which contains a long insert containing the HNH domain, the RuvC-like domain is adjacent in the Cpf1 sequence. See, e.g., Zetsche et al. (2015) Cell 163(3):759-771, incorporated herein by reference in its entirety for all purposes. Exemplary Cpf1 proteins are Francisella tularensis 1, Francisella tularensis subsp.novicida, Prevotella albensis, Lachnospiraceae bacterium MC2017 1, Butyrivibrio proteoclasticus, Peregrinibacteria bacterium GW2011_GWA2_33_10, Parcubacteria bacterium GW2011_GWC2_44_17, Smithella sp.SCADC, Acidaminococcus sp.BV3L6, Lachnospiraceae bacterium MA2020, Candidatus Methanoplasma termitum, Eubacterium eligens, Moraxella bovoculi 237, Leptospira inadai, Lachnospiraceae bacterium ND2006, Porphyromonas crevioricanis Cpf1 from Francisella novicida U112 (FnCpf1, assigned UniProt accession number A0Q7Q2) is an exemplary Cpf1 protein.
[0174] The Cas protein can be a wild-type protein (i.e., naturally occurring), a modified Cas protein (i.e., a Cas protein variant), or a fragment of a wild-type or modified Cas protein. The Cas protein can also be an active variant or fragment with respect to catalytic activity of the wild-type or modified Cas protein. An active variant or fragment with respect to catalytic activity can comprise at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more sequence identity with the wild-type or modified Cas protein or portion thereof, and the active variant retains the ability to cleave at the desired cleavage site and thus retains nick-inducing or double-strand break-inducing activity. Assays for nick-inducing or double-strand break-inducing activity are known and generally measure the overall activity and specificity of the Cas protein on a DNA substrate containing the cleavage site.
[0175] One example of a modified Cas protein is the modified SpCas9-HF1 protein, which is a high-fidelity variant of Streptococcus pyogenes Cas9 with modifications (N497A / R661A / Q695A / Q926A) designed to reduce nonspecific DNA contacts. See, e.g., Kleinstiver et al. (2016) Nature 529(7587):490-495, incorporated herein by reference in its entirety for all purposes. Another example of a modified Cas protein is the modified eSpCas9 variant (K848A / K1003A / R1060A) designed to reduce off-target effects. See, e.g., Slaymaker et al. (2016) Science 351(6268):84-88, incorporated herein by reference in its entirety for all purposes. Other SpCas9 variants include K855A and K810A / K1003A / R1060A. These and other modified Cas proteins are reviewed, for example, in Cebrian-Serrano and Davies (2017) Mamm. Genome 28(7):247-261, which is incorporated by reference in its entirety for all purposes. Another example of a modified Cas9 protein is xCas9, an SpCas9 variant capable of recognizing an expanded range of PAM sequences. See, for example, Hu et al. (2018) Nature 556:57-63, which is incorporated by reference in its entirety for all purposes.
[0176] Cas proteins can be modified to increase or decrease one or more of nucleic acid binding affinity, nucleic acid binding specificity, and enzymatic activity. Cas proteins can also be modified to alter other activities or properties of the protein, such as stability. For example, one or more nuclease domains of a Cas protein can be modified, deleted, or inactivated, or the Cas protein can be truncated to remove domains that are not essential for protein function, or an activity or property of a Cas protein can be optimized (e.g., enhanced or reduced).
[0177] Cas proteins can contain at least one nuclease domain, such as a DNase domain. For example, wild-type Cpf1 proteins generally contain a RuvC-like domain, likely in a dimeric conformation, that cleaves both strands of target DNA. Cas proteins can also contain at least two nuclease domains, such as a DNase domain. For example, wild-type Cas9 proteins generally contain a RuvC-like nuclease domain and an HNH-like nuclease domain. The RuvC domain and the HNH domain can each cleave different strands of double-stranded DNA, creating a double-strand break in the DNA. See, e.g., Jinek et al. (2012) Science 337(6096):816-821, incorporated herein by reference in its entirety for all purposes.
[0178] One or more or all of the nuclease domains can be deleted or mutated so that they no longer function or have reduced nuclease activity. For example, if one of the nuclease domains is deleted or mutated in a Cas9 protein, the resulting Cas9 protein can be called a nickase and can generate single-strand breaks in double-stranded target DNA but cannot generate double-strand breaks (i.e., it can cleave either the complementary strand or the non-complementary strand, but not both). If both nuclease domains are deleted or mutated, the resulting Cas protein (e.g., Cas9) has reduced ability to cleave both strands of double-stranded DNA (e.g., a nuclease-null or nuclease-inactive Cas protein, or a Cas protein without catalytic activity (dCas)). An example of a mutation that converts Cas9 into a nickase is the D10A (alanine to aspartic acid at position 10 of Cas9) mutation in the RuvC domain of Cas9 from S. pyogenes. Similarly, H939A (histidine to alanine at amino acid position 839), H840A (histidine to alanine at amino acid position 840), or N863A (asparagine to alanine at amino acid position N863) in the HNH domain of Cas9 from S. pyogenes can convert Cas9 into a nickase. Other examples of mutations that convert Cas9 into a nickase include corresponding mutations in Cas9 from S. thermophilus. See, e.g., Sapranauskas et al. (2011) Nucleic Acids Res. 39(21):9275-9282 and WO 2013 / 141680, each of which is incorporated by reference in its entirety for all purposes. Such mutations can be generated using methods such as site-directed mutagenesis, PCR-mediated mutagenesis, or total gene synthesis. Examples of other nickase-generating mutations can be found, for example, in WO 2013 / 176772 and WO 2013 / 142578, each of which is incorporated by reference in its entirety for all purposes.When all of the nuclease domains are deleted or mutated in a Cas protein (e.g., both nuclease domains are deleted or mutated in a Cas9 protein), the resulting Cas protein (e.g., Cas9) has a reduced ability to cleave both strands of double-stranded DNA (e.g., a nuclease-null or nuclease-inactive Cas protein). One specific example is the D10A / H840AS.pyogenes Cas9 double mutant, or the corresponding double mutant of a Cas9 from another species when optimally aligned with S.pyogenes Cas9. Another specific example is the D10A / N863AS.pyogenes Cas9 double mutant, or the corresponding double mutant of a Cas9 from another species when optimally aligned with S.pyogenes Cas9. An example of a catalytically inactive Cas9 protein (dCas9) comprises, consists essentially of, or consists of an amino acid sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the dCas9 protein sequence set forth in SEQ ID NO:44.
[0179] Examples of inactivating mutations in the catalytic domain of xCas9 are the same as those described above for SpCas9. Examples of inactivating mutations in the catalytic domain of the Staphylococcus aureus Cas9 protein are also known. For example, the Staphylococcus aureus Cas9 enzyme (SaCas9) can contain substitutions at position N580 (e.g., an N580A substitution) and at position D10 (e.g., a D10A substitution) to generate a nuclease-inactive Cas protein. See, for example, International Publication No. 2016 / 106236, incorporated herein by reference in its entirety for all purposes. Examples of inactivating mutations in the catalytic domain of Nme2Cas9 are also known (e.g., a combination of D16A and H588A). Examples of inactivating mutations in the catalytic domain of St1Cas9 are also known (e.g., a combination of D9A, D598A, H599A, and N622A). Examples of inactivating mutations in the catalytic domain of St3Cas9 are also known (e.g., a combination of D10A and N870A). Examples of inactivating mutations in the catalytic domain of CjCas9 are also known (e.g., a combination of D8A and H559A). Examples of inactivating mutations in the catalytic domain of FnCas9 and RHA FnCas9 are also known (e.g., N995A).
[0180] Examples of inactivating mutations in the catalytic domain of the Cpf1 protein are also known. For the Cpf1 proteins from Francisella novicida U112 (FnCpf1), Acidaminococcus sp. BV3L6 (AsCpf1), Lachnospiraceae bacterium ND2006 (LbCpf1), and Moraxella bovoculi 237 (MbCpf1 Cpf1), such mutations can include mutations at positions 908, 993, or 1263 of AsCpf1 or corresponding positions in Cpf1 orthologs, or at positions 832, 925, 947, or 1180 of LbCpf1 or corresponding positions in Cpf1 orthologs. Such mutations can include, for example, one or more of the mutations D908A, E993A, and D1263A in AsCpf1 or corresponding mutations in Cpf1 orthologs, or D832A, E925A, D947A, and D1180A in LbCpf1 or corresponding mutations in Cpf1 orthologs. See, e.g., U.S. Patent Application Publication No. 2016 / 0208243, which is incorporated by reference in its entirety for all purposes.
[0181] Cas proteins can also be operably linked to heterologous polypeptides as fusion proteins. For example, in addition to a transcription activation domain, Cas proteins can be fused to a cleavage domain or an epigenetic modification domain. See WO 2014 / 089290, the entire contents of which are incorporated herein by reference for all purposes. Cas proteins can also be fused to heterologous polypeptides that provide increased or decreased stability. The fusion domain or heterologous polypeptide can be located at the N-terminus, C-terminus, or internally within the Cas protein.
[0182] As an example, a Cas protein can be fused to one or more heterologous polypeptides that provide subcellular localization. Such heterologous polypeptides can include one or more nuclear localization signals (NLSs), such as a monopartite SV40 NLS and / or a bipartite alpha importin NLS for targeting to the nucleus, a mitochondrial localization signal for targeting to mitochondria, an ER retention signal, etc. See, for example, Lange et al. (2007) J. Biol. Chem. 282(8):5101-5105, incorporated herein by reference in its entirety for all purposes. Such subcellular localization signals can be located at the N-terminus, C-terminus, or anywhere within the Cas protein. The NLS can include a stretch of basic amino acids and can be a mono- or bi-karyotic sequence. Optionally, the Cas protein can comprise two or more NLSs, including an N-terminal NLS (e.g., an alpha-importin NLS or a monokaryotic NLS) and a C-terminal NLS (e.g., an SV40 NLS or a bikaryotic NLS). The Cas protein can also comprise two or more NLSs at the N-terminus and / or two or more NLSs at the C-terminus.
[0183] The Cas protein can also be operably linked to a cell penetration domain or protein transduction domain. For example, the cell penetration domain can be derived from the HIV-1 TAT protein, the TLM cell penetration motif from human hepatitis B virus, MPG, Pep-1, VP22, a cell penetration peptide from herpes simplex virus, or a polyarginine peptide sequence. See, for example, WO 2014 / 089290 and WO 2013 / 176772, each of which is incorporated by reference in its entirety for all purposes. The cell penetration domain can be located at the N-terminus, C-terminus, or anywhere within the Cas protein.
[0184] The Cas protein may also be operably linked to a heterologous polypeptide, such as a fluorescent protein, a purification tag, or an epitope tag, to facilitate tracking or purification. Examples of fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, Emerald, Azami Green, Monomeric Azami). Green, CopGFP, AceGFP, ZsGreenl), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, ZsYellowl), blue fluorescent proteins (e.g., eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., eCFP, Cerulean, CyPet, AmCyanl, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRedl, AsRed2, eqFP611, mRaspberry, mStrawberry, Jred), orange fluorescent proteins (e.g., mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato), and any other suitable fluorescent proteins.Examples of tags include glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, hemagglutinin (HA), nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, histidine (His), biotin carboxyl carrier protein (BCCP), and calmodulin.
[0185] The Cas protein can be tethered to a labeled nucleic acid. Such tethering (i.e., physical linkage) can be achieved through covalent or non-covalent interactions, and the tethering can be direct (e.g., through direct fusion or chemical conjugation, which can be achieved by modification of cysteine or lysine residues on the protein or intein modifications) or can be achieved through one or more intervening linker or adapter molecules, such as streptavidin or aptamers. See, for example, Pierce et al. (2005) Mini Rev. Med. Chem. 5(1):41-55, Duckworth et al. (2007) Angew. Chem. Int. Ed. Engl. 46(46):8819-8822, Schaeffer and Dixon (2009) Australian J. Chem. 62(10):1328-1332, Goodman et al. (2009) Chembiochem. 10(9):1551-1557, and Khatwani et al. (2012) Bioorg. Med. Chem. 20(14):4532-4539, each of which is incorporated by reference in its entirety for all purposes. Non-covalent strategies for synthesizing protein-nucleic acid conjugates include biotin-streptavidin and nickel-histidine methods. Covalent protein-nucleic acid conjugates can be synthesized by connecting appropriately functionalized nucleic acids and proteins using a variety of chemistries. Some of these chemistries involve direct attachment of oligonucleotides to amino acid residues on the protein surface (e.g., lysine amines or cysteine thiols), while other, more complex schemes require post-translational modifications of the protein or the involvement of catalytic or reactive protein domains. Methods for covalently attaching proteins to nucleic acids can include, for example, chemical crosslinking of oligonucleotides to protein lysine or cysteine residues, expressed protein ligation, chemoenzymatic methods, and the use of photoaptamers. Labeled nucleic acids can be tethered to the C-terminus, N-terminus, or internal regions of the Cas protein.In one example, the labeled nucleic acid is tethered to the C-terminus or N-terminus of the Cas protein. Similarly, the Cas protein can be tethered to the 5'-terminus, 3'-terminus, or internal region of the labeled nucleic acid. That is, the labeled nucleic acid can be tethered in any orientation and polarity. For example, the Cas protein can be tethered to the 5'-terminus or 3'-terminus of the labeled nucleic acid.
[0186] (2) Transcriptional activation domain The chimeric Cas proteins disclosed herein can comprise one or more transcription activation domains. Transcription activation domains include regions of naturally occurring transcription factors that, in conjunction with a DNA-binding domain (e.g., a catalytically inactive Cas protein complexed with a guide RNA), can activate transcription from a promoter by contacting the transcription machinery directly or through other proteins, such as coactivators. Transcription activation domains also include functional fragments or variants of such regions of transcription factors, as well as engineered transcription activation domains derived from native, naturally occurring transcription activation domains or artificially generated or synthesized to activate transcription of a target gene. A functional fragment is a fragment that can activate transcription of a target gene when operably linked to a suitable DNA-binding domain. A functional variant is a variant that can activate transcription of a target gene when operably linked to a suitable DNA-binding domain.
[0187] Particular transcription activation domains for use in the chimeric Cas proteins disclosed herein include the VP64 transcription activation domain or a functional fragment or variant thereof. VP64 is a tetrameric repeat of the minimal activation domain from the herpes simplex VP16 activation domain. For example, the transcription activation domain can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VP64 transcription activation domain protein sequence set forth in SEQ ID NO:45.
[0188] Other examples of transcription activation domains include herpes simplex virus VP16 transactivation domain, VP64 (four-fold tandem repeat of herpes simplex virus VP16), NF-κB p65 (NF-κB transactivation subunit p65) activation domain, MyoD1 transactivation domain, HSF1 transactivation domain (transactivation domain from human heat shock factor 1), RTA (Epstein-Barr virus R transactivation domain), SET7 / 9 transactivation domain, p53 activation domain 1, p53 activation domain 2, CREB (cAMP response element binding protein) activation domain, E2A activation domain, NFAT (nuclear factor of activated T cells) activation domain, and functional fragments and variants thereof. See, e.g., U.S. Patent Application Publication No. 2016 / 0298125, U.S. Patent Application Publication No. 2016 / 0281072, and WO 2016 / 049258, each of which is incorporated by reference in its entirety for all purposes. Other examples of transcription activation domains include Gcn4, MLL, Rtg3, Gln3, Oaf1, Pip2, Pdr1, Pdr3, Pho4, Leu3, and functional fragments and variants thereof. See, e.g., U.S. Patent Application Publication No. 2016 / 0298125, which is incorporated by reference in its entirety for all purposes. Still other examples of transcription activation domains include Sp1, Vax, GATA4, and functional fragments and variants thereof. See, e.g., WO 2016 / 149484, which is incorporated by reference in its entirety for all purposes. Other examples include activation domains from Oct1, Oct-2A, AP-2, CTF1, P300, CBP, PCAF, SRC1, PvALF, ERF-2, OsGAI, HALF-1, C1, AP1, ARF-5, ARF-6, ARF-7, ARF-8, CPRF1, CPRF4, MYC-RP / GP, and TRAB1PC4, and functional fragments and variants thereof. See, e.g., U.S. Patent Application Publication No. 2016 / 0237456, European Patent Application No. 3045537, and International Publication No. WO 2011 / 146121, each of which is incorporated by reference in its entirety for all purposes.Additional suitable transcription activation domains are known, see, e.g., WO 2011 / 146121, which is incorporated by reference in its entirety for all purposes.
[0189] B. Chimeric Adapter Protein Also provided are chimeric adapter proteins capable of binding to guide RNAs disclosed elsewhere herein. The chimeric adapter proteins disclosed herein are useful in dCas-synergistic activation mediator (SAM)-like systems to increase the number and diversity of transcription activation domains directed to target sequences within target genes to activate transcription of the target genes. Nucleic acids encoding the chimeric adapter proteins can be integrated into the genome of cells or non-human animals (e.g., cells or non-human animals comprising a chimeric Cas protein expression cassette integrated into their genome) as disclosed elsewhere herein, or the chimeric adapter proteins or nucleic acids can be introduced into such cells and non-human animals using methods disclosed elsewhere herein (e.g., LNP-mediated delivery or AAV-mediated delivery).
[0190] Such a chimeric adapter protein comprises (a) an adapter (i.e., an adapter domain or adapter protein) that specifically binds to an adapter-binding element in the guide RNA, and (b) one or more heterologous transcriptional activation domains. For example, such a fusion protein can comprise one, two, three, four, five, or more transcriptional activation domains (e.g., two or more heterologous transcriptional activation domains). In one example, such a chimeric adapter protein can comprise (a) an adapter (i.e., an adapter domain or adapter protein) that specifically binds to an adapter-binding element in the guide RNA, and (b) two or more heterologous transcriptional activation domains. For example, the chimeric adapter protein can comprise (a) an MS2 coat protein adapter that specifically binds to one or more MS2 aptamers in the guide RNA (e.g., two MS2 aptamers at distinct locations in the guide RNA), and (b) one or more (e.g., two or more transcriptional activation domains). For example, the two transcriptional activation domains can be p65 and HSF1 transcriptional activation domains, or functional fragments or variants thereof. However, chimeric adapter proteins are also provided in which the transcription activation domain comprises other transcription activation domains or functional fragments or variants thereof.
[0191] One or more transcription activation domains can be fused directly to the adapter. Alternatively, one or more transcription activation domains can be linked to the adapter via a linker or a combination of linkers, or via one or more additional domains. Similarly, when two or more transcription activation domains are present, they can be fused directly to each other, or linked to each other via a linker or a combination of linkers, or via one or more additional domains. Linkers that can be used in these fusion proteins can include any sequence that does not interfere with the function of the fusion protein. Exemplary linkers are short (e.g., 2-20 amino acids) and typically flexible (e.g., containing flexible amino acids such as glycine, alanine, and serine). Some specific examples of linkers include one or more units of GGGS (SEQ ID NO: 46) or GGGGS (SEQ ID NO: 47), for example, two, three, four, or more repeats of GGGS (SEQ ID NO: 46) or GGGGS (SEQ ID NO: 47) in any combination. Other linker sequences can also be used.
[0192] The one or more transcription activation domains and adapters can be in any order within the chimeric adapter protein. As one option, the one or more transcription activation domains can be C-terminal to the adapter, and the adapter can be N-terminal to the one or more transcription activation domains. For example, the one or more transcription activation domains can be C-terminal to the chimeric adapter protein, and the adapter can be N-terminal to the chimeric adapter protein. However, the one or more transcription activation domains can be C-terminal to the adapter without being C-terminal to the chimeric adapter protein (e.g., when a nuclear localization signal is C-terminal to the chimeric adapter protein). Similarly, the adapter can be N-terminal to the one or more transcription activation domains without being N-terminal to the chimeric adapter protein (e.g., when a nuclear localization signal is N-terminal to the chimeric adapter protein). As another option, the one or more transcription activation domains can be N-terminal to the adapter, and the adapter can be C-terminal to the one or more transcription activation domains. For example, the one or more transcription activation domains can be N-terminal to the chimeric adapter protein, and the adapter can be C-terminal to the chimeric adapter protein. As a further alternative, when a chimeric adapter protein comprises two or more transcription activation domains, the two or more transcription activation domains can flank the adapter.
[0193] The chimeric adapter protein can also be operably linked or fused to an additional heterologous polypeptide. The fused or linked heterologous polypeptide can be located at the N-terminus, C-terminus, or anywhere internal to the chimeric adapter protein. For example, the chimeric adapter protein can further comprise a nuclear localization signal. A specific example of such a protein includes MS2 coat protein (adapter) linked (either directly or via an NLS) to the C-terminus of the p65 transcription activation domain of the MS2 coat protein (MCP) and to the C-terminus of the HSF1 transcription activation domain of the p65 transcription activation domain. Such a protein can comprise, from N-terminus to C-terminus, MCP, a nuclear localization signal, a p65 transcription activation domain, and an HSF1 transcription activation domain. For example, the chimeric adapter protein can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the MCP-p65-HSF1 chimeric adapter protein sequence set forth in SEQ ID NO:48.
[0194] The chimeric adapter protein can also be fused or linked to one or more heterologous polypeptides that provide subcellular localization. Such heterologous polypeptides can include, for example, one or more nuclear localization signals (NLSs), such as the SV40 NLS and / or the alpha-importin NLS, for targeting to the nucleus, a mitochondrial localization signal for targeting to mitochondria, an ER retention signal, etc. See, for example, Lange et al. (2007) J. Biol. Chem. 282:5101-5105, which is incorporated herein by reference in its entirety for all purposes. The NLS can include, for example, a stretch of basic amino acids and can be a monokaryotic or bikaryotic sequence. Optionally, the chimeric adapter protein includes two or more NLSs, including an N-terminal NLS (e.g., an alpha-importin NLS) and / or a C-terminal NLS (e.g., an SV40 NLS).
[0195] The chimeric adapter protein can also be operably linked to a cell penetration domain or protein transduction domain. For example, the cell penetration domain can be derived from the HIV-1 TAT protein, the TLM cell penetration motif from human hepatitis B virus, MPG, Pep-1, VP22, a cell penetration peptide from herpes simplex virus, or a polyarginine peptide sequence. See, for example, WO 2014 / 089290 and WO 2013 / 176772, each of which is incorporated by reference in its entirety for all purposes. As another example, the chimeric adapter protein can be fused or linked to a heterologous polypeptide to provide increased or decreased stability.
[0196] The chimeric adapter protein may also be operably linked to a heterologous polypeptide, such as a fluorescent protein, a purification tag, or an epitope tag, to facilitate tracking or purification. Examples of fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, Emerald, Azami Green, Monomeric Azami). Green, CopGFP, AceGFP, ZsGreenl), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, ZsYellowl), blue fluorescent proteins (e.g., eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., eCFP, Cerulean, CyPet, AmCyanl, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRedl, AsRed2, eqFP611, mRaspberry, mStrawberry, Jred), orange fluorescent proteins (e.g., mOrange, mKO, Kusabira-Orange, Monomeric Examples of tags include glutathione-S-transferase (GST), chitin-binding protein (CBP), maltose-binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, hemagglutinin (HA), nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, histidine (His), biotin carboxyl carrier protein (BCCP), and calmodulin.
[0197] The chimeric adapter protein can be tethered to a labeled nucleic acid. Such tethering (i.e., physical linkage) can be achieved through covalent or non-covalent interactions, and tethering can be achieved directly (e.g., via direct fusion or chemical conjugation, which can be achieved by modification of cysteine or lysine residues on the protein or intein modifications) or through one or more intervening linker or adapter molecules, such as streptavidin or aptamers. See, for example, Pierce et al. (2005) Mini Rev. Med. Chem. 5(1):41-55, Duckworth et al. (2007) Angew. Chem. Int. Ed. Engl. 46(46):8819-8822, Schaeffer and Dixon (2009) Australian J. Chem. 62(10):1328-1332, Goodman et al. (2009) Chembiochem. 10(9):1551-1557, and Khatwani et al. (2012) Bioorg. Med. Chem. 20(14):4532-4539, each of which is incorporated by reference in its entirety for all purposes. Non-covalent strategies for synthesizing protein-nucleic acid conjugates include biotin-streptavidin and nickel-histidine methods. Covalent protein-nucleic acid conjugates can be synthesized by connecting appropriately functionalized nucleic acids and proteins using a variety of chemistries. Some of these chemistries involve direct attachment of oligonucleotides to amino acid residues on the protein surface (e.g., lysine amines or cysteine thiols), while other, more complex schemes require post-translational modifications of the protein or the involvement of catalytic or reactive protein domains. Methods for covalently attaching proteins to nucleic acids can include, for example, chemical crosslinking of oligonucleotides to protein lysine or cysteine residues, expressed protein ligation, chemoenzymatic methods, and the use of photoaptamers. The labeled nucleic acid can be tethered to the C-terminus, N-terminus, or internal region of the chimeric adapter protein. Similarly, the chimeric adapter protein can be tethered to the 5'-terminus, 3'-terminus, or internal region of the labeled nucleic acid.That is, the labeled nucleic acid can be tethered in any orientation and polarity.
[0198] (1) Adaptor protein or adaptor domain An adapter (i.e., an adapter domain or adapter protein) is a nucleic acid-binding domain (e.g., a DNA-binding domain and / or an RNA-binding domain) that specifically recognizes and binds to a distinct sequence (e.g., binds to a distinct DNA and / or RNA sequence, such as an aptamer, in a sequence-specific manner). Aptamers include nucleic acids that can bind to target molecules with high affinity and specificity through their ability to adopt a specific three-dimensional conformation. Such adapters can, for example, bind to specific RNA sequences and secondary structures. These sequences (i.e., adapter-binding elements) can be engineered into guide RNAs. For example, an MS2 aptamer can be engineered into a guide RNA to specifically bind to MS2 coat protein (MCP). For example, an adapter can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the MCP sequence set forth in SEQ ID NO:49.
[0199] Some specific examples of adapters and targets include RNA-binding protein / aptamer combinations found among the diversity of bacteriophage coat proteins. For example, the following adapter proteins or functional fragments or variants thereof can be used: MS2 coat protein (MCP), PP7, Qβ, F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, φCb5, φCb8r, φCb12r, φCb23r, 7s, and PRR1. See, for example, International Publication No. WO 2016 / 049258, the entire contents of which are incorporated herein by reference for all purposes. A functional fragment or variant of an adapter protein retains the ability to bind to a specific adapter binding element (e.g., the ability to bind to a specific adapter binding sequence in a sequence-specific manner). For example, a PP7 Pseudomonas bacteriophage coat protein variant can be used in which amino acids 68-69 are mutated to SG and amino acids 70-75 are deleted from the wild-type protein. See, e.g., Wu et al. (2012) Biophys. J. 102(12):2936-2944 and Chao et al. (2007) Nat. Struct. Mol. Biol. 15(1):103-105, each of which is incorporated by reference in its entirety for all purposes. Similarly, MCP variants, such as the N55K mutation, can also be used. See, e.g., Spingola and Peabody (1994) J. Biol. Chem. 269(12):9006-9010, each of which is incorporated by reference in its entirety for all purposes.
[0200] Other examples of adaptor proteins that can be used include all or a portion (e.g., a DNA-binding form) of the endoribonuclease Csy4 or lambda N protein. See, e.g., U.S. Patent Application Publication No. 2016 / 0312198, which is incorporated by reference in its entirety for all purposes.
[0201] (2) Transcriptional activation domain The chimeric adapter proteins disclosed herein comprise one or more transcription activation domains. Such transcription activation domains can be naturally occurring transcription activation domains, functional fragments or functional variants of naturally occurring transcription activation domains, or engineered or synthetic transcription activation domains. Transcription activation domains that can be used include those described elsewhere herein for use in chimeric Cas proteins.
[0202] Particular transcription activation domains for use in the chimeric adapter proteins disclosed herein include p65 and / or HSF1 transcription activation domains, or functional fragments or variants thereof. The HSF1 transcription activation domain can be the transcription activation domain of human heat shock factor 1 (HSF1). The p65 transcription activation domain can be the transcription activation domain of transcription factor p65, also known as nuclear factor NF-kappa-B p65 subunit, encoded by the RELA gene. By way of example, the transcription activation domain can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the p65 transcription activation domain protein sequence set forth in SEQ ID NO:50. As another example, the transcription activation domain can comprise, consist essentially of, or consist of an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the HSF1 transcription activation domain protein sequence set forth in SEQ ID NO:51.
[0203] C. SAM guide RNA and guide RNA array Also provided are guide RNAs and guide RNA arrays that can bind to chimeric Cas proteins and chimeric adapter proteins disclosed elsewhere herein to activate transcription of target genes. Nucleic acids encoding guide RNAs can be integrated into the genome of non-human animal cells or animals (e.g., SAM-compatible cells or non-human animals) as disclosed elsewhere herein, or the guide RNAs or nucleic acids can be introduced into such non-human animal cells and animals using methods disclosed elsewhere herein (e.g., LNP-mediated delivery or AAV-mediated delivery). Delivery methods can be selected to provide tissue-specific delivery of the recombinase as disclosed elsewhere herein.
[0204] The nucleic acid encoding the guide RNA or guide RNA array can encode one or more guide RNAs (or, when the guide RNA is introduced into a non-human animal cell or a non-human animal, one or more guide RNAs can be introduced). For example, two or more, three or more, four or more, or five or more guide RNAs can be encoded or introduced. Each guide RNA coding sequence can be operably linked to the same promoter (e.g., a U6 promoter) or to a different promoter (e.g., each guide RNA coding sequence is operably linked to its own U6 promoter). Two or more of the guide RNAs can target different target sequences in a single target gene. For example, two or more, three or more, four or more, or five or more guide RNAs can each target a different target sequence in a single target gene. Similarly, a guide RNA can target multiple target genes (e.g., two or more, three or more, four or more, or five or more target genes). Examples of guide RNA target sequences are disclosed elsewhere herein.
[0205] (1) Guide RNA A "guide RNA" or "gRNA" is an RNA molecule that binds to a Cas protein (e.g., a Cas9 protein) and targets the Cas protein to a specific location within a target DNA. A guide RNA can comprise two segments: a "DNA-targeting segment" and a "protein-binding segment." A "segment" includes a section or region of a molecule, such as a contiguous stretch of nucleotides in an RNA. Some gRNAs, such as those of Cas9, can comprise two separate RNA molecules: an "activator RNA" (e.g., tracrRNA) and a "targeter RNA" (e.g., CRISPR RNA or crRNA). Other gRNAs are single RNA molecules (single RNA polynucleotides), which may also be referred to as "single-molecule gRNAs," "single guide RNAs," or "sgRNAs." See, for example, International Publication Nos. WO 2013 / 176772, WO 2014 / 065596, WO 2014 / 089290, WO 2014 / 093622, WO 2014 / 099750, WO 2013 / 142578, and WO 2014 / 131833, each of which is incorporated by reference in its entirety for all purposes. Guide RNA refers to either CRISPR RNA (crRNA) or a combination of crRNA and trans-activating CRISPR RNA (tracrRNA). The crRNA and tracrRNA can be associated as a single RNA molecule (single guide RNA or sgRNA) or as two separate RNA molecules (dual guide RNA or dgRNA). For example, in the case of Cas9, a single guide RNA can include a crRNA fused to a tracrRNA (e.g., via a linker). For example, in the case of Cpfl, only the crRNA is required to achieve binding to the target sequence. The terms "guide RNA" and "gRNA" include both double-molecule (i.e., modular) gRNAs and single-molecule gRNAs. In some of the methods and compositions disclosed herein, the gRNA is a S. pyogenes Cas9 gRNA or its equivalent.
[0206] Exemplary bimolecular gRNAs include a crRNA-like ("CRISPR RNA" or "targeter RNA" or "crRNA" or "crRNA repeat") molecule and a corresponding tracrRNA-like ("trans-activating CRISPR RNA" or "activator RNA" or "tracrRNA") molecule. The crRNA contains both the DNA-targeting segment (single strand) of the gRNA and a stretch of nucleotides that forms one half of the dsRNA duplex of the protein-binding segment of the gRNA. An example of a crRNA tail located downstream (3') of the DNA-targeting segment comprises, consists essentially of, or consists of GUUUUAGAGCUAUGCU (SEQ ID NO: 73). Any of the DNA-targeting segments disclosed herein can be attached to the 5' end of SEQ ID NO: 73 to form a crRNA.
[0207] The corresponding tracrRNA (activator-RNA) contains a stretch of nucleotides that forms the other half of the dsRNA duplex of the protein-binding segment of the gRNA. The stretch of nucleotides in the crRNA is complementary to the stretch of nucleotides in the tracrRNA and hybridizes with it to form the dsRNA duplex of the protein-binding domain of the gRNA. Thus, each crRNA can be said to have a corresponding tracrRNA. Exemplary tracrRNA sequences comprise, consist essentially of, or consist of AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 74), AAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 75), or GUUGGAACCAUUCAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 76).
[0208] In systems where both a crRNA and a tracrRNA are required, the crRNA and the corresponding tracrRNA hybridize to form a gRNA. In systems where only a crRNA is required, the crRNA can be the gRNA. The crRNA additionally provides a single-stranded DNA targeting segment that hybridizes to the complementary strand of the target DNA. When used for intracellular modification, the exact sequence of a given crRNA or tracrRNA molecule can be designed to be unique to the species in which the RNA molecule is used. See, for example, Mali et al. (2013) Science 339(6121):823-826, Jinek et al. (2012) Science 337(6096):816-821, Hwang et al. (2013) Nat. Biotechnol. 31(3):227-229, Jiang et al. (2013) Nat. Biotechnol. 31(3):233-239, and Cong et al. (2013) Science 339(6121):819-823, each of which is incorporated by reference in its entirety for all purposes.
[0209] The DNA-targeting segment (crRNA) of a given gRNA contains a nucleotide sequence that is complementary to a sequence on the complementary strand of the target DNA, as described in more detail below. The DNA-targeting segment of a gRNA interacts with the target DNA in a sequence-specific manner through hybridization (i.e., base pairing). Thus, the nucleotide sequence of the DNA-targeting segment may vary and determines the location within the target DNA at which the gRNA and target DNA interact. The DNA-targeting segment of a given gRNA can be modified to hybridize to any desired sequence within the target DNA. Naturally occurring crRNAs vary depending on the CRISPR / Cas system and organism, but often contain a targeting segment 21-72 nucleotides long flanked by two direct repeats (DRs) 21-46 nucleotides long (see, e.g., WO 2014 / 131833, incorporated herein by reference in its entirety for all purposes). In S. pyogenes, the DRs are 36 nucleotides long, and the targeting segment is 30 nucleotides long. The 3'-located DR is complementary to and hybridizes with the corresponding tracrRNA, which in turn binds to the Cas protein.
[0210] A DNA-targeting segment can have a length of, for example, at least about 12, at least about 15, at least about 17, at least about 18, at least about 19, at least about 20, at least about 25, at least about 30, at least about 35, or at least about 40 nucleotides. Such a DNA-targeting segment can have a length of, for example, about 12 to about 100, about 12 to about 80, about 12 to about 50, about 12 to about 40, about 12 to about 30, about 12 to about 25, or about 12 to about 20 nucleotides. For example, a DNA-targeting segment can be about 15 to about 25 nucleotides (e.g., about 17 to about 20 nucleotides, or about 17, about 18, about 19, or about 20 nucleotides). See, e.g., U.S. Patent Application Publication No. 2016 / 0024523, which is incorporated by reference in its entirety for all purposes. For Cas9 derived from S. pyogenes, a typical DNA-targeting segment is 16-20 nucleotides or 17-20 nucleotides in length. For Cas9 derived from S. aureus, a typical DNA-targeting segment is 21-23 nucleotides in length. For Cpf1, a typical DNA-targeting segment is at least 16 nucleotides in length or at least 18 nucleotides in length.
[0211] In one example, the DNA targeting segment can be about 20 nucleotides in length. However, shorter and longer sequences can also be used for the targeting segment (e.g., 15-25 nucleotides in length, such as 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length). The degree of identity between the DNA targeting segment and the corresponding guide RNA target sequence (or the degree of complementarity between the DNA targeting segment and the other strand of the guide RNA target sequence) can be, for example, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%. The DNA targeting segment and the corresponding guide RNA target sequence can contain one or more mismatches. For example, the DNA-targeting segment of a guide RNA and the corresponding guide RNA target sequence can include 1 to 4, 1 to 3, 1 to 2, 1, 2, 3, or 4 mismatches (e.g., the total length of the guide RNA target sequence is at least 17, at least 18, at least 19, or at least 20 or more nucleotides). For example, the DNA-targeting segment of a guide RNA and the corresponding guide RNA target sequence can include 1 to 4, 1 to 3, 1 to 2, 1, 2, 3, or 4 mismatches where the total length of the guide RNA target sequence is 20 nucleotides.
[0212] The tracrRNA can be in any form (e.g., full-length or active portion) and can be of various lengths, including primary transcripts or processed forms. For example, the tracrRNA (as part of a single guide RNA or as a separate molecule as part of a bimolecular gRNA) can comprise, consist essentially of, or consist of all or a portion of the wild-type tracrRNA sequence (e.g., about 20 or more, about 26 or more, about 32 or more, about 45 or more, about 48 or more, about 54 or more, about 63 or more, about 67 or more, about 85 or more, or more nucleotides of the wild-type tracrRNA sequence). Examples of wild-type tracrRNA sequences from S. pyogenes include 171-, 89-, 75-, and 65-nucleotide versions. See, e.g., Deltcheva et al. (2011) Nature 471(7340):602-607; WO 2014 / 093661, each of which is incorporated by reference in its entirety for all purposes. Examples of tracrRNAs within single guide RNAs (sgRNAs) include the tracrRNA segments found within the +48, +54, +67, and +85 versions of the sgRNA, where "+n" indicates that up to +n nucleotides of the wild-type tracrRNA are included in the sgRNA. See U.S. Patent No. 8,697,359, which is incorporated by reference in its entirety for all purposes.
[0213] The percent complementarity between the DNA-targeting segment of the guide RNA and the complementary strand of the target DNA can be at least 60% (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%). The percent complementarity between the DNA-targeting segment and the complementary strand of the target DNA can be at least 60% over about 20 consecutive nucleotides. As an example, the percent complementarity between the DNA-targeting segment and the complementary strand of the target DNA can be 100% over 14 consecutive nucleotides at the 5'-end of the complementary strand of the target DNA and as low as 0% over the remainder. In such cases, the DNA-targeting segment can be considered to be 14 nucleotides in length. As another example, the percent complementarity between the DNA-targeting segment and the complementary strand of the target DNA can be 100% over seven consecutive nucleotides at the 5' end of the complementary strand of the target DNA and as low as 0% over the remainder. In such cases, the DNA-targeting segment can be considered 7 nucleotides long. In some guide RNAs, at least 17 nucleotides within the DNA-targeting segment are complementary to the complementary strand of the target DNA. For example, the DNA-targeting segment can be 20 nucleotides long and contain one, two, or three mismatches with the complementary strand of the target DNA. In one example, the mismatch is not adjacent to the region of the complementary strand that corresponds to the protospacer adjacent motif (PAM) sequence (i.e., the reverse complement of the PAM sequence) (e.g., the mismatch is at the 5' end of the DNA-targeting segment of the guide RNA, or the mismatch is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, or at least 19 base pairs away from the region of the complementary strand that corresponds to the PAM sequence).
[0214] The protein-binding segment of a gRNA can contain two consecutive nucleotides that are complementary to each other. The complementary nucleotides of the protein-binding segment hybridize to form a double-stranded RNA duplex (dsRNA). The protein-binding segment of the gRNA interacts with a Cas protein, and the gRNA guides the bound Cas protein to a specific nucleotide sequence within the target DNA via the DNA-targeting segment.
[0215] A single guide RNA can include a DNA-targeting segment and a scaffold sequence (i.e., the protein-binding or Cas-binding sequence of the guide RNA). For example, such a guide RNA can have a 5' DNA-targeting segment attached to a 3' scaffold sequence. Exemplary scaffold sequences are GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU (version 1, SEQ ID NO: 77), GUUGGAACCAUUCAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (version 2, SEQ ID NO: 78), GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (version 3, SEQ ID NO: 79), GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAG
[0047] The nucleic acid sequence of claim 1, further comprising: UGGCACCGAGUCGGUGC (version 4, SEQ ID NO: 80), GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (version 5, SEQ ID NO: 81), GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (version 6, SEQ ID NO: 82), or GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUU (version 7, SEQ ID NO: 83).A guide RNA targeting any of the guide RNA target sequences disclosed herein (e.g., any of SEQ ID NOS: 90-95) can include, for example, a DNA-targeting segment (e.g., any of SEQ ID NOS: 96-101) on the 5' end of the guide RNA fused to any of the exemplary guide RNA scaffold sequences on the 3' end of the guide RNA. That is, any of the DNA-targeting segments disclosed herein can be attached to the 5' end of any one of the above scaffold sequences to form a single guide RNA (chimeric guide RNA). In a specific example, a guide RNA targeting SEQ ID NOS: 93 or 94 can include, for example, a DNA-targeting segment of SEQ ID NOS: 99 or 100 on the 5' end of the guide RNA fused to, for example, any of the exemplary guide RNA scaffold sequences on the 3' end of the guide RNA. In another specific example, a guide RNA targeting SEQ ID NOS: 93 can include, for example, a DNA-targeting segment of SEQ ID NOS: 99 on the 5' end of the guide RNA fused to, for example, any of the exemplary guide RNA scaffold sequences on the 3' end of the guide RNA.
[0216] Guide RNAs can include modifications or sequences that provide additional desired characteristics (e.g., modified or modulated stability, intracellular targeting, tracking with fluorescent labels, binding sites for proteins or protein complexes, etc.) Guide RNAs can include one or more modified nucleosides or nucleotides, or one or more non-naturally occurring and / or naturally occurring components or structures used in place of or in addition to the canonical A, G, C, and U residues. Examples of such modifications include, for example, a 5' cap (e.g., a 7-methylguanylate cap (m7G)), a 3' polyadenylation tail (i.e., a 3' poly(A) tail), a riboswitch sequence (e.g., allowing for control of stability and / or control of accessibility by proteins and / or protein complexes), a stability control sequence, a sequence that forms a dsRNA duplex (i.e., a hairpin), a modification or sequence that targets the RNA to a subcellular location (e.g., the nucleus, mitochondria, chloroplasts, etc.), a modification or sequence that provides tracking (e.g., direct conjugation to a fluorescent molecule, conjugation to a moiety that facilitates fluorescent detection, a sequence that allows for fluorescent detection, etc.), a modification or sequence that provides a binding site for a protein (e.g., a protein that acts on DNA such as a transcriptional activator), and combinations thereof. Other examples of modifications include an engineered stem-loop duplex, an engineered bulge region, an engineered hairpin 3' of a stem-loop duplex, or any combination thereof. See, e.g., U.S. Patent Application Publication No. 2015 / 0376586, which is incorporated by reference in its entirety for all purposes. A bulge can be an unpaired region of nucleotides within a duplex comprised of a crRNA-like region and a minimal tracrRNA-like region. A bulge can include an unpaired 5'-XXXY-3' region on one side of the duplex, where X can be any purine and Y can be a nucleotide that can form a wobble base pair with a nucleotide on the opposite strand, and an unpaired nucleotide region on the other side of the duplex.
[0217] Unmodified nucleic acids may be susceptible to degradation. Exogenous nucleic acids may also induce an innate immune response. Modifications may help introduce stability and reduce immunogenicity. Guide RNAs can include modified nucleosides and nucleotides, including, for example, one or more of the following: (1) modification or substitution of one or both of the non-linked phosphate oxygens and / or one or more of the linked phosphate oxygens in the phosphodiester backbone linkage; (2) modification or substitution of a component of the ribose sugar, such as modification or substitution of the 2' hydroxyl on the ribose sugar; (3) replacement of the phosphate moiety with a dephosphorylatable linker; (4) modification or substitution of a naturally occurring nucleobase; (5) substitution or modification of the ribose-phosphate backbone; (6) modification of the 3' or 5' end of the oligonucleotide (e.g., removal, modification, or substitution of the terminal phosphate group or conjugation of a moiety); and (7) sugar modification. Other possible guide RNA modifications include modification or substitution of uracil or poly-uracil tracts. See, e.g., International Publication No. WO 2015 / 048577 and U.S. Patent Application Publication No. 2016 / 0237455, each of which is incorporated by reference in its entirety for all purposes. Similar modifications can be made to Cas-encoding nucleic acids, such as Cas mRNA. For example, Cas mRNA can be modified by using synonymous codons to deplete uridines.
[0218] Chemical modifications such as those described above can be combined to provide modified gRNAs and / or mRNAs containing residues (nucleosides and nucleotides) that can have two, three, four, or more modifications. For example, modified residues can have modified sugars and modified nucleobases. In one example, all bases of a gRNA are modified (e.g., all bases have modified phosphate groups, such as phosphorothioate groups). For example, all or substantially all phosphate groups of a gRNA can be replaced with phosphorothioate groups. Alternatively or additionally, modified gRNAs can include at least one modified residue at or near the 5' end. Alternatively or additionally, modified gRNAs can include at least one modified residue at or near the 3' end.
[0219] Some gRNAs contain one, two, three or more modified residues. For example, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the positions in the modified gRNA can be modified nucleosides or nucleotides.
[0220] Unmodified nucleic acids may be prone to degradation. Exogenous nucleic acids may also induce innate immune responses. Modifications may help to introduce stability and reduce immunogenicity. Some gRNAs described herein may contain one or more modified nucleosides or nucleotides to introduce stability against intracellular or serum-based nucleases. Some modified gRNAs described herein may exhibit reduced innate immune responses when introduced into a population of cells.
[0221] The gRNAs disclosed herein can include backbone modifications in which the phosphate group of a modified residue can be modified by replacing one or more of its oxygens with different substituents. The modifications can include extensively replacing unmodified phosphate moieties with modified phosphate groups, as described herein. Backbone modifications of the phosphate backbone can also include changes that result in either uncharged linkers or charged linkers with asymmetric charge distribution.
[0222] Examples of modified phosphate groups include phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, alkyl or aryl phosphonates, and phosphotriesters. The phosphorus atom of an unmodified phosphate group is achiral. However, replacing one of the non-bridging oxygens with one of the atoms or groups of atoms listed above can make the phosphorus atom chiral. The stereogenic phosphorus atom can have either the "R" configuration (Rp) or the "S" configuration (Sp). The backbone can also be modified by replacing the bridging oxygen (i.e., the oxygen connecting the phosphate to the nucleoside) with nitrogen (bridging phosphoramidates), sulfur (bridging phosphorothioates), and carbon (bridging methylene phosphonates). Substitutions can occur at both the bonded oxygen and the bonded oxygen.
[0223] The phosphate group can be substituted into phosphorus-free connectors with certain backbone modifications. In some embodiments, the charged phosphate group can be replaced with a neutral moiety. Examples of moieties that can replace the phosphate group include, but are not limited to, methylphosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formate, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, and methyleneoxymethylimino.
[0224] Scaffolds that can mimic nucleic acids can also be constructed such that the phosphate linker and ribose sugar are replaced with nuclease-resistant nucleoside or nucleotide surrogates. Such modifications can include backbone and sugar modifications. In some embodiments, the nucleobases can be tethered by a surrogate backbone. Examples include, but are not limited to, morpholino, cyclobutyl, pyrrolidine, and peptide nucleic acid (PNA) nucleoside surrogates.
[0225] Modified nucleosides and nucleotides can include one or more modifications to the sugar group (sugar modifications). For example, the 2' hydroxyl group (OH) can be modified (e.g., substituted with several different oxy or deoxy substituents). Modifications to the 2' hydroxyl group can increase the stability of nucleic acids because the hydroxyl cannot be deprotonated to form a 2'-alkoxide ion.
[0226] Examples of 2' hydroxyl group modifications include alkoxy or aryloxy (or "R" can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), polyethyleneglycol (PEG), O(CH2CHO) n Examples of suitable 2' hydroxyl group modifications include CH2CH2OR, where R can be, for example, H or an optionally substituted alkyl, and n can be an integer from 0 to 20 (e.g., 0 to 4, 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8, 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20). The 2' hydroxyl group modification can be 2'-O-Me. Similarly, the 2' hydroxyl group modification can be a 2'-fluoro modification, which replaces the 2' hydroxyl group with fluoride. The 2' hydroxyl group modification can be, for example, C 1-6 Alkylene or C 1-6 and locked nucleic acids (LNAs) which may be connected to the 4' carbon of the same ribose sugar by a heteroalkylene bridge, exemplary bridges being methylene, propylene, ether or amino bridges; O-amino (amino may be, for example, NH; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine or polyamino) and aminoalkoxy, O(CH). n-amino, (amino can be, for example, NH; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine, or polyamino). 2' hydroxyl group modifications can include unlocked nucleic acids (UNA), in which the ribose ring lacks a C2'-C3' bond. 2' hydroxyl group modifications can include methoxyethyl groups (MOE) (OCH2CH2OCH3, e.g., PEG derivatives).
[0227] Deoxy 2' modifications include hydrogen (i.e., deoxyribose sugars, e.g., in partial overhanging portions of dsRNA), halo (e.g., bromo, chloro, fluoro, or iodo), amino (amino can be, e.g., NH, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid), NH(CHCHNH) n These may include CH2CH2-amino (amino, e.g., as described herein), -NHC(O)R (R may be, e.g., alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), cyanomercapto, alkyl-thio-alkyl, thioalkoxy, as well as alkyl, cycloalkyl, aryl, alkenyl, and alkynyl, which may be optionally substituted, e.g., with amino, as described herein.
[0228] Sugar modifications can include sugar groups that can contain one or more carbons with the opposite stereochemical configuration to the corresponding carbon in ribose. Thus, modified nucleic acids can include nucleotides containing, for example, arabinose as the sugar. Modified nucleic acids can also include abasic sugars. These abasic sugars can also be further modified at one or more of the constituent sugar atoms. Modified nucleic acids can also include one or more sugars that are L-configured (e.g., L-nucleosides).
[0229] The modified nucleosides and modified nucleotides described herein that can be incorporated into modified nucleic acids can contain modified bases, also referred to as nucleobases. Examples of nucleobases include, but are not limited to, adenine (A), guanine (G), cytosine (C), and uracil (U). These nucleobases can be modified or completely replaced to provide modified residues that can be incorporated into modified nucleic acids. The nucleobases of the nucleotides can be independently selected from purines, pyrimidines, purine analogs, or pyrimidine analogs. In some embodiments, the nucleobases can include, for example, naturally occurring synthetic derivatives of bases.
[0230] In dual guide RNAs, the crRNA and tracrRNA can each contain modifications. Such modifications can be at one or both ends of the crRNA and / or tracrRNA. In sgRNAs, one or more residues at one or both ends of the sgRNA can be chemically modified, and / or internal nucleosides can be modified, and / or the entire sgRNA can be chemically modified. Some gRNAs contain 5'-end modifications. Some gRNAs contain 3'-end modifications.
[0231] The guide RNAs disclosed herein may comprise one of the modification patterns disclosed in WO 2018 / 107028 (A1), which is incorporated by reference in its entirety for all purposes. The guide RNAs disclosed herein may also comprise one of the structure / modification patterns disclosed in U.S. Patent Application Publication No. 2017 / 0114334, which is incorporated by reference in its entirety for all purposes. The guide RNAs disclosed herein may also comprise one of the structure / modification patterns disclosed in WO 2017 / 136794, WO 2017 / 004279, U.S. Patent Application Publication No. 2018 / 0187186, or U.S. Patent Application Publication No. 2019 / 0048338, which are incorporated by reference in their entirety for all purposes.
[0232] As one example, the nucleotides at the 5' or 3' end of the guide RNA can include phosphorothioate linkages (e.g., the base can have a modified phosphate group that is a phosphorothioate group). For example, the guide RNA can include phosphorothioate linkages between the two, three, or four terminal nucleotides at the 5' or 3' end of the guide RNA. As another example, the nucleotides at the 5' and / or 3' end of the guide RNA can have 2'-O-methyl modifications. For example, the guide RNA can include 2'-O-methyl modifications in the two, three, or four terminal nucleotides at the 5' and / or 3' end (e.g., the 5' end) of the guide RNA. See, for example, WO 2017 / 173054(A1) and Finn et al. (2018) Cell Rep. 22(9):2227-2235, each of which is incorporated by reference in its entirety for all purposes. Other possible modifications are described in more detail elsewhere herein. In a specific example, the guide RNA contains 2'-O-methyl analogs and 3' phosphorothioate internucleotide linkages in the first three 5'- and 3'-terminal RNA residues. Such chemical modifications provide the guide RNA with greater stability and protection from exonucleases, allowing it to persist in cells longer than unmodified guide RNAs. Such chemical modifications can also protect against natural intracellular immune responses, which can actively degrade the RNA or trigger immune cascades that lead to cell death.
[0233] As an example, any of the guide RNAs described herein can include at least one modification. In one example, the at least one modification includes a 2'-O-methyl (2'-O-Me) modified nucleotide, a phosphorothioate (PS) internucleotide bond, a 2'-fluoro (2'-F) modified nucleotide, or a combination thereof. For example, the at least one modification can include a 2'-O-methyl (2'-O-Me) modified nucleotide. Alternatively or additionally, the at least one modification can include a phosphorothioate (PS) internucleotide bond. Alternatively or additionally, the at least one modification can include a 2'-fluoro (2'-F) modified nucleotide. In one example, the guide RNAs described herein include one or more 2'-O-methyl (2'-O-Me) modified nucleotides and one or more phosphorothioate (PS) internucleotide bonds.
[0234] The modification can occur anywhere in the guide RNA. For example, the guide RNA can include a modification in one or more of the first five nucleotides at the 5' end of the guide RNA, and the guide RNA can include a modification in one or more of the last five nucleotides at the 3' end of the guide RNA, or a combination thereof. For example, the guide RNA can include phosphorothioate linkages between the first four nucleotides of the guide RNA, phosphorothioate linkages between the last four nucleotides of the guide RNA, or a combination thereof. Alternatively or additionally, the guide RNA can include 2'-O-Me modified nucleotides in the first three nucleotides at the 5' end of the guide RNA, 2'-O-Me modified nucleotides in the last three nucleotides at the 3' end of the guide RNA, or a combination thereof.
[0235] Another chemical modification that has been shown to affect the nucleotide sugar ring is halogen substitution. For example, 2'-fluoro (2'-F) substitution of the nucleotide sugar ring can increase oligonucleotide binding affinity and nuclease stability. An abasic nucleotide refers to a nucleotide lacking a nitrogenous base. An inverted base refers to one that has a linkage inverted from the normal 5' to 3' linkage (i.e., 5' to 5' or 3' to 3' linkage).
[0236] The abasic nucleotide can be linked via a reverse bond. For example, the abasic nucleotide can be linked to the terminal 5' nucleotide via a 5' to 5' bond, or the abasic nucleotide can be linked to the terminal 3' nucleotide via a 3' to 3' bond. A reverse abasic nucleotide at either the terminal 5' or 3' nucleotide can also be called a reverse abasic end cap.
[0237] In one example, one or more of the first 3, 4, or 5 nucleotides at the 5' end and one or more of the last 3, 4, or 5 nucleotides at the 3' end are modified. The modifications can be, for example, 2'-O-Me, 2'-F, reverse-basic nucleotides, phosphorothioate linkages, or other nucleotide modifications known to enhance stability and / or performance.
[0238] In another example, the first four nucleotides at the 5' end and the last four nucleotides at the 3' end can be linked by phosphorothioate bonds.
[0239] In another example, the first three nucleotides of the 5'-terminus and the last three nucleotides of the 3'-terminus can comprise 2'-O-methyl (2'-O-Me) modified nucleotides. In another example, the first three nucleotides of the 5'-terminus and the last three nucleotides of the 3'-terminus can comprise 2'-fluoro (2'-F) modified nucleotides. In another example, the first three nucleotides of the 5'-terminus and the last three nucleotides of the 3'-terminus can comprise reverse-basic nucleotides.
[0240] In some guide RNAs (e.g., single guide RNAs), at least one loop (e.g., two loops) of the guide RNA is modified by the insertion of a distinct RNA sequence that binds to one or more adapters (i.e., adapter proteins or domains). Such adapter proteins can be used to further recruit one or more heterologous functional domains, such as a transcription activation domain. Examples of fusion proteins comprising such adapter proteins (i.e., chimeric adapter proteins) are disclosed elsewhere herein. For example, the MS2 binding loop ggccAACAUGAGGAUCACCCAUGUCUGCAGggcc (SEQ ID NO: 52) can replace nucleotides +13 to +16 and nucleotides +53 to +56 of the sgRNA scaffold (backbone) set forth in SEQ ID NOs: 77, 79, 81, or 82, or the sgRNA backbone of the S. pyogenes CRISPR / Cas9 system, as described in WO 2016 / 049258 and Konermann et al. (2015) Nature 517(7536):583-588, respectively, which are incorporated by reference in their entireties for all purposes. See, e.g., Figure 6. Guide RNA numbering, as used herein, refers to the numbering of nucleotides in the guide RNA scaffold sequence (i.e., the sequence downstream of the DNA-targeting segment of the guide RNA). For example, the first nucleotide of the guide RNA scaffold is +1, the second nucleotide of the scaffold is +2, etc. Residues corresponding to nucleotides +13 to +16 in SEQ ID NO:77, 79, 81, or 82 are the loop sequence in a region spanning nucleotides +9 to +21 in SEQ ID NO:77, 79, 81, or 82, a region referred to herein as the tetraloop. Residues corresponding to nucleotides +53 to +56 in SEQ ID NO:77, 79, 81, or 82 are the loop sequence in a region spanning nucleotides +48 to +61 in SEQ ID NO:77, 79, 81, or 82, a region referred to herein as stem-loop 2. Other stem-loop sequences in SEQ ID NO:77, 79, 81, or 82 include stem-loop 1 (nucleotides +33 to +41) and stem-loop 3 (nucleotides +63 to +75).The resulting structure is an sgRNA scaffold in which each of the tetraloop and stem-loop 2 sequences is replaced by an MS2-binding loop. The tetraloop and stem-loop 2 protrude from the Cas9 protein, such that adding the MS2-binding loop should not interfere with any Cas9 residues. Additionally, the proximity of the tetraloop and stem-loop 2 sites to DNA indicates that localization to these locations may result in a high degree of interaction between the DNA and any recruited proteins, such as transcriptional activators. Thus, in some sgRNAs, the nucleotides corresponding to positions +13 to +16 and / or +53 to +56 of the guide RNA scaffolds set forth in SEQ ID NOs: 77, 79, 81, or 82, or corresponding residues, are replaced by distinct RNA sequences capable of binding to one or more adaptor proteins or domains when optimally aligned with one of these scaffolds / backbones. Alternatively or additionally, adaptor-binding sequences can be added to the 5' or 3' end of the guide RNA. An exemplary guide RNA scaffold comprising a tetraloop and an MS2 binding loop in the stem-loop 2 region can comprise, consist essentially of, or consist of the sequence set forth in SEQ ID NO: 66 or 71. An exemplary generic single guide RNA comprising a tetraloop and an MS2 binding loop in the stem-loop 2 region can comprise, consist essentially of, or consist of the sequence set forth in SEQ ID NO: 68 or 72.
[0241] The guide RNA may be provided in any form. For example, the gRNA may be provided in the form of RNA, either as two molecules (separate crRNA and tracrRNA) or as a single molecule (sgRNA), and optionally in the form of a complex with a Cas protein. The gRNA may also be provided in the form of DNA encoding the gRNA. The DNA encoding the gRNA can encode a single RNA molecule (sgRNA) or separate RNA molecules (e.g., separate crRNA and tracrRNA). In the latter case, the DNA encoding the gRNA may be provided as a single DNA molecule or as separate DNA molecules encoding the crRNA and tracrRNA, respectively.
[0242] When the gRNA is provided in the form of DNA, the gRNA can be expressed transiently, conditionally, or constitutively in the cell. The DNA encoding the gRNA can be stably integrated into the genome of the cell and operably linked to a promoter active in the cell. Alternatively, the DNA encoding the gRNA can be operably linked to a promoter in an expression construct. For example, the DNA encoding the gRNA can be within a vector containing a heterologous nucleic acid. Promoters that can be used in such expression constructs include, for example, promoters active in one or more of eukaryotic cells, human cells, non-human cells, mammalian cells, non-human mammalian cells, rodent cells, mouse cells, rat cells, pluripotent cells, embryonic stem (ES) cells, adult stem cells, developmentally restricted progenitor cells, induced pluripotent stem (iPS) cells, or one-cell stage embryos. Such promoters can be, for example, conditional promoters, inducible promoters, constitutive promoters, or tissue-specific promoters. Such promoters can also be, for example, bidirectional promoters. Specific examples of suitable promoters include RNA polymerase III promoters such as the human U6 promoter, the rat U6 polymerase III promoter, or the mouse U6 polymerase III promoter.
[0243] Alternatively, gRNAs can be prepared by a variety of other methods. For example, gRNAs can be prepared by in vitro transcription using, for example, T7 RNA polymerase (see, for example, International Publication Nos. WO 2014 / 089290 and WO 2014 / 065596, each of which is incorporated by reference in its entirety for all purposes). Guide RNAs can also be synthetically produced molecules prepared by chemical synthesis. For example, guide RNAs can be chemically synthesized to include 2'-O-methyl analogs and 3' phosphorothioate internucleotide linkages in the first three 5'- and 3'-terminal RNA residues.
[0244] The guide RNA (or nucleic acid encoding the guide RNA) can be a composition comprising one or more guide RNAs (e.g., 1, 2, 3, 4, or more guide RNAs) and a carrier that increases the stability of the guide RNA (e.g., extends the period during which degradation products remain below a threshold value, e.g., below 0.5% by weight of the starting nucleic acid or protein, under defined storage conditions (e.g., −20° C., 4° C., or ambient temperature), or increases stability in vivo). Non-limiting examples of such carriers include poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic-acid) (PLGA) microspheres, liposomes, micelles, reverse micelles, lipid cochleates, and lipid microtubules. Such compositions can further comprise a Cas protein, such as a Cas9 protein, or a nucleic acid encoding a Cas protein.
[0245] (2) Guide RNA target sequence The target DNA of a guide RNA includes a nucleic acid sequence present in the DNA to which the DNA-targeting segment of the gRNA binds when conditions sufficient for binding exist. Suitable DNA / RNA binding conditions include physiological conditions normally present in cells. Other suitable DNA / RNA binding conditions (e.g., conditions in cell-free systems) are known in the art (see, e.g., Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., Harbor Laboratory Press 2001), incorporated herein by reference in its entirety for all purposes). The strand of the target DNA that is complementary to and hybridizes with the gRNA can be referred to as the "complementary strand," and the strand of the target DNA that is complementary to the "complementary strand" (and therefore not complementary to the Cas protein or gRNA) can be referred to as the "non-complementary strand" or "template strand."
[0246] The target DNA includes both the sequence on the complementary strand to which the guide RNA hybridizes and the corresponding sequence on the non-complementary strand (e.g., adjacent to the protospacer adjacent motif (PAM)). As used herein, the term "guide RNA target sequence" specifically refers to the sequence on the non-complementary strand that corresponds to (i.e., its reverse complement) the sequence to which the guide RNA hybridizes on the complementary strand. That is, the guide RNA target sequence refers to the sequence on the non-complementary strand adjacent to the PAM (e.g., upstream or 5' of the PAM in the case of Cas9). The guide RNA target sequence is equivalent to the DNA-targeting segment of the guide RNA, but contains thymine instead of uracil. As an example, the guide RNA target sequence of the SpCas9 enzyme can refer to the sequence upstream of the 5'-NGG-3' PAM on the non-complementary strand. Guide RNA is designed to have complementarity with the complementary strand of target DNA, and the hybridization between the DNA targeting segment of guide RNA and the complementary strand of target DNA promotes the formation of CRISPR complex.Complete complementarity is not necessarily required, as long as there is sufficient complementarity to cause hybridization and promote the formation of CRISPR complex.When guide RNA is referred to herein as targeting guide RNA target sequence, it means that guide RNA hybridizes with the complementary strand sequence of target DNA, which is the reverse complement of guide RNA target sequence on non-complementary strand.
[0247] The target DNA or guide RNA target sequence can comprise any polynucleotide and can be located, for example, in the nucleus or cytoplasm of a cell, or in a cellular organelle such as a mitochondria or chloroplast. The target DNA or guide RNA target sequence can be any nucleic acid sequence endogenous or exogenous to the cell. The guide RNA target sequence can be a sequence that encodes a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory sequence), or can include both.
[0248] It may be preferred that the target sequence be adjacent to the transcription start site of a gene. For example, the target sequence may be within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair of the transcription start site. The target sequence can be within 0, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair upstream, or within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, or 1 base pair downstream of the transcription start site. Optionally, the target sequence is within the region (-200 to +1) 200 base pairs upstream of the transcription start site and 1 base pair downstream of the transcription start site.
[0249] The target sequence can be within any gene desired to be targeted for transcriptional activation. In some cases, the target gene can be a non-expressed gene or a weakly expressed gene (e.g., minimally expressed above background, such as 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, or 2-fold). The target gene can also be expressed at a low level compared to a control gene. The target gene can also be epigenetically silenced. The term "epigenetically silenced" refers to a gene that is not transcribed or is transcribed at a reduced level relative to the transcription level of the gene in a control sample (e.g., a corresponding control cell, such as a normal cell) due to a mechanism other than a genetic change such as a mutation. Epigenetic mechanisms of gene silencing are well known and include, for example, hypermethylation of CpG dinucleotides in CpG islands in the 5' regulatory region of a gene, such that gene transcription is reduced or inhibited, and structural changes in chromatin, for example, through histone acetylation.
[0250] A target gene may include a gene expressed in a specific organ or tissue. A target gene may include a disease-associated gene. A disease-associated gene refers to any gene that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from disease-affected tissues compared to tissues or cells of non-disease controls. It may be a gene that becomes expressed at an abnormally high level, where the altered expression correlates with the occurrence and / or progression of the disease. A disease-associated gene also refers to a gene that possesses a mutation or genetic variation involved in the etiology of the disease. The transcription or translation product may be known or unknown, and may be at a normal or abnormal level.
[0251] One specific example of such a target gene is the Myoc gene (e.g., the humanized MYOC locus described elsewhere herein). Exemplary guide RNA target sequences (without PAM) in the mouse Myoc gene are set forth in SEQ ID NOS: 90-95. Guide RNA DNA-targeting segments corresponding to the guide RNA target sequences set forth in SEQ ID NOS: 90-95 are set forth in SEQ ID NOS: 96-101, respectively. A specific example of a guide RNA target sequence is SEQ ID NOS: 93 or 94 (with corresponding DNA-targeting segments set forth in SEQ ID NOS: 99 or 100, respectively). Another specific example of a guide RNA target sequence is SEQ ID NOS: 93 (with corresponding DNA-targeting segments set forth in SEQ ID NOS: 99).
[0252] Site-specific binding and cleavage of target DNA by a Cas protein can occur at a location determined by both (i) base-pairing complementarity between the guide RNA and the complementary strand of the target DNA and (ii) a short motif, called a protospacer adjacent motif (PAM), on the non-complementary strand of the target DNA. The PAM can be adjacent to the guide RNA target sequence. Optionally, the guide RNA target sequence can be adjacent to the PAM at its 3' end (e.g., in the case of Cas9). Alternatively, the guide RNA target sequence can be adjacent to the PAM at its 5' end (e.g., in the case of Cpf1). For example, the cleavage site of the Cas protein can be about 1 to about 10 or about 2 to about 5 base pairs (e.g., 3 base pairs) upstream or downstream (e.g., within the guide RNA target sequence) of the PAM sequence. In the case of SpCas9, the PAM sequence (i.e., on the non-complementary strand) can be 5'-N1GG-3', where N1 is any DNA nucleotide, and PAM is immediately 3' to the guide RNA target sequence on the non-complementary strand of the target DNA. Thus, the sequence corresponding to PAM on the complementary strand (i.e., the reverse complement) is 5'-CCN2-3', where N2 is any DNA nucleotide, and is immediately 5' to the sequence where the DNA-targeting segment of the guide RNA hybridizes to the complementary strand of the target DNA. In some such cases, N1 and N2 can be complementary, and the N1-N2 base pair can be any base pair (e.g., N1=C and N2=G, N1=G and N2=C, N1=A and N2=T, or N1=T and N2=A). For Cas9 from Staphylococcus aureus, the PAM can be NNGRRT or NNGRR, where N can be A, G, C, or T, and R can be G or A. For Cas9 from Campylobacter jejuni, the PAM can be, for example, NNNNACAC or NNNNRYAC, where N can be A, G, C, or T, and R can be G or A. In some cases (e.g., for FnCpfl), the PAM sequence can be upstream of the 5' end and have the sequence 5'-TTN-3'.
[0253] An example of a guide RNA target sequence is a 20-nucleotide DNA sequence immediately preceding the NGG motif recognized by the SpCas9 protein. For example, two examples of a guide RNA target sequence + PAM are GN 19 NGG (SEQ ID NO: 84) or N 20 NGG (SEQ ID NO: 85). See, for example, International Publication No. 2014 / 165825, the entire contents of which are incorporated herein by reference for all purposes. The guanine at the 5' end can promote transcription by RNA polymerase in cells. Another example of a guide RNA target sequence + PAM is a sequence with two guanine nucleotides at the 5' end (e.g., GGN 20 NGG; SEQ ID NO: 86), which can facilitate efficient transcription by T7 polymerase in vitro. See, e.g., WO 2014 / 065596, incorporated herein by reference in its entirety for all purposes. Other guide RNA target sequences and PAMs can be 4-22 nucleotides in length and have SEQ ID NOs: 84-86 (including 5' G or GG and 3' GG or NGG). Still other guide RNA target sequences plus PAMs can be 14-20 nucleotides in length and have SEQ ID NOs: 84-86.
[0254] Formation of a CRISPR complex hybridized to the target DNA can result in cleavage of one or both strands of the target DNA within or near the region corresponding to the guide RNA target sequence (i.e., the guide RNA target sequence on the non-complementary strand of the target DNA and its reverse complement on the complementary strand to which the guide RNA hybridizes). For example, the cleavage site can be within the guide RNA target sequence (e.g., at a defined position relative to the PAM sequence). A "cleavage site" includes the location in the target DNA where the Cas protein generates a single-stranded or double-stranded break. The cleavage site can be only in one strand (e.g., when a nickase is used) or on both strands of double-stranded DNA. The cleavage site can be at the same position on both strands (e.g., Cas9, which generates a blunt end) or at a different site on each strand (e.g., Cpf1, which generates a sticky end (i.e., an overhang)). Sticky ends can be generated, for example, by using two Cas proteins, each generating a single-stranded break at a different cleavage site on a different strand, thereby generating a double-stranded break. For example, a first nickase can generate a single-stranded break on a first strand of double-stranded DNA (dsDNA), and a second nickase can generate a single-stranded break on a second strand of the dsDNA such that an overhang sequence is generated. In some cases, the guide RNA target sequence or cleavage site for the nickase on the first strand is separated from the guide RNA target sequence or cleavage site for the nickase on the second strand by at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 75, at least 100, at least 250, at least 500, or at least 1,000 base pairs.
[0255] D. Recombinases and Recombinase-Deficient Non-Human Animals Cells or non-human animals comprising a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, a SAM expression cassette, a guide RNA expression cassette (e.g., one or more guide RNA expression cassettes), or a recombinase expression cassette downstream of a polyadenylation signal or transcription terminator adjacent to a recombinase recognition site recognized by a site-specific recombinase disclosed herein can further comprise a recombinase expression cassette that drives expression of the site-specific recombinase. A nucleic acid encoding the recombinase can be integrated into the genome, or the recombinase or nucleic acid can be introduced into such cells and non-human animals using methods disclosed elsewhere herein (e.g., LNP-mediated delivery or AAV-mediated delivery). Delivery methods can be selected to provide tissue-specific delivery of the recombinase as disclosed elsewhere herein.
[0256] Site-specific recombinases include enzymes that can promote recombination between recombinase recognition sites where the two recombination sites are physically separated within a single nucleic acid or on separate nucleic acids. Examples of recombinases include Cre, Flp, and Dre recombinases. One example of a Cre recombinase gene is Crei, in which the two exons encoding Cre recombinase are separated by an intron, preventing expression in prokaryotic cells. Such recombinases may further contain a nuclear localization signal to promote nuclear localization (e.g., NLS-Crei). Recombinase recognition sites include nucleotide sequences that are recognized by a site-specific recombinase and can serve as substrates for recombination events. Examples of recombinase recognition sites include FRT, FRT11, FRT71, attp, att, rox, and lox sites such as loxP, lox511, lox2272, lox66, lox71, loxM2, and lox5171.
[0257] The recombinase expression cassette can be integrated into a different target genome locus than other expression cassettes disclosed herein, or can be integrated into the genome at the same target locus (e.g., the Rosa26 locus, such as integrated into the first intron of the Rosa26 locus). For example, a cell or non-human animal can be heterozygous for each of a SAM expression cassette (or a chimeric Cas protein expression cassette or a chimeric adapter protein expression cassette) and a recombinase expression cassette, and have one allele of the target genome gene containing the SAM expression cassette and a second allele of the target genome gene containing the recombinase target cassette. Similarly, a cell or non-human animal can be heterozygous for each of a guide RNA expression cassette (e.g., a guide RNA array expression cassette) and a recombinase expression cassette, and have one allele of the target genome gene containing the guide RNA expression cassette and a second allele of the target genome gene containing the recombinase target cassette.
[0258] The recombinase gene in the recombinase expression cassette can be operably linked to any suitable promoter. Examples of promoters are described elsewhere herein. For example, the promoter can be a tissue-specific promoter or a developmental stage-specific promoter. Such promoters are advantageous because they can selectively activate transcription of the target gene only in a desired tissue or at a desired developmental stage. For example, in the case of a Cas protein, this can reduce the possibility of Cas-mediated toxicity in vivo. Exemplary promoters for mouse recombinase are known and are described, for example, in U.S. Patent Application Publication No. 2019 / 0284572 and International Publication No. 2019 / 183123, each of which is incorporated herein by reference in its entirety for all purposes.
[0259] E. Nucleic acids encoding chimeric Cas proteins, chimeric adaptor proteins, guide RNAs, synergistic activation mediators, or recombinases Also provided are nucleic acids encoding chimeric Cas proteins, chimeric adapter proteins, guide RNAs, recombinases, or any combination thereof. Chimeric Cas proteins, chimeric adapter proteins, and guide RNAs are described in more detail elsewhere herein. For example, the nucleic acid can be a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, a synergistic activation mediator (SAM) expression cassette comprising nucleic acids encoding both a chimeric Cas protein and a chimeric adapter protein, a guide RNA or guide RNA array expression cassette, a recombinase expression cassette, or any combination thereof. Such nucleic acids can be RNA (e.g., messenger RNA (mRNA)) or DNA, single-stranded or double-stranded, linear or circular. The DNA can be part of a vector, such as an expression vector or a targeting vector. The vector can also be a viral vector, such as an adenoviral, adeno-associated viral, lentiviral, or retroviral vector. When any of the nucleic acids disclosed herein are introduced into a cell, the encoded chimeric Cas protein, chimeric adapter protein, or guide RNA can be expressed transiently, conditionally, or constitutively within the cell.
[0260] Optionally, the nucleic acid can be codon-optimized for efficient translation into a protein in a particular cell or organism. For example, the nucleic acid can be modified to alternative codons that have a higher frequency of usage in bacterial cells, yeast cells, human cells, non-human cells, mammalian cells, rodent cells, mouse cells, rat cells, or any other host cell of interest, compared to the naturally occurring polynucleotide sequence.
[0261] The nucleic acid or expression cassette can be stably integrated into the genome (i.e., chromosomally) of the cell or non-human animal, or can be located outside of the chromosome (e.g., extrachromosomally replicating DNA). The stably integrated expression cassette or nucleic acid can be randomly integrated into the genome of the non-human animal (i.e., transgenic) or can be integrated into a predetermined region of the genome of the non-human animal (i.e., knock-in). In one example, the nucleic acid or expression cassette is stably integrated into a safe harbor locus, as described elsewhere herein. The target genomic locus into which the nucleic acid or expression cassette is stably integrated can be heterozygous for the nucleic acid or expression cassette, or homozygous for the nucleic acid or expression cassette. For example, the target genomic locus or non-human animal cell or non-human animal can be heterozygous for the SAM expression cassette and heterozygous for the guide RNA expression cassette, optionally each at the same target genomic locus on a different allele.
[0262] The nucleic acids or expression cassettes described herein can be operably linked to any suitable promoter for expression in vivo in a non-human animal, or in a cell in vitro or ex vivo. The non-human animal can be any suitable animal described elsewhere herein. By way of example, the nucleic acid or expression cassette (e.g., a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, or a SAM cassette comprising a nucleic acid encoding both a chimeric Cas protein and a chimeric adapter protein) can be operably linked to an endogenous promoter at a target genomic locus, such as the Rosa26 promoter. Alternatively, the cassette nucleic acid or expression cassette can be operably linked to an exogenous promoter, such as a constitutively active promoter (e.g., a CAG promoter or a U6 promoter), a conditional promoter, an inducible promoter, a temporally restricted promoter (e.g., a developmentally regulated promoter), or a spatially restricted promoter (e.g., a cell-specific or tissue-specific promoter). Such promoters are well known and are discussed elsewhere herein. Promoters that can be used in expression constructs include, for example, promoters active in one or more of eukaryotic cells, human cells, non-human cells, mammalian cells, non-human mammalian cells, rodent cells, mouse cells, rat cells, hamster cells, rabbit cells, pluripotent cells, embryonic stem (ES) cells, or zygotes. Such promoters can be, for example, conditional promoters, inducible promoters, constitutive promoters, or tissue-specific promoters.
[0263] For example, the nucleic acid encoding the guide RNA can be operably linked to a U6 promoter, such as a human U6 promoter or a mouse U6 promoter. Specific examples of suitable promoters (e.g., for expressing the guide RNA) include RNA polymerase III promoters, such as a human U6 promoter, a rat U6 polymerase III promoter, or a mouse U6 polymerase III promoter.
[0264] Optionally, the promoter can be a bidirectional promoter that drives expression of a first gene (e.g., a gene encoding a chimeric Cas protein) and a second gene (e.g., a gene encoding a guide RNA or a chimeric adapter protein) in opposite directions. Such a bidirectional promoter can consist of (1) a complete conventional unidirectional Pol III promoter containing three external control elements: a distal sequence element (DSE), a proximal sequence element (PSE), and a TATA box; and (2) a second basic Pol III promoter containing a PSE and a TATA box fused in reverse orientation to the 5' end of the DSE. For example, in the H1 promoter, the DSE is adjacent to the PSE and TATA box, and the promoter can be made bidirectional by adding a PSE and a TATA box from the U6 promoter to create a hybrid promoter in which transcription in the opposite direction is controlled. See, e.g., U.S. Patent Application Publication No. 2016 / 0074535, incorporated herein by reference in its entirety for all purposes. Bidirectional promoters can be used to express two genes simultaneously, generating a compact expression cassette for ease of delivery.
[0265] One or more of the nucleic acids can be together in a multicistronic expression construct. For example, a nucleic acid encoding a chimeric Cas protein and a nucleic acid encoding a chimeric adapter protein can be together in a bicistronic expression construct. See, e.g., Figures 4A and 4B. A multicistronic expression vector simultaneously expresses two or more separate proteins from the same mRNA (i.e., transcripts generated from the same promoter). Suitable strategies for multicistronic expression of proteins include, for example, the use of 2A peptides and internal ribosome entry sites (IRES). For example, such constructs can include (1) nucleic acids encoding one or more chimeric Cas proteins and one or more chimeric adaptor proteins, (2) nucleic acids encoding two or more chimeric adaptor proteins, (3) nucleic acids encoding two or more chimeric Cas proteins, (4) nucleic acids encoding two or more guide RNAs or two or more guide RNA arrays, (5) nucleic acids encoding one or more chimeric Cas proteins and one or more guide RNAs or guide RNA arrays, (6) nucleic acids encoding one or more chimeric adaptor proteins and one or more guide RNAs or guide RNA arrays, or (7) nucleic acids encoding one or more chimeric Cas proteins, one or more chimeric adaptor proteins, and one or more guide RNAs or guide RNA arrays. As one example, such multicistronic vectors can use one or more internal ribosome entry sites (IRES) to enable translation initiation from internal regions of mRNA. As another example, such multicistronic vectors can employ one or more 2A peptides. These peptides are small, "self-cleaving" peptides, generally 18-22 amino acids in length, that produce equimolar levels of multiple genes from the same mRNA. The ribosome skips synthesis of the glycyl-prolyl peptide bond at the C-terminus of the 2A peptide, causing a "cleavage" between the 2A peptide and the peptide immediately downstream.See, e.g., Kim et al. (2011) PLoS One 6(4):e18556, which is incorporated by reference in its entirety for all purposes. "Cleavage" occurs between the C-terminal glycine and proline residues, with the upstream cistron adding several residues to its end and the downstream cistron beginning with a proline. As a result, the "cleaved" downstream peptide has a proline at its N-terminus. 2A-mediated cleavage is a universal phenomenon in all eukaryotic cells. 2A peptides have been identified from picornaviruses, insect viruses, and type C rotaviruses. See, e.g., Szymczak et al. (2005) Expert Opin. Biol. Ther. 5(5):627-638, which is incorporated by reference in its entirety for all purposes. Examples of 2A peptides that can be used include Thoseaasigna virus 2A (T2A), porcine teschovirus-1 2A (P2A), equine rhinitis A virus (ERAV) 2A (ERAV 2A, E2A), and FMDV 2A (FMDV 2A, F2A). Exemplary T2A, P2A, E2A, and F2A sequences include: T2A (EGRGSLLTCGDVEENPGP, SEQ ID NO: 53), P2A (ATNFSLLKQAGDVEENPGP, SEQ ID NO: 54), E2A (QCTNYALLKLAGDVESNPGP, SEQ ID NO: 55), and F2A (VKQTLNFDLLKLAGDVESNPGP, SEQ ID NO: 56). A GSG residue can be added to the 5' end of any of these peptides to improve cleavage efficiency.
[0266] Either the nucleic acid or the expression cassette can contain a polyadenylation signal or transcription terminator upstream of the coding sequence. The term polyadenylation signal sequence refers to any sequence that directs the termination of transcription and the addition of a poly(A) tail to an mRNA transcript. In eukaryotes, transcription terminators are recognized by protein factors, and termination is followed by polyadenylation, the process of adding a poly(A) tail to an mRNA transcript in the presence of poly(A) polymerase. Mammalian poly(A) signals typically consist of a core sequence approximately 45 nucleotides long, which may be flanked by various auxiliary sequences that serve to increase the efficiency of cleavage and polyadenylation. The core sequence, termed the polyA recognition motif or sequence, consists of a highly conserved upstream element (AATAAA or AAUAAA) within the mRNA that is recognized by the cleavage and polyadenylation-specificity factor (CPSF), and a poorly defined downstream region (rich in U or G and U) that is bound by the cleavage stimulation factor (CstF). Examples of transcription terminators that can be used include the human growth hormone (HGH) polyadenylation signal, the simian virus 40 (SV40) late polyadenylation signal, the rabbit beta globin polyadenylation signal, the bovine growth hormone (BGH) polyadenylation signal, the phosphoglycerate kinase (PGK) polyadenylation signal, the AOX1 transcription termination sequence, the CYC1 transcription termination sequence, or any transcription termination sequence known to be suitable for regulating gene expression in eukaryotic cells. For example, a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, a SAM expression cassette, a guide RNA expression cassette, or a recombinase expression cassette can include a polyadenylation signal or transcription terminator upstream of the coding sequence in the expression cassette.The polyadenylation signal or transcription terminator can be adjacent to a recombinase recognition site recognized by a site-specific recombinase. Optionally, the recombinase recognition site also flanks a selection cassette containing, for example, a coding sequence for a drug resistance protein. Optionally, the recombinase recognition site does not flank the selection cassette. The polyadenylation signal or transcription terminator prevents transcription and expression of the protein or RNA encoded by the coding sequence (e.g., a chimeric Cas protein, a chimeric adapter protein, a guide RNA, or a recombinase). However, upon exposure to the site-specific recombinase, the polyadenylation signal or transcription terminator is excised, allowing the protein or RNA to be expressed.
[0267] Such configuration of an expression cassette (e.g., a chimeric Cas protein expression cassette or a SAM expression cassette) can enable tissue- or developmental stage-specific expression in a non-human animal containing the expression cassette if the polyadenylation signal or transcription terminator is excised in a tissue- or developmental stage-specific manner. For example, in the case of a chimeric Cas protein, this can reduce toxicity resulting from long-term expression of the chimeric Cas protein in a cell or non-human animal, or expression of the chimeric Cas protein in undesired developmental stages or undesired cells or tissue types within the non-human animal. See, e.g., Parikh et al. (2015) PLoS One 10(1):e0116484, incorporated herein by reference in its entirety for all purposes. Excision of the polyadenylation signal or transcription terminator in a tissue- or developmental stage-specific manner can be achieved if the non-human animal containing the expression cassette further comprises a coding sequence for a site-specific recombinase operably linked to a tissue- or developmental stage-specific promoter. The polyadenylation signal or transcription terminator is then excised only in those tissues or those developmental stages, allowing tissue- or developmental stage-specific expression. In one example, a chimeric Cas protein, a chimeric adapter protein, a chimeric Cas protein and a chimeric adapter protein, or a guide RNA can be expressed in a liver-specific manner. Examples of such promoters that have been used to develop such "recombinase-deficient" strains of non-human animals are disclosed elsewhere herein.
[0268] Any transcription terminator or polyadenylation signal can be used. As used herein, "transcription terminator" refers to a DNA sequence that causes the termination of transcription. In eukaryotes, transcription terminators are recognized by protein factors, and termination is followed by polyadenylation, the process of adding a poly(A) tail to an mRNA transcript in the presence of poly(A) polymerase. Mammalian poly(A) signals typically consist of a core sequence approximately 45 nucleotides long, which may be flanked by various auxiliary sequences that help increase the efficiency of cleavage and polyadenylation. The core sequence, referred to as the poly(A) recognition motif or poly(A) recognition sequence, consists of a highly conserved upstream element (AATAAA or AAUAAA) in the mRNA that is recognized by the cleavage and polyadenylation specificity factor (CPSF), and a poorly defined downstream region (rich in U or G and U) that is bound by the cleavage stimulation factor (CstF). Examples of transcription terminators that can be used include, for example, the human growth hormone (HGH) polyadenylation signal, the simian virus 40 (SV40) late polyadenylation signal, the rabbit beta globin polyadenylation signal, the bovine growth hormone (BGH) polyadenylation signal, the phosphoglycerate kinase (PGK) polyadenylation signal, the AOX1 transcription termination sequence, the CYC1 transcription termination sequence, or any transcription termination sequence known to be suitable for regulating gene expression in eukaryotic cells.
[0269] Site-specific recombinases include enzymes that can promote recombination between recombinase recognition sites where the two recombination sites are physically separated within a single nucleic acid or on separate nucleic acids. Examples of recombinases include Cre, Flp, and Dre recombinases. One example of a Cre recombinase gene is Crei, in which the two exons encoding Cre recombinase are separated by an intron, preventing expression in prokaryotic cells. Such recombinases may further contain a nuclear localization signal to promote nuclear localization (e.g., NLS-Crei). Recombinase recognition sites include nucleotide sequences that are recognized by site-specific recombinases and can serve as substrates for recombination events. Examples of recombinase recognition sites include FRT, FRT11, FRT71, attp, att, rox, and lox sites such as loxP, lox511, lox2272, lox66, lox71, loxM2, and lox5171.
[0270] The expression cassettes disclosed herein can also include other components. Such expression cassettes (e.g., chimeric Cas protein expression cassettes, chimeric adapter protein expression cassettes, SAM expression cassettes, guide RNA expression cassettes, or recombinase expression cassettes) can further include a 3' splicing sequence at the 5' end of the expression cassette and / or a second polyadenylation signal following the coding sequence (e.g., encoding a chimeric Cas protein, chimeric adapter protein, guide RNA, or recombinase). The term 3' splicing sequence refers to a nucleic acid sequence at a 3' intron / exon boundary that can be recognized and bound by the splicing machinery. The expression cassette can further include a selection cassette containing, for example, a coding sequence for a drug resistance protein. Examples of suitable selection markers include neomycin phosphotransferase (neomycin phosphotransferase). r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puro r ), blasticidin S deaminase (bsr r), xanthine / guanine phosphoribosyltransferase (gpt), or herpes simplex virus thymidine kinase (HSV-k). Optionally, the selection cassette may be flanked by recombinase recognition sites for a site-specific recombinase. When the expression cassette also contains recombinase recognition sites adjacent to a polyadenylation signal upstream of the coding sequence, as described above, the selection cassette may be flanked by the same recombinase recognition sites or by different sets of recombinase recognition sites recognized by different recombinases.
[0271] The expression cassette can also include nucleic acids encoding one or more reporter proteins, such as a fluorescent protein (e.g., green fluorescent protein). Any suitable reporter protein can be used. For example, fluorescent reporter proteins defined elsewhere herein can be used, or non-fluorescent reporter proteins can be used. Examples of fluorescent reporter proteins are provided elsewhere herein. Non-fluorescent reporter proteins include reporter proteins that can be used in histochemical or bioluminescence assays, such as beta-galactosidase, luciferase (e.g., Renilla luciferase, firefly luciferase, and NanoLuc luciferase), and beta-glucuronidase. The expression cassette can include a reporter protein that can be detected in a flow cytometry assay (e.g., a fluorescent reporter protein such as green fluorescent protein) and / or a reporter protein that can be detected in a histochemical assay (e.g., a beta-galactosidase protein). One example of such a histochemical assay is the visualization of in situ beta-galactosidase expression histochemically through the hydrolysis of X-Gal (5-bromo-4-chloro-3-indoyl-bD-galactopyranoside), which produces a blue precipitate, or using fluorogenic substrates such as beta-methyl umbelliferyl galactoside (MUG) and fluorescein digalactoside (FDG).
[0272] The expression cassettes described herein can be in any form. For example, the expression cassette can be within a vector, such as a viral vector, or a plasmid. The expression cassette can be operably linked to a promoter in an expression construct that can direct protein or RNA expression (e.g., upon removal of an upstream polyadenylation signal). Alternatively, the expression cassette can be within a targeting vector. For example, the targeting vector can include homology arms flanking the expression cassette, which are suitable for directing recombination with a desired target genomic locus to facilitate genomic integration and / or replacement of endogenous sequences.
[0273] The expression cassettes described herein can be in vitro, can be in a cell (e.g., embryonic stem cell) ex vivo (e.g., integrated into the genome or extrachromosomal), or can be in an organism (e.g., a non-human animal) in vivo (e.g., integrated into the genome or extrachromosomal). If ex vivo, the expression cassette can be in any type of cell from any organism, such as a totipotent cell such as an embryonic stem cell (e.g., mouse or rat embryonic stem cell) or an induced pluripotent stem cell (e.g., human induced pluripotent stem cell). If in vivo, the expression cassette can be in any type of organism (e.g., a non-human animal as further described elsewhere herein).
[0274] Specific examples of nucleic acids encoding catalytically inactive Cas proteins can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the dCas9 protein sequence set forth in SEQ ID NO:44. Optionally, the nucleic acid can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:57 (optionally, the sequence encodes a protein that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the dCas9 protein sequence set forth in SEQ ID NO:44).
[0275] Specific examples of nucleic acids encoding chimeric Cas proteins can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the Cas9 protein sequence set forth in SEQ ID NO:43. Optionally, the nucleic acid can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:58 (optionally, the sequence encodes a protein that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the dCas9 protein sequence set forth in SEQ ID NO:43).
[0276] Specific examples of adaptor-encoding nucleic acids can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the MCP sequence set forth in SEQ ID NO:49. Optionally, the nucleic acid can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:59 (optionally, the sequence encodes a protein that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the MCP sequence set forth in SEQ ID NO:44).
[0277] Specific examples of nucleic acids encoding chimeric adapter proteins can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the chimeric adapter protein sequence set forth in SEQ ID NO:48. Optionally, the nucleic acid can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:60 (optionally, the sequence encodes a protein that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the chimeric adapter protein sequence set forth in SEQ ID NO:48).
[0278] Specific examples of nucleic acids encoding transcription activation domains can comprise, consist essentially of, or consist of nucleic acids encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VP64, p65, or HSF1 sequences set forth in SEQ ID NOs: 45, 50, or 51, respectively. Optionally, the nucleic acid can comprise, consist essentially of, or consist of a nucleic acid encoding an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 61, 62, or 63, respectively (optionally, the sequence encodes a protein that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VP64, p65, or HSF1 sequence set forth in SEQ ID NO: 45, 55, or 51, respectively).
[0279] One exemplary synergistic activation mediator (SAM) expression cassette comprises, from 5' to 3', (a) a 3' splicing sequence, (b) a first recombinase recognition site (e.g., a loxP site), (c) a coding sequence for a drug resistance gene (e.g., neomycin phosphotransferase (neomycin phosphotransferase (neomycin phosphotransferase)), (d) a coding sequence for a drug resistance gene (e.g., ... r(d) a nucleotide sequence encoding a 2A protein (e.g., a P2A or T2A coding sequence), (e) a polyadenylation signal, (f) a chimeric Cas protein coding sequence (e.g., a dCas9-NLS-VP64 fusion protein or an NLS-dCas9-NLS-VP64 fusion protein), (g) a 2A protein coding sequence (e.g., a P2A or T2A coding sequence), and (h) a chimeric adaptor protein coding sequence (e.g., MCP-NLS-p65-HSF1). Another exemplary synergistic activation mediator (SAM) expression cassette comprises, from 5' to 3', (a) a 3' splicing sequence, (b) a first recombinase recognition site (e.g., a loxP site), (c) a coding sequence for a drug resistance gene (e.g., neomycin phosphotransferase (neomy ... r ) coding sequence), (d) a polyadenylation signal (e.g., a PGK polyadenylation signal and / or an SV40 polyadenylation signal, such as a combination of a PGK polyadenylation signal and three SV40 polyadenylation signals), (e) a second recombinase recognition site (e.g., a loxP site), (f) a chimeric Cas protein coding sequence (e.g., a dCas9-NLS-VP64 fusion protein or an NLS-dCas9-NLS-VP64 fusion protein), (g) a 2A protein coding sequence (e.g., a P2A or T2A coding sequence), (e) a chimeric adaptor protein coding sequence (e.g., MCP-NLS-p65-HSF1), (f) a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and (g) another polyadenylation signal (e.g., a BGH polyadenylation signal). See, for example, Figure 4A and SEQ ID NO:64 (coding sequence set forth in SEQ ID NO:69 and encoded protein set forth in SEQ ID NO:67).
[0280] One exemplary general guide RNA array expression cassette includes, from 5' to 3', (a) a 3' splicing sequence, (b) a first recombinase recognition site (e.g., a rox site), (c) a coding sequence for a drug resistance gene (e.g., puromycin-N-acetyltransferase (puro)), and (d) a coding sequence for a drug resistance gene (e.g., a puromycin-N-acetyltransferase (puro)). r) coding sequence), (d) a polyadenylation signal (e.g., a PGK polyadenylation signal and / or an SV40 polyadenylation signal, such as a combination of a PGK polyadenylation signal and three SV40 polyadenylation signals), (e) a second recombinase recognition site (e.g., a rox site), and (f) a guide RNA array comprising one or more guide RNA genes (e.g., a first U6 promoter followed by a first guide RNA coding sequence and a first terminator sequence, a second U6 promoter followed by a second guide RNA coding sequence and a second terminator sequence, and a third U6 promoter followed by a third guide RNA coding sequence and a third terminator sequence). See, for example, SEQ ID NO: 65. The region of SEQ ID NO: 65 containing the promoters and guide RNA coding sequences is set forth in SEQ ID NO: 70. The recombinase recognition sites in the guide RNA array expression cassette can be the same as or different from the recombinase recognition sites in the SAM expression cassette (e.g., recognized by the same recombinase or different recombinases).
[0281] Another exemplary general guide RNA array expression cassette includes one or more guide RNA genes (e.g., a first U6 promoter followed by a first guide RNA coding sequence, a second U6 promoter followed by a second guide RNA coding sequence, and a third U6 promoter followed by a third guide RNA coding sequence). Such a general guide RNA array expression cassette is set forth in SEQ ID NO:70.
[0282] F. Genomic loci for integration The nucleic acids and expression cassettes described herein can be integrated into the genome at a target genomic locus in a non-human animal cell or animal. Any target genomic locus capable of expressing a gene can be used.
[0283] An example of a target genomic locus into which the nucleic acids or cassettes described herein can be stably integrated is a safe harbor locus in the genome of a non-human animal cell or animal. Interactions between the integrated exogenous DNA and the host genome can limit the reliability and safety of integration and can lead to overt phenotypic effects not due to targeted gene modification but instead due to unintended effects of integration on surrounding endogenous genes. For example, randomly inserted transgenes are susceptible to position effects and silencing, making their expression unreliable and unpredictable. Similarly, integration of exogenous DNA into a chromosomal locus can affect surrounding endogenous genes and chromatin, thereby altering cellular behavior and phenotype. Safe harbor loci include chromosomal loci in which a transgene or other exogenous nucleic acid insertion can be stably and reliably expressed in all tissues of interest without overtly altering cellular behavior or phenotype (i.e., without causing any adverse effects to the host cell). See, e.g., Sadelain et al. (2012) Nat. Rev. Cancer 12:51-58, which is incorporated by reference in its entirety for all purposes. For example, a safe harbor locus can be a locus where expression of an inserted gene sequence is not perturbed by read-through expression from adjacent genes. For example, a safe harbor locus can include a chromosomal locus where exogenous DNA can integrate and function in a predictable manner without adversely affecting the structure or expression of endogenous genes. A safe harbor locus can include extragenic or intragenic regions, such as intragenic loci that are nonessential, dispensable, or can be disrupted without obvious phenotypic consequences.
[0284] For example, the Rosa26 locus and its equivalents in humans provide an open chromatin structure in all tissues and are ubiquitously expressed during embryonic development and in adults. See, e.g., Zambrowicz et al. (1997) Proc. Natl. Acad. Sci. USA 94:3789-3794, the entire contents of which are incorporated herein by reference for all purposes. In addition, the Rosa26 locus can be targeted with high efficiency, and disruption of the Rosa26 gene does not produce any obvious phenotype. Other examples of safe harbor loci include CCR5, HPRT, AAVS1, and albumin. See, for example, U.S. Patent Nos. 7,888,121, 7,972,854, 7,914,796, 7,951,925, 8,110,379, 8,409,861, and 8,586,526, as well as U.S. Patent Publication Nos. 2003 / 0232410, 2005 / 0208489, 2005 / 0208489, and 2005 / 0208489, each of which is incorporated herein by reference in its entirety for all purposes. See, e.g., 2006 / 0063231, 2008 / 0159996, 2010 / 00218264, 2012 / 0017290, 2011 / 0265198, 2013 / 0137104, 2013 / 0122591, 2013 / 0177983, 2013 / 0177960, and 2013 / 0122591. Because biallelic targeting of safe harbor loci such as the Rosa26 locus has no negative consequences, different genes or reporters can be targeted to the two Rosa26 alleles. In one example, the expression cassette is integrated into an intron of the Rosa26 locus, such as the first intron of the Rosa26 locus. See, e.g., Figure 5.
[0285] The expression cassette integrated into the target genome locus can be operably linked to an endogenous promoter at the target genome locus, or can be operably linked to an exogenous promoter heterologous to the target genome locus. In one example, a chimeric Cas protein expression cassette, a chimeric adapter protein expression cassette, or a synergistic activation mediator (SAM) expression cassette is integrated into the target genome locus (e.g., the Rosa26 locus) and operably linked to an endogenous promoter (e.g., the Rosa26 promoter) at the target genome locus. In another example, a guide RNA expression cassette is integrated into the target genome locus (e.g., the Rosa26 locus) and operably linked to one or more heterologous promoters (e.g., U6 promoters, such as different U6 promoters upstream of each guide RNA coding sequence).
[0286] IV. Methods Using Non-Human Animals Comprising a Humanized MYOC Locus Various methods are provided for using non-human animals and non-human animal cells comprising the humanized MYOC locus (e.g., comprising the Y437H mutation) described elsewhere herein. Such methods can be, for example, to increase MYOC expression, elevate intraocular pressure, model glaucoma, or evaluate or optimize the delivery or efficacy of a human MYOC-targeting reagent (e.g., a therapeutic molecule or complex) or candidate glaucoma therapeutic agent in vivo or ex vivo or in vitro. Because the non-human animals and non-human animal cells comprise a humanized MYOC locus, the non-human animals and non-human animal cells more accurately reflect the efficacy of human MYOC-targeting reagents. Because the non-human animals disclosed herein comprise a humanized endogenous MYOC locus rather than a transgenic insertion of human MYOC sequences at a random genomic locus, and because the humanized endogenous MYOC locus comprises the corresponding human genomic MYOC sequence from both coding and non-coding regions (e.g., from both exon and intron regions) rather than an artificial cDNA sequence, such non-human animals and non-human animal cells are particularly useful for testing genome editing reagents designed to target the human MYOC gene. Such non-human animals are also particularly useful for testing candidate glaucoma therapeutic agents because the non-human animals disclosed herein exhibit a phenotype of elevated intraocular pressure that reflects the phenotype observed in glaucoma patients.
[0287] A. Methods of Increasing MYOC Expression, Raising Intraocular Pressure, or Modeling Glaucoma Various methods are provided for increasing MYOC (e.g., human MYOC) expression, elevating intraocular pressure, or modeling glaucoma in vivo using non-human animals comprising a humanized MYOC locus (e.g., comprising a Y437H mutation) and a SAM expression cassette as described elsewhere herein. Such methods for increasing MYOC expression, elevating intraocular pressure, or modeling glaucoma can include administering to the non-human animal one or more DNAs encoding one or more guide RNAs or one or more SAM guide RNAs as described elsewhere herein, thereby increasing MYOC expression. The methods can increase MYOC mRNA expression and / or protein expression. Such methods for increasing MYOC expression can also be for increasing MYOC expression in non-human animal cells by administering to the non-human animal cells one or more DNAs encoding one or more guide RNAs or one or more SAM guide RNAs, as described elsewhere herein.
[0288] Each of the one or more guide RNAs can include one or more adapter binding elements to which a chimeric adapter protein can specifically bind, and each of the one or more guide RNAs forms a complex with the chimeric Cas protein and the chimeric adapter protein and guides them to a target sequence within the humanized MYOC locus, thereby increasing expression of the humanized MYOC locus.
[0289] Such methods may further comprise measuring expression of MYOC messenger RNA encoded by the humanized MYOC locus or measuring expression of myocilin protein encoded by the humanized MYOC locus after administering one or more guide RNAs or one or more DNAs encoding one or more guide RNAs.
[0290] In some methods, human MYOC mRNA or protein expression is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 11-fold, at least about 12-fold, at least about 13-fold, at least about 14-fold, or at least about 15-fold (e.g., at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold). In some methods, human MYOC mRNA or protein expression is increased by at least about 2-fold to at least about 25-fold, at least about 3-fold to at least about 25-fold, at least about 4-fold to at least about 25-fold, at least about 5-fold to at least about 25-fold, at least about 6-fold to at least about 25-fold, at least about 7-fold to at least about 25-fold, at least about 8-fold to at least about 25-fold, at least about 9-fold to at least about 25-fold, at least about 10-fold to at least about 25-fold, at least about 2-fold to at least about 20-fold, at least about 2-fold to at least about 15-fold, or at least about 10-fold to at least about 15-fold. Increased human MYOC mRNA or protein expression can be in the eye, limbal ring, retina, ciliary body, trabecular meshwork, or cornea. In a specific example, increased expression is in the limbal ring.
[0291] In some methods, a non-human animal develops one or more signs or symptoms of glaucoma after administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs. Glaucoma is a chronic optic neuropathy characterized by the progressive loss of retinal ganglion cell (RGC) axons, resulting in irreversible vision loss. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Elevated IOP is caused by increased resistance to aqueous humor outflow through the trabecular meshwork (TM). Aqueous humor is produced by the ciliary body, circulates through the anterior chamber, and drains through the TM meshwork. In most cases of glaucoma, there is increased resistance to aqueous humor in the TM. Pathogenic MYOC mutant proteins aggregate intracellularly, leading to trabecular meshwork (TM) stress, elevated IOP, and glaucoma.
[0292] Such methods can further include measuring intraocular pressure (IOP) after administering the one or more guide RNAs or one or more DNAs encoding the one or more guide RNAs. In one example, the method results in an IOP that is at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, or at least about 22 mmHg (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg). In one example, the method results in an IOP that is about 15 to about 22, about 16 to about 22, about 17 to about 22, about 18 to about 22, about 19 to about 22, about 15 to about 21, about 15 to about 20, or about 16 to about 21 mmHg (e.g., 15 to 22, 16 to 22, 17 to 22, 18 to 22, 19 to 22, 15 to 21, 15 to 20, or 16 to 21 mmHg).
[0293] In some methods, IOP is increased by a certain amount relative to before administration of the one or more guide RNAs or one or more DNAs encoding the one or more guide RNAs, or relative to a control non-human animal (e.g., a non-human animal having a humanized MYOC locus described herein but not administered the one or more guide RNAs, or a wild-type non-human animal). In one example, IOP is increased by at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, or at least about 6 mmHg (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg). In one example, IOP is increased by about 1 to about 7, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 5 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 4 to about 6, or about 5 to about 6 mmHg (e.g., 1 to 6, 2 to 6, 3 to 6, 4 to 6, or 5 to 6 mmHg).
[0294] The guide RNA or DNA encoding the guide RNA can be administered (introduced into a cell or introduced into an animal so that the guide RNA or DNA gains access to the interior of a cell in a non-human animal) in any form, in any delivery vehicle, and by any administration route. For example, administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs can include, in some methods, adenovirus-mediated delivery (e.g., recombinant adenovirus type 5 (Ad5)), lentivirus-mediated delivery, adeno-associated virus (AAV)-mediated delivery, or lipid nanoparticle (LNP)-mediated delivery. In one example, the guide RNA or DNA encoding the guide RNA is administered via LNP-mediated delivery (e.g., at a dose of about 0.1 mg / kg to about 2 mg / kg). In another example, the guide RNA or DNA encoding the guide RNA is administered via AAV-mediated delivery (e.g., using an AAV with a serotype for delivery to the eye, such as recombinant AAV2.Y3F). The guide RNA can be administered as RNA or DNA. When administered as DNA, each guide RNA coding sequence can be operably linked to a different U6 promoter, for example. The guide RNA or the DNA encoding the guide RNA can be administered by any suitable administration route. For example, the guide RNA or the DNA encoding the guide RNA can be administered via intravitreal injection or intracameral injection.
[0295] In some methods, the target sequence of the guide RNA can include a regulatory sequence within the humanized MYOC locus. For example, the regulatory sequence can include a promoter or enhancer. In some methods, the target sequence of the guide RNA can be within 200 base pairs of the transcription start site of the genetically modified endogenous MYOC locus, or within a region 200 base pairs upstream of the transcription start site and 1 base pair downstream of the transcription start site.
[0296] In some methods, the guide RNAs each comprise two adapter binding elements to which a chimeric adapter protein can specifically bind. For example, a first adapter binding element can be within a first loop of each of the one or more guide RNAs, and a second adapter binding element can be within a second loop of each of the one or more guide RNAs. In a specific example, each guide RNA can be a single guide RNA comprising a CRISPR RNA (crRNA) portion fused to a trans-activating CRISPR RNA (tracrRNA) portion, wherein the first loop is a tetraloop corresponding to residues 13-16 of SEQ ID NO: 77, 79, 81, or 82, and the second loop is stem-loop 2 corresponding to residues 53-56 of SEQ ID NO: 77, 79, 81, or 82. In another specific example, the adapter binding element comprises the sequence set forth in SEQ ID NO: 52. In another specific example, each of the one or more guide RNAs comprises the sequence set forth in SEQ ID NO: 66, 68, 71, or 72.
[0297] In one example, the guide RNA can target a sequence comprising a sequence set forth in any one of SEQ ID NOs: 90-95. Similarly, the guide RNA can comprise a sequence set forth in any one of SEQ ID NOs: 96-101. In another example, the guide RNA can target a sequence comprising a sequence set forth in any one of SEQ ID NOs: 93-94. Similarly, the guide RNA can comprise a sequence set forth in any one of SEQ ID NOs: 99-100. In another example, the guide RNA can target a sequence comprising a sequence set forth in SEQ ID NO: 93. Similarly, the guide RNA can comprise a sequence set forth in SEQ ID NO: 99.
[0298] In some methods, the one or more guide RNAs comprise multiple guide RNAs that target the humanized MYOC locus (e.g., at least two or at least three guide RNAs that target the humanized MYOC locus).
[0299] B. Methods for Testing the Efficacy of Human MYOC-Targeting Reagents or Candidate Glaucoma Therapeutics Various methods are provided for evaluating the delivery or efficacy of a human MYOC targeting reagent or candidate glaucoma therapeutic agent in vivo, ex vivo, or in vitro using a non-human animal or non-human animal cells containing a humanized MYOC locus (e.g., containing a Y437H mutation) described elsewhere herein. Such methods can include (a) introducing a human MYOC targeting reagent or candidate glaucoma therapeutic agent into a non-human animal and (b) evaluating the activity of the human MYOC targeting reagent or candidate therapeutic agent. Similarly, such methods can include (a) introducing a human MYOC targeting reagent or candidate glaucoma therapeutic agent into non-human animal cells and (b) evaluating the activity of the human MYOC targeting reagent or candidate therapeutic agent. Evaluation can be, for example, compared to a control non-human animal or non-human animal cells containing a humanized MYOC locus that has not been administered the human MYOC targeting reagent or candidate glaucoma therapeutic agent, or compared to the non-human animal or non-human animal cells prior to administration of the human MYOC targeting reagent or candidate glaucoma therapeutic agent.
[0300] In methods in which the non-human animal or non-human animal cell also comprises a CRISPR / Cas synergistic activation mediator system component, such methods can further comprise, prior to step (a), administering to the non-human animal or non-human animal cell one or more SAM guide RNAs or one or more DNAs encoding one or more SAM guide RNAs as described elsewhere herein, wherein each of the one or more guide RNAs comprises one or more adaptor binding elements to which a chimeric adaptor protein can specifically bind, and each of the one or more guide RNAs forms a complex with the chimeric Cas protein and the chimeric adaptor protein and guides them to a target sequence within the humanized MYOC locus, thereby increasing expression of the humanized MYOC locus. When the evaluating step is performed in comparison to a control non-human animal or non-human animal cell that has not received the human MYOC targeting reagent or candidate glaucoma therapeutic agent, the method can further comprise administering to the control non-human animal or non-human animal cell one or more guide RNAs or one or more DNAs encoding one or more SAM guide RNAs as described elsewhere herein.
[0301] In methods that further comprise administering to the non-human animal or non-human animal cell, prior to step (a), one or more SAM guide RNAs or one or more DNAs encoding one or more SAM guide RNAs, as described elsewhere herein, any suitable amount of time can occur between the step of administering the one or more SAM guide RNAs or one or more DNAs encoding one or more SAM guide RNAs and the step of administering the human MYOC targeting reagent or candidate glaucoma therapeutic agent. In one example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent can be administered at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 15 days, at least about 20 days, at least about 25 days, or at least about 30 days after administering the one or more guide RNAs or one or more DNAs encoding one or more guide RNAs. In another example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent is administered about 1 to about 2 days, about 1 to about 3 days, about 1 to about 4 days, about 1 to about 5 days, about 1 to about 6 days, about 1 to about 7 days, about 1 to about 8 days, about 1 to about 9 days, about 1 to about 10 days, about 1 to about 15 days, about 1 to about 20 days, about 1 to about 25 days, or about 1 to about 30 days after administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs. In another example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent is administered about 1 to about 30 days, about 2 to about 30 days, about 3 to about 30 days, about 4 to about 30 days, about 5 to about 30 days, about 6 to about 30 days, about 7 to about 30 days, about 8 to about 30 days, about 9 to about 30 days, about 10 to about 30 days, about 15 to about 30 days, about 20 to about 30 days, or about 25 to about 30 days after administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs.In another example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent can be administered at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 9 weeks, at least about 10 weeks, or at least about 15 weeks after administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs. In another example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent is administered about 1 to about 2 weeks, about 1 to about 3 weeks, about 1 to about 4 weeks, about 1 to about 5 weeks, about 1 to about 6 weeks, about 1 to about 7 weeks, about 1 to about 8 weeks, about 1 to about 9 weeks, about 1 to about 10 weeks, or about 1 to about 15 weeks after administration of one or more guide RNAs or one or more DNAs encoding one or more guide RNAs. In another example, the human MYOC targeting reagent or candidate glaucoma therapeutic agent is administered about 1 week to about 15 weeks, about 2 weeks to about 15 weeks, about 3 weeks to about 15 weeks, about 4 weeks to about 15 weeks, about 5 weeks to about ...
Claims
1. A non-human animal comprising in its genome a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence; Optionally, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences.
2. The non-human animal of claim 1 , wherein the humanized endogenous MYOC locus comprises a mutation associated with glaucoma.
3. The non-human animal of claim 2 , wherein the human MYOC sequence comprises the mutation.
4. The non-human animal of any one of claims 1 to 3, wherein the humanized endogenous MYOC locus comprises a Y437H mutation.
5. The non-human animal of claim 4 , wherein the human MYOC sequence comprises the Y437H mutation.
6. The non-human animal of any one of claims 1 to 5, wherein the humanized endogenous MYOC locus comprises an endogenous MYOC promoter, and the human MYOC sequence is operably linked to the endogenous MYOC promoter.
7. The non-human animal of any one of claims 1 to 6, wherein at least one intron and at least one exon of the endogenous MYOC locus have been deleted and replaced with the corresponding human MYOC sequence.
8. The non-human animal of any one of claims 1 to 7, wherein the humanized endogenous MYOC locus comprises a human MYOC 3' untranslated region.
9. The non-human animal of any one of claims 1 to 8, wherein the endogenous MYOC 5' untranslated region is not deleted and not replaced with the corresponding human MYOC sequence.
10. The non-human animal of any one of claims 1 to 9, wherein the humanized endogenous MYOC locus encodes a human myocilin protein.
11. The non-human animal described in claim 10, wherein the human myocilin protein sequence comprises the sequence set forth in SEQ ID NO: 4, and optionally the human myocilin protein sequence is encoded by a coding sequence comprising the sequence set forth in SEQ ID NO:
5.
12. The non-human animal of any one of claims 1 to 11, wherein the entire MYOC coding sequence of the endogenous MYOC locus has been deleted and replaced with the corresponding human MYOC sequence.
13. 13. The non-human animal of any one of claims 1 to 12, wherein the region of the endogenous MYOC locus from the MYOC start codon to the MYOC stop codon has been deleted and replaced with the corresponding human MYOC sequence.
14. a region of the endogenous MYOC locus from the MYOC start codon to the MYOC stop codon has been deleted and replaced with a human MYOC sequence including the corresponding human MYOC sequence and a human MYOC 3' untranslated region; the human MYOC sequence comprises a Y437H mutation, the endogenous MYOC 5' untranslated region is not deleted or replaced with the human MYOC sequence; The non-human animal of any one of claims 1 to 13, wherein the humanized endogenous MYOC locus comprises an endogenous MYOC promoter, and the human MYOC sequence is operably linked to the endogenous MYOC promoter.
15. (i) the human MYOC sequence in the humanized endogenous MYOC locus comprises a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:87; and / or (ii) the humanized endogenous MYOC locus encodes a myocilin protein comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:4; and / or (iii) the humanized endogenous MYOC locus comprises a myocilin coding sequence comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO:5; and / or (iv) The non-human animal of any one of claims 1 to 14, wherein the humanized endogenous MYOC locus comprises a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 88 or 89.
16. The non-human animal of any one of claims 1 to 15, wherein the humanized endogenous MYOC locus does not comprise a selection cassette or a reporter gene.
17. The non-human animal of any one of claims 1 to 16, wherein the non-human animal is homozygous for the humanized endogenous MYOC locus.
18. The non-human animal of any one of claims 1 to 17, wherein the non-human animal comprises the humanized endogenous MYOC locus in its germline.
19. The non-human animal according to any one of claims 1 to 18, wherein the non-human animal is a mammal.
20. The non-human animal of claim 19, wherein the non-human animal is a rat or a mouse.
21. The non-human animal of claim 20 , wherein the non-human animal is a mouse.
22. The non-human animal further comprises an expression cassette integrated into its genome, the expression cassette comprising: (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains; (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains.
23. one or more guide RNAs, or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adapter binding elements to which said chimeric adapter protein can specifically bind; each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus; Optionally, the one or more guide RNAs, or one or more expression cassettes encoding the one or more guide RNAs, are within the trabecular meshwork.
24. further comprising an expression cassette integrated into the second genome encoding one or more guide RNAs, each of which comprises one or more adapter binding elements to which the chimeric adapter protein can specifically bind; each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; 24. The non-human animal of claim 22 or 23, wherein at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus.
25. A first expression cassette is integrated into the Rosa26 locus, the Cas protein is a Cas9 protein comprising mutations corresponding to D10A and N863A when optimally aligned with the Streptococcus pyogenes Cas9 protein; One or more transcription activator domains in the chimeric Cas protein include VP64; the adaptor protein comprises MS2 coat protein or a functional fragment or variant thereof, the one or more transcription activation domains in the chimeric adaptor protein include p65 and HSF1; the non-human animal further comprises one or more guide RNAs or one or more expression cassettes encoding the one or more guide RNAs, the one or more guide RNAs, or one or more expression cassettes encoding the one or more guide RNAs, are within the trabecular meshwork; each of the one or more guide RNAs comprises two adaptor binding elements to which the chimeric adaptor protein can specifically bind; the two adaptor binding elements comprise a first adaptor binding element within a first loop of each of the one or more guide RNAs and a second adaptor binding element within a second loop of each of the one or more guide RNAs; The non-human animal according to any one of claims 22 to 24, wherein the target sequence is within a region 200 base pairs upstream of a transcription start site and 1 base pair downstream of the transcription start site.
26. The non-human animal of any one of claims 22 to 25, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90 to 95.
27. The non-human animal of any one of claims 22 to 25, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93 to 94.
28. The non-human animal of any one of claims 22 to 25, wherein the non-human animal is a mouse and the one or more guide RNAs target a guide RNA target sequence as set forth in SEQ ID NO:
93.
29. 29. The non-human animal of any one of claims 22 to 28, wherein the non-human animal has at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not comprise the one or more guide RNAs or the one or more expression cassettes encoding the one or more guide RNAs.
30. 30. The non-human animal of any one of claims 1 to 29, wherein the non-human animal has elevated intraocular pressure relative to a wild-type or control non-human animal.
31. 31. The non-human animal of claim 30, wherein the non-human animal has an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg.
32. 32. The non-human animal of claim 30 or 31, wherein the non-human animal has an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of the control non-human animal.
33. A non-human animal cell comprising in its genome a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence; Optionally, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences, in a non-human animal cell.
34. The non-human animal cell further comprises an expression cassette integrated into its genome, the expression cassette comprising: (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains; (b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains.
35. one or more guide RNAs, or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adapter binding elements to which said chimeric adapter protein can specifically bind; each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; 35. The non-human animal cell of claim 34, wherein at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus.
36. A non-human animal genome comprising a humanized endogenous MYOC locus in its genome, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence; Optionally, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences.
37. The non-human animal genome further comprises an expression cassette integrated into the genome, the expression cassette comprising: (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains; (b) a nucleic acid encoding a chimeric adapter protein comprising an adapter protein fused to one or more transcription activation domains.
38. A nucleic acid comprising in its genome a humanized non-human MYOC locus, wherein a region of the endogenous MYOC gene has been deleted and replaced with a corresponding human MYOC sequence; Optionally, the region of the endogenous MYOC gene includes both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence includes both MYOC exon and MYOC intron sequences.
39. A targeting vector for generating a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence, the targeting vector comprising an insert nucleic acid comprising the corresponding human MYOC sequence flanked by a 5' homology arm that targets a 5' target sequence in the endogenous MYOC locus and a 3' homology arm that targets a 3' target sequence in the endogenous MYOC locus; Optionally, the region of the endogenous MYOC locus comprises both MYOC exon and MYOC intron sequences, and the corresponding human MYOC sequence comprises both MYOC exon and MYOC intron sequences.
40. 1. A method for evaluating the activity of a human MYOC targeting reagent or candidate glaucoma therapeutic agent, comprising: (a) administering the human MYOC targeting reagent or the candidate glaucoma therapeutic agent to a non-human animal according to any one of claims 1 to 32; (b) evaluating the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in the non-human animal.
41. The non-human animal further comprises an expression cassette integrated into its genome, the expression cassette comprising: (a) a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains; (b) a nucleic acid encoding a chimeric adapter protein comprising an adapter protein fused to one or more transcription activation domains.
42. The method further comprises, prior to step (a), administering one or more guide RNAs, or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which said chimeric adaptor protein can specifically bind; each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; 42. The method of Claim 41, wherein at least one of the one or more guide RNAs targets the humanized endogenous MYOC locus.
43. 43. The method of claim 42, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95.
44. 43. The method of claim 42, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94.
45. 43. The method of claim 42, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences set forth in SEQ ID NO:
93.
46. 46. The method of any one of claims 42 to 45, wherein the guide RNA or the one or more expression cassettes encoding the one or more guide RNAs are administered via adenovirus-, lentivirus-, or adeno-associated virus (AAV)-mediated delivery.
47. 47. The method of claim 46, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered via recombinant AAV2.Y3F mediated delivery.
48. 47. The method of claim 46, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered via lentiviral mediated delivery.
49. 49. The method of any one of claims 42 to 48, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered to the non-human animal via intravitreal or intracameral injection.
50. 50. The method of any one of claims 42 to 49, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered to the non-human animal at least 1 week prior to step (a), or from about 1 week to about 10 weeks prior to step (a).
51. 51. The method of any one of claims 40-50, wherein step (b) comprises evaluating the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in an eye of the non-human animal.
52. 52. The method of any one of claims 40-51, wherein step (a) comprises administering said human MYOC targeting reagent and step (b) comprises measuring expression of MYOC messenger RNA encoded by said humanized endogenous MYOC locus.
53. 53. The method of any one of claims 40-52, wherein step (a) comprises administering the human MYOC targeting reagent and step (b) comprises measuring expression of myocilin protein encoded by the humanized endogenous MYOC locus.
54. 54. The method of any one of claims 40-53, wherein step (a) comprises administering the human MYOC targeting reagent, wherein the human MYOC targeting reagent is a genome editing agent, and step (b) comprises assessing modification of the humanized endogenous MYOC locus.
55. 55. The method of claim 54, wherein step (b) comprises determining the frequency of insertions or deletions within the humanized endogenous MYOC locus.
56. 56. The method of any one of claims 40-55, wherein the human MYOC targeting reagent comprises a nuclease agent designed to target a region of the human MYOC gene.
57. 57. The method of Claim 56, wherein the nuclease agent comprises a Cas protein and a guide RNA designed to target a guide RNA target sequence in the human MYOC gene.
58. 58. The method of claim 57, wherein the Cas protein is a Cas9 protein.
59. 59. The method of any one of claims 40-58, wherein step (a) comprises administering the human MYOC targeting reagent, the human MYOC targeting reagent comprising an exogenous donor nucleic acid, the exogenous donor nucleic acid designed to target the human MYOC gene, and optionally, the exogenous donor nucleic acid delivered via AAV.
60. 54. The method of any one of claims 40-53, wherein the human MYOC targeting reagent is an RNAi agent or an antisense oligonucleotide.
61. The method of any one of claims 40-53, wherein the human MYOC targeting reagent is an antigen binding protein.
62. The method of any one of claims 40-53, wherein the human MYOC targeting reagent is a small molecule.
63. 63. The method of any one of claims 40-62, wherein evaluating the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in the non-human animal comprises evaluating intraocular pressure.
64. 64. The method of any one of claims 40 to 63, wherein said evaluating is performed in comparison to an untreated control non-human animal.
65. 52. The method of any one of claims 40-51, wherein step (a) comprises administering the candidate glaucoma therapeutic agent and step (b) comprises assessing intraocular pressure.
66. 66. The method of claim 65, wherein the candidate glaucoma therapeutic agent is an inhibitor of aqueous humor formation.
67. 66. The method of claim 65, wherein the candidate glaucoma therapeutic agent increases the outflow of aqueous humor.
68. The method of any one of claims 40-51, wherein the candidate glaucoma therapeutic agent is an ANGPTL7 targeting reagent.
69. 69. The method of claim 68, wherein the ANGPTL7 targeting reagent is an RNAi agent or an antisense oligonucleotide.
70. 1. A method for optimizing the activity of a human MYOC-targeting reagent or candidate glaucoma therapeutic in vivo, comprising: (I) carrying out a method according to any one of claims 40 to 69 for a first time on a first non-human animal; (II) altering a variable element and performing the method of step (I) a second time in a second non-human animal using the altered variable element; (III) comparing the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in step (I) with the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in step (II), and selecting a method that results in a higher activity.
71. A method for producing a non-human animal according to any one of claims 1 to 32, comprising the steps of: (a) introducing into a non-human animal host embryo a genetically modified non-human animal embryonic stem (ES) cell that comprises in its genome a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence; (b) gestating the non-human animal host embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal that comprises the humanized endogenous MYOC locus.
72. 72. The method of claim 71, further comprising, prior to step (a), modifying the genome of the non-human animal ES cell to contain the humanized endogenous MYOC locus.
73. A method for producing a non-human animal according to any one of claims 1 to 32, comprising the steps of: (a) modifying the genome of a one-cell stage embryo of a non-human animal to include in its genome a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence, thereby generating a genetically modified embryo of the non-human animal; (b) gestating the genetically modified embryo of the non-human animal in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal that comprises the humanized endogenous MYOC locus.
74. 74. The method of any one of claims 71-73, further comprising mating the F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus with a non-human animal that comprises a genomically integrated expression cassette comprising a nucleic acid encoding a chimeric clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and further comprising a nucleic acid encoding a chimeric adaptor protein comprising an adaptor protein fused to one or more transcription activation domains.
75. A method for producing a non-human animal according to any one of claims 22 to 32, comprising the steps of: (a) introducing into a non-human animal host embryo a genetically modified non-human animal embryonic stem (ES) cell, the genome of which comprises (i) a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence, and (ii) an expression cassette integrated into the genome, the expression cassette comprising a nucleic acid encoding a Cas protein, the Cas protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and a nucleic acid encoding a chimeric adaptor protein, the adaptor protein comprising a fused to one or more transcription activation domains; (b) gestating the non-human animal host embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus and the expression cassette integrated into the genome.
76. 76. The method of claim 75, further comprising, prior to step (a), modifying the genome of the non-human animal ES cell to contain said humanized endogenous MYOC locus and an expression cassette integrated into said genome.
77. A method for producing a non-human animal according to any one of claims 22 to 32, comprising the steps of: (a) providing a non-human animal one-cell stage embryo, the genome of which comprises (i) a humanized endogenous MYOC locus, wherein a region of the endogenous MYOC locus has been deleted and replaced with a corresponding human MYOC sequence, and (ii) an expression cassette integrated into the genome, the expression cassette comprising a nucleic acid encoding a Cas protein, the Cas protein comprising a nuclease-inactive Cas protein fused to one or more transcription activation domains, and a nucleic acid encoding a chimeric adaptor protein, the adaptor protein comprising a fused to one or more transcription activation domains; (b) gestating the non-human animal one-cell stage embryo in a surrogate mother, wherein the surrogate mother produces an F0 progeny genetically modified non-human animal comprising the humanized endogenous MYOC locus and the expression cassette integrated into the genome.
78. The method according to any one of claims 71 to 77, wherein the non-human animal is a mouse or a rat.
79. 79. The method of claim 78, wherein the non-human animal is a mouse.
80. A method for increasing MYOC expression in a non-human animal, comprising administering to a non-human animal according to any one of claims 22 to 32 one or more guide RNAs or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which said chimeric adaptor protein can specifically bind, each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; wherein at least one of said one or more guide RNAs targets said humanized endogenous MYOC locus.
81. A method for increasing intraocular pressure in a non-human animal, comprising administering to a non-human animal according to any one of claims 22 to 32 one or more guide RNAs or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which said chimeric adaptor protein can specifically bind, each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; wherein at least one of said one or more guide RNAs targets said humanized endogenous MYOC locus.
82. A method for modeling glaucoma in a non-human animal, comprising administering to a non-human animal according to any one of claims 22 to 32 one or more guide RNAs or one or more expression cassettes encoding said one or more guide RNAs, each guide RNA comprising one or more adaptor binding elements to which said chimeric adaptor protein can specifically bind, each of the one or more guide RNAs is capable of forming a complex with the Cas protein and directing it to a target sequence within a target gene; wherein at least one of said one or more guide RNAs targets said humanized endogenous MYOC locus.
83. 83. The method of any one of claims 80-82, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 90-95.
84. 83. The method of any one of claims 80-82, wherein the non-human animal is a mouse and the one or more guide RNAs target one or more guide RNA target sequences selected from SEQ ID NOs: 93-94.
85. The method of any one of claims 80 to 82, wherein the non-human animal is a mouse and the one or more guide RNAs target a guide RNA target sequence as set forth in SEQ ID NO:
93.
86. 86. The method of any one of claims 80-85, wherein the guide RNA or the one or more expression cassettes encoding the one or more guide RNAs are administered via adenovirus-, lentivirus-, or adeno-associated virus (AAV)-mediated delivery.
87. 87. The method of claim 86, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered via recombinant AAV2.Y3F mediated delivery.
88. 87. The method of Claim 86, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered via lentiviral mediated delivery.
89. 89. The method of any one of claims 80 to 88, wherein the guide RNA, or the one or more expression cassettes encoding the one or more guide RNAs, are administered to the non-human animal via intravitreal or intracameral injection.
90. 90. The method of any one of claims 80-89, wherein the method results in increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork, and optionally wherein the method results in at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, or at least 15-fold increased MYOC mRNA or protein expression in the eye, limbal ring, retina, ciliary body, or trabecular meshwork relative to a control non-human animal that does not comprise the one or more guide RNAs or one or more expression cassettes encoding the one or more guide RNAs.
91. 91. The method of any one of claims 80-90, wherein the method results in elevated intraocular pressure, optionally wherein the method results in the non-human animal having an intraocular pressure that is at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 mmHg higher than the intraocular pressure of the control non-human animal.
92. 92. The method of any one of claims 80-91, wherein the method results in an intraocular pressure of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or at least 22 mmHg.
93. 1. A method for evaluating the activity of a human MYOC targeting reagent or candidate glaucoma therapeutic agent, comprising: (a) administering the human MYOC targeting reagent or the candidate therapeutic agent for glaucoma to the non-human animal cell according to any one of claims 33 to 35; (b) evaluating the activity of the human MYOC targeting reagent or the candidate glaucoma therapeutic agent in the non-human animal cell.
Citation Information
Patent Citations
Transcription modulation in animals using crispr / CAS systems
WO2019183123A1
